CINXE.COM
Efficacy of Second-line Nivolumab Versus Tyrosine Kinase Inhibitors for Renal Cell Carcinoma With Bone Metastases | Anticancer Research
<!DOCTYPE html> <html lang="en" dir="ltr" xmlns="http://www.w3.org/1999/xhtml" xmlns:mml="http://www.w3.org/1998/Math/MathML"> <head prefix="og: http://ogp.me/ns# article: http://ogp.me/ns/article# book: http://ogp.me/ns/book#" > <!--[if IE]><![endif]--> <link rel="dns-prefetch" href="//cdn.jsdelivr.net" /> <link rel="dns-prefetch" href="//cdn.foxycart.com" /> <link rel="dns-prefetch" href="//scholar.google.com" /> <meta http-equiv="Content-Type" content="text/html; charset=utf-8" /> <meta name="Generator" content="Drupal 7 (http://drupal.org)" /> <link rel="canonical" href="https://ar.iiarjournals.org/content/45/2/639" /> <link rel="alternate" type="application/pdf" title="Full Text (PDF)" href="/content/45/2/639.full.pdf" /> <link rel="alternate" type="text/plain" title="Full Text (Plain)" href="/content/45/2/639.full.txt" /> <link rel="alternate" type="application/vnd.ms-powerpoint" title="Powerpoint" href="/content/45/2/639.ppt" /> <meta name="issue_cover_image" content="https://ar.iiarjournals.org/sites/default/files/highwire/anticanres/45/2.cover-source.jpg" /> <meta name="type" content="article" /> <meta name="category" content="research-article" /> <meta name="HW.identifier" content="/anticanres/45/2/639.atom" /> <meta name="HW.pisa" content="anticanres;45/2/639" /> <meta name="DC.Format" content="text/html" /> <meta name="DC.Language" content="en" /> <meta name="DC.Title" content="Efficacy of Second-line Nivolumab Versus Tyrosine Kinase Inhibitors for Renal Cell Carcinoma With Bone Metastases" /> <meta name="DC.Identifier" content="10.21873/anticanres.17451" /> <meta name="DC.Date" content="2025-02-01" /> <meta name="DC.Publisher" content="International Institute of Anticancer Research" /> <meta name="DC.Rights" content="Copyright © 2025 International Institute of Anticancer Research (Dr. George J. Delinasios), All rights reserved.. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY-NC-ND) 4.0 international license (https://creativecommons.org/licenses/by-nc-nd/4.0)." /> <meta name="DC.AccessRights" content="open-access" /> <meta name="DC.Description" content="Background/Aim: Combination therapy with immune checkpoint inhibitors has become the standard first-line treatment for metastatic renal cell carcinoma (mRCC), leading to changes in second-line treatment options, such as nivolumab or tyrosine kinase inhibitors (TKIs). However, very few studies have compared the efficacy of these drugs in patients with mRCC, particularly those with bone metastases (BM), which are associated with a poor prognosis. This study compared the efficacy of nivolumab and TKIs as second-line treatments for mRCC patients with BM and examined the microenvironments of primary tumors and BM lesions. Patients and Methods: This multi-institutional retrospective study included 87 mRCC patients with BM who received either nivolumab or TKIs as second-line treatments. We analyzed tumor-infiltrating immune cells expressing CD8 and CD20, along with PD-L1, HIF2α, c-MET, VEGFR2, and AXL, in primary tumors and BM sites using immunohistochemistry. Results: This analysis indicated that poor-risk classification, as per the International Metastatic RCC Database Consortium criteria (p<0.01), and elevated serum alkaline phosphatase levels (p=0.031) were significantly associated with poor prognosis. No significant difference in overall survival was observed between patients receiving nivolumab and those receiving TKIs. However, the objective response rate of patients with BM lesions was significantly higher when receiving TKIs than when receiving nivolumab (p=0.014). Immunohistochemistry revealed significantly higher VEGFR2 expression in BM lesions than primary tumors. Conclusion: TKIs could be a promising second-line treatment option for mRCC patients with bone-limited metastases." /> <meta name="DC.Contributor" content="GAKU YAMAMICHI" /> <meta name="DC.Contributor" content="TAIGO KATO" /> <meta name="DC.Contributor" content="AKIHIRO YOSHIMURA" /> <meta name="DC.Contributor" content="MASARU TANI" /> <meta name="DC.Contributor" content="YUKI HORIBE" /> <meta name="DC.Contributor" content="YUTONG LIU" /> <meta name="DC.Contributor" content="NESRINE SASSI" /> <meta name="DC.Contributor" content="YOHEI OKUDA" /> <meta name="DC.Contributor" content="TOSHIKI OKA" /> <meta name="DC.Contributor" content="TOSHIHIRO UEMURA" /> <meta name="DC.Contributor" content="AKINARU YAMAMOTO" /> <meta name="DC.Contributor" content="YU ISHIZUYA" /> <meta name="DC.Contributor" content="TAKUJI HAYASHI" /> <meta name="DC.Contributor" content="YOSHIYUKI YAMAMOTO" /> <meta name="DC.Contributor" content="KOJI HATANO" /> <meta name="DC.Contributor" content="ATSUNARI KAWASHIMA" /> <meta name="DC.Contributor" content="TETSUYA TAKAO" /> <meta name="DC.Contributor" content="KENSAKU NISHIMURA" /> <meta name="DC.Contributor" content="SHINGO TAKADA" /> <meta name="DC.Contributor" content="MASAO TSUJIHATA" /> <meta name="DC.Contributor" content="NORIO NONOMURA" /> <meta name="article:published_time" content="2025-02-01" /> <meta name="article:section" content="Clinical Studies" /> <meta name="citation_title" content="Efficacy of Second-line Nivolumab Versus Tyrosine Kinase Inhibitors for Renal Cell Carcinoma With Bone Metastases" /> <meta name="citation_abstract" lang="en" content="<p>Background/Aim: Combination therapy with immune checkpoint inhibitors has become the standard first-line treatment for metastatic renal cell carcinoma (mRCC), leading to changes in second-line treatment options, such as nivolumab or tyrosine kinase inhibitors (TKIs). However, very few studies have compared the efficacy of these drugs in patients with mRCC, particularly those with bone metastases (BM), which are associated with a poor prognosis. This study compared the efficacy of nivolumab and TKIs as second-line treatments for mRCC patients with BM and examined the microenvironments of primary tumors and BM lesions. Patients and Methods: This multi-institutional retrospective study included 87 mRCC patients with BM who received either nivolumab or TKIs as second-line treatments. We analyzed tumor-infiltrating immune cells expressing CD8 and CD20, along with PD-L1, HIF2α, c-MET, VEGFR2, and AXL, in primary tumors and BM sites using immunohistochemistry. Results: This analysis indicated that poor-risk classification, as per the International Metastatic RCC Database Consortium criteria (p&lt;0.01), and elevated serum alkaline phosphatase levels (p=0.031) were significantly associated with poor prognosis. No significant difference in overall survival was observed between patients receiving nivolumab and those receiving TKIs. However, the objective response rate of patients with BM lesions was significantly higher when receiving TKIs than when receiving nivolumab (p=0.014). Immunohistochemistry revealed significantly higher VEGFR2 expression in BM lesions than primary tumors. Conclusion: TKIs could be a promising second-line treatment option for mRCC patients with bone-limited metastases.</p>" /> <meta name="citation_journal_title" content="Anticancer Research" /> <meta name="citation_publisher" content="International Institute of Anticancer Research" /> <meta name="citation_publication_date" content="2025/02/01" /> <meta name="citation_mjid" content="anticanres;45/2/639" /> <meta name="citation_id" content="45/2/639" /> <meta name="citation_public_url" content="https://ar.iiarjournals.org/content/45/2/639" /> <meta name="citation_abstract_html_url" content="https://ar.iiarjournals.org/content/45/2/639.abstract" /> <meta name="citation_full_html_url" content="https://ar.iiarjournals.org/content/45/2/639.full" /> <meta name="citation_pdf_url" content="https://ar.iiarjournals.org/content/anticanres/45/2/639.full.pdf" /> <meta name="citation_issn" content="0250-7005" /> <meta name="citation_issn" content="1791-7530" /> <meta name="citation_doi" content="10.21873/anticanres.17451" /> <meta name="citation_pmid" content="39890197" /> <meta name="citation_volume" content="45" /> <meta name="citation_issue" content="2" /> <meta name="citation_article_type" content="Research Article" /> <meta name="citation_section" content="Clinical Studies" /> <meta name="citation_firstpage" content="639" /> <meta name="citation_lastpage" content="650" /> <meta name="citation_access" content="all" /> <meta name="citation_author" content="GAKU YAMAMICHI" /> <meta name="citation_author_institution" content="Department of Urology, Osaka University Graduate School of Medicine, Osaka, Japan" /> <meta name="citation_author" content="TAIGO KATO" /> <meta name="citation_author_institution" content="Department of Urology, Osaka University Graduate School of Medicine, Osaka, Japan" /> <meta name="citation_author_email" content="kato@uro.med.osaka-u.ac.jp" /> <meta name="citation_author" content="AKIHIRO YOSHIMURA" /> <meta name="citation_author_institution" content="Department of Urology, Osaka University Graduate School of Medicine, Osaka, Japan" /> <meta name="citation_author" content="MASARU TANI" /> <meta name="citation_author_institution" content="Department of Urology, Osaka University Graduate School of Medicine, Osaka, Japan" /> <meta name="citation_author" content="YUKI HORIBE" /> <meta name="citation_author_institution" content="Department of Urology, Osaka University Graduate School of Medicine, Osaka, Japan" /> <meta name="citation_author" content="YUTONG LIU" /> <meta name="citation_author_institution" content="Department of Urology, Osaka University Graduate School of Medicine, Osaka, Japan" /> <meta name="citation_author" content="NESRINE SASSI" /> <meta name="citation_author_institution" content="Department of Urology, Osaka University Graduate School of Medicine, Osaka, Japan" /> <meta name="citation_author" content="YOHEI OKUDA" /> <meta name="citation_author_institution" content="Department of Urology, Osaka University Graduate School of Medicine, Osaka, Japan" /> <meta name="citation_author" content="TOSHIKI OKA" /> <meta name="citation_author_institution" content="Department of Urology, Osaka University Graduate School of Medicine, Osaka, Japan" /> <meta name="citation_author" content="TOSHIHIRO UEMURA" /> <meta name="citation_author_institution" content="Department of Urology, Osaka University Graduate School of Medicine, Osaka, Japan" /> <meta name="citation_author" content="AKINARU YAMAMOTO" /> <meta name="citation_author_institution" content="Department of Urology, Osaka University Graduate School of Medicine, Osaka, Japan" /> <meta name="citation_author" content="YU ISHIZUYA" /> <meta name="citation_author_institution" content="Department of Urology, Osaka University Graduate School of Medicine, Osaka, Japan" /> <meta name="citation_author" content="TAKUJI HAYASHI" /> <meta name="citation_author_institution" content="Department of Urology, Osaka University Graduate School of Medicine, Osaka, Japan" /> <meta name="citation_author" content="YOSHIYUKI YAMAMOTO" /> <meta name="citation_author_institution" content="Department of Urology, Osaka University Graduate School of Medicine, Osaka, Japan" /> <meta name="citation_author" content="KOJI HATANO" /> <meta name="citation_author_institution" content="Department of Urology, Osaka University Graduate School of Medicine, Osaka, Japan" /> <meta name="citation_author" content="ATSUNARI KAWASHIMA" /> <meta name="citation_author_institution" content="Department of Urology, Osaka University Graduate School of Medicine, Osaka, Japan" /> <meta name="citation_author" content="TETSUYA TAKAO" /> <meta name="citation_author_institution" content="Department of Urology, Osaka General Medical Center, Osaka, Japan" /> <meta name="citation_author" content="KENSAKU NISHIMURA" /> <meta name="citation_author_institution" content="Department of Urology, National Hospital Organization Osaka National Hospital, Osaka, Japan" /> <meta name="citation_author" content="SHINGO TAKADA" /> <meta name="citation_author_institution" content="Department of Urology, Osaka Police Hospital, Osaka, Japan" /> <meta name="citation_author" content="MASAO TSUJIHATA" /> <meta name="citation_author_institution" content="Department of Urology, Osaka Rosai Hospital, Osaka, Japan" /> <meta name="citation_author" content="NORIO NONOMURA" /> <meta name="citation_author_institution" content="Department of Urology, Osaka University Graduate School of Medicine, Osaka, Japan" /> <meta name="citation_reference" content="citation_journal_title=Eur Urol;citation_author=L. Bukavina;citation_author=K. Bensalah;citation_author=F. Bray;citation_author=M. Carlo;citation_author=B. Challacombe;citation_author=JA. Karam;citation_author=W. Kassouf;citation_author=T. Mitchell;citation_author=R. Montironi;citation_author=T. O’Brien;citation_author=V. Panebianco;citation_author=G. Scelo;citation_author=B. Shuch;citation_author=H. van Poppel;citation_author=CD. Blosser;citation_author=SP. Psutka;citation_title=Epidemiology of renal cell carcinoma: 2022 update;citation_pages=529-542;citation_volume=82;citation_year=2022;citation_issue=5;citation_pmid=36100483;citation_doi=10.1016/j.eururo.2022.08.019" /> <meta name="citation_reference" content="citation_journal_title=Diagnostics (Basel);citation_author=AI. Parosanu;citation_author=C. Baston;citation_author=IM. Stanciu;citation_author=CF. Parlog;citation_author=C. Nitipir;citation_title=Second-line treatment of metastatic renal cell carcinoma in the era of predictive biomarkers;citation_pages=2430;citation_volume=13;citation_year=2023;citation_issue=14;citation_pmid=37510173;citation_doi=10.3390/diagnostics13142430" /> <meta name="citation_reference" content="citation_journal_title=Eur Urol;citation_author=B. Ljungberg;citation_author=L. Albiges;citation_author=Y. Abu-Ghanem;citation_author=J. Bedke;citation_author=U. Capitanio;citation_author=S. Dabestani;citation_author=S. Fernández-Pello;citation_author=RH. Giles;citation_author=F. Hofmann;citation_author=M. Hora;citation_author=T. Klatte;citation_author=T. Kuusk;citation_author=TB. Lam;citation_author=L. Marconi;citation_author=T. Powles;citation_author=R. Tahbaz;citation_author=A. Volpe;citation_author=A. Bex;citation_title=European Association of Urology guidelines on renal cell carcinoma: the 2022 update;citation_pages=399-410;citation_volume=82;citation_year=2022;citation_issue=4;citation_pmid=35346519;citation_doi=10.1016/j.eururo.2022.03.006" /> <meta name="citation_reference" content="citation_journal_title=Int J Urol;citation_author=T. Kato;citation_author=S. Yumiba;citation_author=W. Nakata;citation_author=K. Nakano;citation_author=A. Nagahara;citation_author=K. Matsuzaki;citation_author=Y. Hayashi;citation_author=K. Hatano;citation_author=A. Kawashima;citation_author=T. Takao;citation_author=K. Nishimura;citation_author=Y. Nakai;citation_author=M. Nakayama;citation_author=K. Nishimura;citation_author=S. Takada;citation_author=M. Tsujihata;citation_author=M. Uemura;citation_author=N. Nonomura;citation_author=R. Imamura;citation_title=A comparative study on nivolumab and axitinib as secondary treatment in patients with metastatic renal cell carcinoma: A multi-institutional retrospective study in Japan;citation_pages=723-729;citation_volume=30;citation_year=2023;citation_issue=9;citation_pmid=36578154;citation_doi=10.1111/iju.15130" /> <meta name="citation_reference" content="citation_journal_title=Ann Oncol;citation_author=M. Bianchi;citation_author=M. Sun;citation_author=C. Jeldres;citation_author=SF. Shariat;citation_author=QD. Trinh;citation_author=A. Briganti;citation_author=Z. Tian;citation_author=J. Schmitges;citation_author=M. Graefen;citation_author=P. Perrotte;citation_author=M. Menon;citation_author=F. Montorsi;citation_author=PI. Karakiewicz;citation_title=Distribution of metastatic sites in renal cell carcinoma: a population-based analysis;citation_volume=23;citation_year=2012;citation_issue=4;citation_pmid=21890909;citation_doi=10.1093/annonc/mdr362" /> <meta name="citation_reference" content="citation_journal_title=Eur Urol;citation_author=RR. McKay;citation_author=X. Lin;citation_author=JJ. Perkins;citation_author=DY. Heng;citation_author=R. Simantov;citation_author=TK. Choueiri;citation_title=Prognostic significance of bone metastases and bisphosphonate therapy in patients with renal cell carcinoma;citation_pages=502-509;citation_volume=66;citation_year=2014;citation_issue=3;citation_pmid=24613250;citation_doi=10.1016/j.eururo.2014.02.040" /> <meta name="citation_reference" content="citation_journal_title=Anticancer Research;citation_journal_abbrev=Anticancer Res;citation_author=T. Negishi;citation_author=N. Furubayashi;citation_author=T. Nakagawa;citation_author=N. Nishiyama;citation_author=H. Kitamura;citation_author=Y. Hori;citation_author=K. Kuroiwa;citation_author=Y. Son;citation_author=N. Seki;citation_author=T. Tomoda;citation_author=E. Okajima;citation_author=M. Nakamura;citation_title=Site-specific Response to Nivolumab in Renal Cell Carcinoma;citation_pages=1539-1545;citation_volume=41;citation_year=2021;citation_issue=3;citation_pmid=33788747;citation_doi=10.21873/anticanres.14913" /> <meta name="citation_reference" content="citation_journal_title=J Clin Oncol;citation_author=B. Escudier;citation_author=T. Powles;citation_author=RJ. Motzer;citation_author=T. Olencki;citation_author=O. Arén Frontera;citation_author=S. Oudard;citation_author=F. Rolland;citation_author=P. Tomczak;citation_author=D. Castellano;citation_author=LJ. Appleman;citation_author=H. Drabkin;citation_author=D. Vaena;citation_author=S. Milwee;citation_author=J. Youkstetter;citation_author=JC. Lougheed;citation_author=S. Bracarda;citation_author=TK. Choueiri;citation_title=Cabozantinib, a new standard of care for patients with advanced renal cell carcinoma and bone metastases? Subgroup analysis of the METEOR trial;citation_pages=765-772;citation_volume=36;citation_year=2018;citation_issue=8;citation_pmid=29309249;citation_doi=10.1200/JCO.2017.74.7352" /> <meta name="citation_reference" content="citation_journal_title=Int J Clin Oncol;citation_author=T. Ujike;citation_author=M. Uemura;citation_author=T. Kato;citation_author=K. Hatano;citation_author=A. Kawashima;citation_author=A. Nagahara;citation_author=K. Fujita;citation_author=R. Imamura;citation_author=N. Nonomura;citation_title=Novel diagnostic model for bone metastases in renal cell carcinoma patients based on bone scintigraphy analyzed by computer-aided diagnosis software and bone turnover markers;citation_pages=774-780;citation_volume=27;citation_year=2022;citation_issue=4;citation_pmid=35119579;citation_doi=10.1007/s10147-021-02107-3" /> <meta name="citation_reference" content="citation_journal_abbrev=J Cancer;citation_author=CM. Costelloe;citation_author=HH. Chuang;citation_author=JE. Madewell;citation_author=NT. Ueno;citation_title=Cancer Response Criteria and Bone Metastases: RECIST 1.1, MDA and PERCIST.;citation_pages=80-92;citation_volume=1;citation_year=2010;citation_pmid=20842228;citation_doi=10.7150/jca.1.80" /> <meta name="citation_reference" content="citation_journal_title=PLoS One;citation_author=N. Iga;citation_author=A. Otsuka;citation_author=Y. Yamamoto;citation_author=C. Nakashima;citation_author=T. Honda;citation_author=A. Kitoh;citation_author=S. Nakajima;citation_author=G. Egawa;citation_author=T. Nomura;citation_author=T. Dainichi;citation_author=S. Matsushita;citation_author=H. Tanizaki;citation_author=Y. Yamamoto;citation_author=T. Funakoshi;citation_author=Y. Fujisawa;citation_author=T. Fujimura;citation_author=H. Hata;citation_author=Y. Ishida;citation_author=K. Kabashima;citation_title=Accumulation of exhausted CD8+ T cells in extramammary Paget’s disease;citation_pages=e0211135;citation_volume=14;citation_year=2019;citation_issue=1;citation_pmid=30682105;citation_doi=10.1371/journal.pone.0211135" /> <meta name="citation_reference" content="citation_journal_title=Int J Mol Sci;citation_author=E. Tomiyama;citation_author=K. Fujita;citation_author=MDC. Rodriguez Pena;citation_author=D. Taheri;citation_author=E. Banno;citation_author=T. Kato;citation_author=K. Hatano;citation_author=A. Kawashima;citation_author=T. Ujike;citation_author=M. Uemura;citation_author=T. Takao;citation_author=S. Yamaguchi;citation_author=H. Fushimi;citation_author=K. Yoshimura;citation_author=H. Uemura;citation_author=GJ. Netto;citation_author=N. Nonomura;citation_title=Expression of Nectin-4 and PD-L1 in upper tract urothelial carcinoma;citation_pages=5390;citation_volume=21;citation_year=2020;citation_issue=15;citation_pmid=32751328;citation_doi=10.3390/ijms21155390" /> <meta name="citation_reference" content="citation_journal_title=Clin Cancer Res;citation_author=Y. Ma;citation_author=A. Joyce;citation_author=O. Brandenburg;citation_author=F. Saatchi;citation_author=C. Stevens;citation_author=V. Toffessi Tcheuyap;citation_author=A. Christie;citation_author=QN. Do;citation_author=O. Fatunde;citation_author=A. Macchiaroli;citation_author=SC. Wong;citation_author=L. Woolford;citation_author=Q. Yousuf;citation_author=J. Miyata;citation_author=D. Carrillo;citation_author=O. Onabolu;citation_author=T. McKenzie;citation_author=A. Mishra;citation_author=T. Hardy;citation_author=W. He;citation_author=D. Li;citation_author=A. Ivanishev;citation_author=Q. Zhang;citation_author=I. Pedrosa;citation_author=P. Kapur;citation_author=T. Schluep;citation_author=SB. Kanner;citation_author=J. Hamilton;citation_author=J. Brugarolas;citation_title=HIF2 inactivation and tumor suppression with a tumor-directed RNA-silencing drug in mice and humans;citation_pages=5405-5418;citation_volume=28;citation_year=2022;citation_issue=24;citation_pmid=36190432;citation_doi=10.1158/1078-0432.CCR-22-0963" /> <meta name="citation_reference" content="citation_journal_title=Oncotarget;citation_author=AA. Lalani;citation_author=KP. Gray;citation_author=L. Albiges;citation_author=M. Callea;citation_author=JC. Pignon;citation_author=S. Pal;citation_author=M. Gupta;citation_author=RS. Bhatt;citation_author=DF. McDermott;citation_author=MB. Atkins;citation_author=GFV. Woude;citation_author=LC. Harshman;citation_author=TK. Choueiri;citation_author=S. Signoretti;citation_title=Differential expression of c-Met between primary and metastatic sites in clear-cell renal cell carcinoma and its association with PD-L1 expression;citation_pages=103428-103436;citation_volume=8;citation_year=2017;citation_issue=61;citation_pmid=29262573;citation_doi=10.18632/oncotarget.21952" /> <meta name="citation_reference" content="citation_journal_title=Hum Pathol;citation_author=M. Kim;citation_author=M. Sohn;citation_author=M. Shim;citation_author=S. Choi;citation_author=M. Park;citation_author=E. Kim;citation_author=H. Go;citation_author=Y. Park;citation_author=YM. Cho;citation_author=JY. Ro;citation_author=IG. Jeong;citation_author=C. Song;citation_author=JH. Hong;citation_author=CS. Kim;citation_author=H. Ahn;citation_title=Prognostic value of vascular endothelial growth factor (VEGF), VEGF receptor 2, platelet-derived growth factor- β (PDGF-β), and PDGF-β receptor expression in papillary renal cell carcinoma;citation_pages=78-89;citation_volume=61;citation_year=2017;citation_pmid=27989785;citation_doi=10.1016/j.humpath.2016.12.002" /> <meta name="citation_reference" content="citation_journal_title=Urol Oncol;citation_author=LE. Zucca;citation_author=MA. Morini Matushita;citation_author=RJ. da Silva Oliveira;citation_author=C. Scapulatempo-Neto;citation_author=MA. de Lima;citation_author=GG. Ribeiro;citation_author=CR. Viana;citation_author=FM. Cárcano;citation_author=RM. Reis;citation_title=Expression of tyrosine kinase receptor AXL is associated with worse outcome of metastatic renal cell carcinomas treated with sunitinib;citation_pages=11.e13-11.e21;citation_volume=36;citation_year=2018;citation_issue=1;citation_pmid=28986088;citation_doi=10.1016/j.urolonc.2017.09.003" /> <meta name="citation_reference" content="citation_journal_title=Eur Urol;citation_author=J. Bedke;citation_author=L. Albiges;citation_author=U. Capitanio;citation_author=RH. Giles;citation_author=M. Hora;citation_author=TB. Lam;citation_author=B. Ljungberg;citation_author=L. Marconi;citation_author=T. Klatte;citation_author=A. Volpe;citation_author=Y. Abu-Ghanem;citation_author=S. Dabestani;citation_author=SF. Pello;citation_author=F. Hofmann;citation_author=T. Kuusk;citation_author=R. Tahbaz;citation_author=T. Powles;citation_author=A. Bex;citation_title=The 2021 Updated European Association of Urology Guidelines on Renal Cell Carcinoma: Immune checkpoint inhibitor–based combination therapies for treatment-naive metastatic clear-cell renal cell carcinoma are standard of care;citation_volume=80;citation_year=2021;citation_issue=4;citation_pmid=34074559;citation_doi=10.1016/j.eururo.2021.04.042" /> <meta name="citation_reference" content="citation_journal_title=J Cell Physiol;citation_author=Y. Lai;citation_author=F. Tang;citation_author=Y. Huang;citation_author=C. He;citation_author=C. Chen;citation_author=J. Zhao;citation_author=W. Wu;citation_author=Z. He;citation_title=The tumour microenvironment and metabolism in renal cell carcinoma targeted or immune therapy;citation_pages=1616-1627;citation_volume=236;citation_year=2021;citation_issue=3;citation_pmid=32783202;citation_doi=10.1002/jcp.29969" /> <meta name="citation_reference" content="citation_journal_title=Cancer Metastasis Rev;citation_author=M. Santoni;citation_author=D. Santini;citation_author=F. Massari;citation_author=A. Conti;citation_author=R. Iacovelli;citation_author=L. Burattini;citation_author=G. Tortora;citation_author=M. Falconi;citation_author=R. Montironi;citation_author=S. Cascinu;citation_title=Heterogeneous drug target expression as possible basis for different clinical and radiological response to the treatment of primary and metastatic renal cell carcinoma: suggestions from bench to bedside;citation_pages=321-331;citation_volume=33;citation_year=2014;citation_issue=1;citation_pmid=24337954;citation_doi=10.1007/s10555-013-9453-5" /> <meta name="citation_reference" content="citation_journal_title=BMC Clin Pathol;citation_author=SA. Aziz;citation_author=JA. Sznol;citation_author=A. Adeniran;citation_author=F. Parisi;citation_author=Y. Kluger;citation_author=RL. Camp;citation_author=HM. Kluger;citation_title=Expression of drug targets in primary and matched metastatic renal cell carcinoma tumors;citation_pages=3;citation_volume=13;citation_year=2013;citation_pmid=23374878;citation_doi=10.1186/1472-6890-13-3" /> <meta name="citation_reference" content="citation_journal_title=Sci Rep;citation_author=T. Sazuka;citation_author=Y. Matsushita;citation_author=H. Sato;citation_author=T. Osawa;citation_author=N. Hinata;citation_author=S. Hatakeyama;citation_author=K. Numakura;citation_author=K. Ueda;citation_author=T. Kimura;citation_author=M. Takahashi;citation_author=H. Tanaka;citation_author=Y. Kawasaki;citation_author=T. Kurahashi;citation_author=T. Kato;citation_author=K. Fujita;citation_author=M. Miyake;citation_author=T. Kojima;citation_author=H. Kitamura;citation_author=H. Miyake;citation_author=T. Ichikawa;citation_title=Efficacy and safety of second-line cabozantinib after immuno-oncology combination therapy for advanced renal cell carcinoma: Japanese multicenter retrospective study;citation_pages=20629;citation_volume=13;citation_year=2023;citation_issue=1;citation_pmid=37996622;citation_doi=10.1038/s41598-023-48087-4" /> <meta name="citation_reference" content="citation_journal_title=Cancer Research;citation_journal_abbrev=Cancer Res.;citation_author=L. Zou;citation_author=B. Barnett;citation_author=H. Safah;citation_author=VF. Larussa;citation_author=M. Evdemon-Hogan;citation_author=P. Mottram;citation_author=S. Wei;citation_author=O. David;citation_author=TJ. Curiel;citation_author=W. Zou;citation_title=Bone Marrow Is a Reservoir for CD4+CD25+ Regulatory T Cells that Traffic through CXCL12/CXCR4 Signals;citation_pages=8451-8455;citation_volume=64;citation_year=2004;citation_issue=22;citation_pmid=15548717;citation_doi=10.1158/0008-5472.CAN-04-1987" /> <meta name="citation_reference" content="citation_journal_title=The Journal of Immunology;citation_journal_abbrev=J. Immunol.;citation_author=B. Almand;citation_author=JI. Clark;citation_author=E. Nikitina;citation_author=J. van Beynen;citation_author=NR. English;citation_author=SC. Knight;citation_author=DP. Carbone;citation_author=DI. Gabrilovich;citation_title=Increased Production of Immature Myeloid Cells in Cancer Patients: A Mechanism of Immunosuppression in Cancer;citation_pages=678-689;citation_volume=166;citation_year=2001;citation_issue=1;citation_pmid=11123353;citation_doi=10.4049/jimmunol.166.1.678" /> <meta name="citation_reference" content="citation_journal_title=New England Journal of Medicine;citation_journal_abbrev=NEJM;citation_author=J. Brugarolas;citation_title=Renal-Cell Carcinoma -- Molecular Pathways and Therapies;citation_pages=185-187;citation_volume=356;citation_year=2007;citation_issue=2;citation_pmid=17215538;citation_doi=10.1056/NEJMe068263" /> <meta name="citation_reference" content="citation_journal_title=Front Immunol;citation_author=AJ. Oliver;citation_author=PKH. Lau;citation_author=AS. Unsworth;citation_author=S. Loi;citation_author=PK. Darcy;citation_author=MH. Kershaw;citation_author=CY. Slaney;citation_title=Tissue-dependent tumor microenvironments and their impact on immunotherapy responses;citation_pages=70;citation_volume=9;citation_year=2018;citation_pmid=29445373;citation_doi=10.3389/fimmu.2018.00070" /> <meta name="citation_reference" content="citation_journal_title=Vaccines (Basel);citation_author=A. Botticelli;citation_author=A. Cirillo;citation_author=S. Scagnoli;citation_author=B. Cerbelli;citation_author=L. Strigari;citation_author=A. Cortellini;citation_author=L. Pizzuti;citation_author=P. Vici;citation_author=F. De Galitiis;citation_author=FR. Di Pietro;citation_author=E. Cerbelli;citation_author=M. Ghidini;citation_author=G. D’Amati;citation_author=C. Della Rocca;citation_author=S. Mezi;citation_author=A. Gelibter;citation_author=R. Giusti;citation_author=E. Cortesi;citation_author=PA. Ascierto;citation_author=M. Nuti;citation_author=P. Marchetti;citation_title=The agnostic role of site of metastasis in predicting outcomes in cancer patients treated with immunotherapy;citation_pages=203;citation_volume=8;citation_year=2020;citation_issue=2;citation_pmid=32353934;citation_doi=10.3390/vaccines8020203" /> <meta name="citation_reference" content="citation_journal_title=Neoplasma;citation_author=E. Vrdoljak;citation_author=C. Magri;citation_author=M. Gamulin;citation_author=L. Bošković;citation_author=T. Omrčen;citation_author=Ž. Bajić;citation_author=T. Dienes;citation_author=L. Geczi;citation_title=Real-world safety and efficacy of nivolumab for ≥ 2nd line treatment of metastatic renal cell carcinoma: A retrospective cohort study in Croatia, Hungary, and Malta;citation_pages=208-215;citation_volume=68;citation_year=2021;citation_issue=01;citation_pmid=32940046;citation_doi=10.4149/neo_2020_200512N519" /> <meta name="citation_reference" content="citation_journal_title=Oncoimmunology;citation_author=Z. Lin;citation_author=L. Liu;citation_author=Y. Xia;citation_author=X. Chen;citation_author=Y. Xiong;citation_author=Y. Qu;citation_author=J. Wang;citation_author=Q. Bai;citation_author=J. Guo;citation_author=J. Xu;citation_title=Tumor infiltrating CD19(+) B lymphocytes predict prognostic and therapeutic benefits in metastatic renal cell carcinoma patients treated with tyrosine kinase inhibitors;citation_pages=e1477461;citation_volume=7;citation_year=2018;citation_issue=10;citation_pmid=30288343;citation_doi=10.1080/2162402X.2018.1477461" /> <meta name="citation_reference" content="citation_journal_title=Eur J Immunol;citation_author=H. Tao;citation_author=L. Lu;citation_author=Y. Xia;citation_author=F. Dai;citation_author=Y. Wang;citation_author=Y. Bao;citation_author=SK. Lundy;citation_author=F. Ito;citation_author=Q. Pan;citation_author=X. Zhang;citation_author=F. Zheng;citation_author=G. Shu;citation_author=B. Fang;citation_author=J. Jiang;citation_author=J. Xia;citation_author=S. Huang;citation_author=Q. Li;citation_author=AE. Chang;citation_title=Antitumor effector B cells directly kill tumor cells via the Fas/FasL pathway and are regulated by IL-10;citation_pages=999-1009;citation_volume=45;citation_year=2015;citation_issue=4;citation_pmid=25545618;citation_doi=10.1002/eji.201444625" /> <meta name="citation_reference" content="citation_journal_title=Biomed Res Int;citation_author=B. Shuch;citation_author=R. Falbo;citation_author=F. Parisi;citation_author=A. Adeniran;citation_author=Y. Kluger;citation_author=HM. Kluger;citation_author=LB. Jilaveanu;citation_title=MET expression in primary and metastatic clear cell renal cell carcinoma: Implications of correlative biomarker assessment to MET pathway inhibitors;citation_pages=192406;citation_volume=2015;citation_year=2015;citation_pmid=26448928;citation_doi=10.1155/2015/192406" /> <meta name="citation_reference" content="citation_journal_title=Mol Cancer Ther;citation_author=FM. Yakes;citation_author=J. Chen;citation_author=J. Tan;citation_author=K. Yamaguchi;citation_author=Y. Shi;citation_author=P. Yu;citation_author=F. Qian;citation_author=F. Chu;citation_author=F. Bentzien;citation_author=B. Cancilla;citation_author=J. Orf;citation_author=A. You;citation_author=AD. Laird;citation_author=S. Engst;citation_author=L. Lee;citation_author=J. Lesch;citation_author=YC. Chou;citation_author=AH. Joly;citation_title=Cabozantinib (XL184), a novel MET and VEGFR2 inhibitor, simultaneously suppresses metastasis, angiogenesis, and tumor growth;citation_volume=10;citation_year=2011;citation_issue=12;citation_pmid=21926191;citation_doi=10.1158/1535-7163.MCT-11-0264" /> <meta name="citation_reference" content="citation_journal_title=In Vivo;citation_journal_abbrev=In Vivo;citation_author=J. Kopecky;citation_author=O. Kubecek;citation_author=T. Buchler;citation_author=B. Melichar;citation_author=A. Poprach;citation_author=M. Zemanova;citation_author=J. Katolicka;citation_author=I. Kiss;citation_author=J. Hajek;citation_author=H. Studentova;citation_author=M. Spisarova;citation_title=Administration of Nivolumab in Metastatic Renal Cell Cancer Following Treatment With mTOR Inhibitors;citation_pages=2981-2990;citation_volume=35;citation_year=2021;citation_issue=5;citation_pmid=34410998;citation_doi=10.21873/invivo.12593" /> <meta name="citation_reference" content="citation_journal_title=Q J Nucl Med Mol Imaging;citation_author=A. Castello;citation_author=E. Lopci;citation_title=Response assessment of bone metastatic disease: seeing the forest for the trees RECIST, PERCIST, iRECIST, and PCWG-2;citation_pages=150-158;citation_volume=63;citation_year=2019;citation_issue=2;citation_pmid=31286751;citation_doi=10.23736/S1824-4785.19.03193-5" /> <meta name="citation_reference" content="citation_journal_title=Front Oncol;citation_author=Y. Asano;citation_author=N. Yamamoto;citation_author=S. Demura;citation_author=K. Hayashi;citation_author=A. Takeuchi;citation_author=S. Kato;citation_author=S. Miwa;citation_author=K. Igarashi;citation_author=T. Higuchi;citation_author=H. Yonezawa;citation_author=Y. Araki;citation_author=S. Morinaga;citation_author=S. Saito;citation_author=T. Sone;citation_author=K. Kasahara;citation_author=H. Tsuchiya;citation_title=The therapeutic effect and clinical outcome of immune checkpoint inhibitors on bone metastasis in advanced non-small-cell lung cancer;citation_pages=871675;citation_volume=12;citation_year=2022;citation_pmid=35433422;citation_doi=10.3389/fonc.2022.871675" /> <meta name="citation_reference" content="citation_journal_title=Anticancer Research;citation_journal_abbrev=Anticancer Res;citation_author=K. Ueda;citation_author=N. Ito;citation_author=Y. Sakai;citation_author=S. Ohnishi;citation_author=T. Hirano;citation_author=H. Kurose;citation_author=K. Chikui;citation_author=K. Uemura;citation_author=K. Nishihara;citation_author=M. Nakiri;citation_author=S. Suekane;citation_author=T. Igawa;citation_title=Efficacy and Safety of Nivolumab With Ipilimumab in Elderly Patients With Advanced Renal Cell Carcinoma;citation_pages=5087-5093;citation_volume=44;citation_year=2024;citation_issue=11;citation_pmid=39477306;citation_doi=10.21873/anticanres.17333" /> <meta name="citation_reference" content="citation_journal_title=Anticancer Research;citation_journal_abbrev=Anticancer Res;citation_author=G. Ishikawa;citation_author=K. Tamura;citation_author=Y. Tsuchiya;citation_author=S. Watanabe;citation_author=T. Ayana;citation_author=S. Asuka;citation_author=K. Watanabe;citation_author=H. Watanabe;citation_author=Y. Matsushita;citation_author=D. Motoyama;citation_author=A. Otsuka;citation_author=T. Inamoto;citation_title=Comparing Immuno-oncology Combination Therapy With Tyrosine Kinase Inhibitor Monotherapy for Advanced Renal Cell Carcinoma;citation_pages=379-386;citation_volume=45;citation_year=2025;citation_issue=1;citation_pmid=39740850;citation_doi=10.21873/anticanres.17426" /> <meta name="citation_fulltext_world_readable" content="" /> <meta name="twitter:title" content="Efficacy of Second-line Nivolumab Versus Tyrosine Kinase Inhibitors for Renal Cell Carcinoma With Bone Metastases" /> <meta name="twitter:card" content="summary_large_image" /> <meta name="twitter:image" content="https://ar.iiarjournals.org/sites/default/files/highwire/anticanres/45/2.cover-source.jpg" /> <meta name="twitter:description" content="Background/Aim: Combination therapy with immune checkpoint inhibitors has become the standard first-line treatment for metastatic renal cell carcinoma (mRCC), leading to changes in second-line treatment options, such as nivolumab or tyrosine kinase inhibitors (TKIs). However, very few studies have compared the efficacy of these drugs in patients with mRCC, particularly those with bone metastases (BM), which are associated with a poor prognosis. This study compared the efficacy of nivolumab and TKIs as second-line treatments for mRCC patients with BM and examined the microenvironments of primary tumors and BM lesions. Patients and Methods: This multi-institutional retrospective study included 87 mRCC patients with BM who received either nivolumab or TKIs as second-line treatments. We analyzed tumor-infiltrating immune cells expressing CD8 and CD20, along with PD-L1, HIF2α, c-MET, VEGFR2, and AXL, in primary tumors and BM sites using immunohistochemistry. Results: This analysis indicated that poor-risk classification, as per the International Metastatic RCC Database Consortium criteria (p<0.01), and elevated serum alkaline phosphatase levels (p=0.031) were significantly associated with poor prognosis. No significant difference in overall survival was observed between patients receiving nivolumab and those receiving TKIs. However, the objective response rate of patients with BM lesions was significantly higher when receiving TKIs than when receiving nivolumab (p=0.014). Immunohistochemistry revealed significantly higher VEGFR2 expression in BM lesions than primary tumors. Conclusion: TKIs could be a promising second-line treatment option for mRCC patients with bone-limited metastases." /> <meta name="og-title" property="og:title" content="Efficacy of Second-line Nivolumab Versus Tyrosine Kinase Inhibitors for Renal Cell Carcinoma With Bone Metastases" /> <meta name="og-url" property="og:url" content="https://ar.iiarjournals.org/content/45/2/639" /> <meta name="og-site-name" property="og:site_name" content="Anticancer Research" /> <meta name="og-description" property="og:description" content="Background/Aim: Combination therapy with immune checkpoint inhibitors has become the standard first-line treatment for metastatic renal cell carcinoma (mRCC), leading to changes in second-line treatment options, such as nivolumab or tyrosine kinase inhibitors (TKIs). However, very few studies have compared the efficacy of these drugs in patients with mRCC, particularly those with bone metastases (BM), which are associated with a poor prognosis. This study compared the efficacy of nivolumab and TKIs as second-line treatments for mRCC patients with BM and examined the microenvironments of primary tumors and BM lesions. Patients and Methods: This multi-institutional retrospective study included 87 mRCC patients with BM who received either nivolumab or TKIs as second-line treatments. We analyzed tumor-infiltrating immune cells expressing CD8 and CD20, along with PD-L1, HIF2α, c-MET, VEGFR2, and AXL, in primary tumors and BM sites using immunohistochemistry. Results: This analysis indicated that poor-risk classification, as per the International Metastatic RCC Database Consortium criteria (p<0.01), and elevated serum alkaline phosphatase levels (p=0.031) were significantly associated with poor prognosis. No significant difference in overall survival was observed between patients receiving nivolumab and those receiving TKIs. However, the objective response rate of patients with BM lesions was significantly higher when receiving TKIs than when receiving nivolumab (p=0.014). Immunohistochemistry revealed significantly higher VEGFR2 expression in BM lesions than primary tumors. Conclusion: TKIs could be a promising second-line treatment option for mRCC patients with bone-limited metastases." /> <meta name="og-type" property="og:type" content="article" /> <meta name="og-image" property="og:image" content="https://ar.iiarjournals.org/sites/default/files/highwire/anticanres/45/2.cover-source.jpg" /> <link rel="shortlink" href="/node/83129" /> <link rel="shortcut icon" href="https://ar.iiarjournals.org/sites/default/files/images/favicon.ico" type="image/vnd.microsoft.icon" /> <meta name="viewport" content="width=device-width, initial-scale=1" /> <title>Efficacy of Second-line Nivolumab Versus Tyrosine Kinase Inhibitors for Renal Cell Carcinoma With Bone Metastases | Anticancer Research</title> <link type="text/css" rel="stylesheet" href="/sites/default/files/advagg_css/css__QEy_BpbtMcsqv3xURK855GSs2fFjOibU10yA758Mn4c__NucWi_bEk5E3BNVDtTt2nhiPtE1A5I24YwRDQ2fojJ0__FTZ25lEcrtnzSW3JzKpn0j1z_ccWiSdhuJwjpWHa4ec.css" media="all" /> <link type="text/css" rel="stylesheet" href="//cdn.jsdelivr.net/qtip2/2.2.1/jquery.qtip.min.css" media="all" /> <link type="text/css" rel="stylesheet" href="/sites/default/files/advagg_css/css__xyG32SHTOp9vgQul8NRCS_oy4totfS7YwKksVhArXIE__f9gcY3eYKu9KPg3LjOpp3PPigKkvVoNjHJs6A9lajDo__FTZ25lEcrtnzSW3JzKpn0j1z_ccWiSdhuJwjpWHa4ec.css" media="all" /> <style type="text/css" media="all"> /* <![CDATA[ */ #sliding-popup.sliding-popup-bottom,#sliding-popup.sliding-popup-bottom .eu-cookie-withdraw-banner,.eu-cookie-withdraw-tab{background:#0779bf}#sliding-popup.sliding-popup-bottom.eu-cookie-withdraw-wrapper{background:transparent}#sliding-popup .popup-content #popup-text h1,#sliding-popup .popup-content #popup-text h2,#sliding-popup .popup-content #popup-text h3,#sliding-popup .popup-content #popup-text p,.eu-cookie-compliance-secondary-button,.eu-cookie-withdraw-tab{color:#fff !important}.eu-cookie-withdraw-tab{border-color:#fff}.eu-cookie-compliance-more-button{color:#fff !important} /* ]]> */ </style> <!--[if lte IE 7]> <link type="text/css" rel="stylesheet" href="/sites/default/files/advagg_css/css__ElJr3PIJEvw3qLXc1cnYiLj2G4KgDPSXFOfm6Phf8hw__JdWGm15cDWjsK6KrFlQVXQix9YgNeYysf22XZHj-Y-c__FTZ25lEcrtnzSW3JzKpn0j1z_ccWiSdhuJwjpWHa4ec.css" media="all" /> <![endif]--> <link type="text/css" rel="stylesheet" href="/sites/default/files/advagg_css/css__BuoDuzoWcz2CL9-rYVqiOwZYB0s9mtqPm1bLrGHX4Z4__WNptNuPkTJ2rxI9jvljwIQXeYY9GgnsTxhjOkFT4fEY__FTZ25lEcrtnzSW3JzKpn0j1z_ccWiSdhuJwjpWHa4ec.css" media="all" /> <link type="text/css" rel="stylesheet" href="/sites/default/files/advagg_css/css__2-pfXaCc4FQjEkSsPsxtZZuEuZpLkYNrLnNNeANwfeE__3w2axNic22mHLXKlqSmMAf1YBlV8oU_dFJFUcKN-kvI__FTZ25lEcrtnzSW3JzKpn0j1z_ccWiSdhuJwjpWHa4ec.css" media="all" /> <!--[if (lt IE 9)&(!IEMobile)]> <link type="text/css" rel="stylesheet" href="/sites/default/files/advagg_css/css__XH6bpcI0f2dImc-p674DLCZtWBGb-QwxJK1YexVGtno__vUceGprdo5nIhV6DH93X7fI3r8RcTJbChbas9TQXeW4__FTZ25lEcrtnzSW3JzKpn0j1z_ccWiSdhuJwjpWHa4ec.css" media="all" /> <![endif]--> <!--[if gte IE 9]><!--> <link type="text/css" rel="stylesheet" href="/sites/default/files/advagg_css/css__oWyrHF_mmv3c4PPGrsNSmh5Ub_1TfiuNA2i1_MOafWg__1kTjT7uqr7v6BlTbuE-4U2S8EzyEcBTxZhvp1VjA-qo__FTZ25lEcrtnzSW3JzKpn0j1z_ccWiSdhuJwjpWHa4ec.css" media="all" /> <!--<![endif]--> <!--[if gte IE 9]><!--> <link type="text/css" rel="stylesheet" href="/sites/default/files/advagg_css/css__-Kek3KTto4Kje1mJ9bp_-a_lv0D9QS29NgfFBV-inOY__90wksBfd5YlmG0UjedmGQFn8Ano49PMQRwGgVOM50YE__FTZ25lEcrtnzSW3JzKpn0j1z_ccWiSdhuJwjpWHa4ec.css" media="all" /> <!--<![endif]--> <link type="text/css" rel="stylesheet" href="/sites/default/files/advagg_css/css__48WIaIRv217q4KGtRvs6_FYimBH-tzeFpIPENiZfFxw__iBfm7f9Zjr1nQCVzxlloL1f_WY5-IVR9o7sZ7ib2wp0__FTZ25lEcrtnzSW3JzKpn0j1z_ccWiSdhuJwjpWHa4ec.css" media="all" /> <script type="text/javascript" src="/sites/default/files/advagg_js/js__w9KfteKl83HqBMjSYP5JDjV5lrM5NMI6GVdsOS39hDk__cIiZpVn2l_LEmnfMHrIFJ4GCKpm7cJ7dwO_wgh0srUk__FTZ25lEcrtnzSW3JzKpn0j1z_ccWiSdhuJwjpWHa4ec.js"></script> <script type="text/javascript" src="//cdn.jsdelivr.net/qtip2/2.2.1/jquery.qtip.min.js"></script> <script type="text/javascript" src="/sites/default/files/advagg_js/js__-QvM1EfJuG2CO4WKkg72Ifwc-EFIXoLU5NraQ66sgD8__C34qOwrCa3ZcD8SWO15uVRM7YUAYeHwp8ejH2kLHAO4__FTZ25lEcrtnzSW3JzKpn0j1z_ccWiSdhuJwjpWHa4ec.js"></script> <script type="text/javascript"> <!--//--><![CDATA[//><!-- /*! * yepnope1.5.4 * (c) WTFPL, GPLv2 */ (function(a,b,c){function d(a){return"[object Function]"==o.call(a)}function e(a){return"string"==typeof a}function f(){}function g(a){return!a||"loaded"==a||"complete"==a||"uninitialized"==a}function h(){var a=p.shift();q=1,a?a.t?m(function(){("c"==a.t?B.injectCss:B.injectJs)(a.s,0,a.a,a.x,a.e,1)},0):(a(),h()):q=0}function i(a,c,d,e,f,i,j){function k(b){if(!o&&g(l.readyState)&&(u.r=o=1,!q&&h(),l.onload=l.onreadystatechange=null,b)){"img"!=a&&m(function(){t.removeChild(l)},50);for(var d in y[c])y[c].hasOwnProperty(d)&&y[c][d].onload()}}var j=j||B.errorTimeout,l=b.createElement(a),o=0,r=0,u={t:d,s:c,e:f,a:i,x:j};1===y[c]&&(r=1,y[c]=[]),"object"==a?l.data=c:(l.src=c,l.type=a),l.width=l.height="0",l.onerror=l.onload=l.onreadystatechange=function(){k.call(this,r)},p.splice(e,0,u),"img"!=a&&(r||2===y[c]?(t.insertBefore(l,s?null:n),m(k,j)):y[c].push(l))}function j(a,b,c,d,f){return q=0,b=b||"j",e(a)?i("c"==b?v:u,a,b,this.i++,c,d,f):(p.splice(this.i++,0,a),1==p.length&&h()),this}function k(){var a=B;return a.loader={load:j,i:0},a}var l=b.documentElement,m=a.setTimeout,n=b.getElementsByTagName("script")[0],o={}.toString,p=[],q=0,r="MozAppearance"in l.style,s=r&&!!b.createRange().compareNode,t=s?l:n.parentNode,l=a.opera&&"[object Opera]"==o.call(a.opera),l=!!b.attachEvent&&!l,u=r?"object":l?"script":"img",v=l?"script":u,w=Array.isArray||function(a){return"[object Array]"==o.call(a)},x=[],y={},z={timeout:function(a,b){return b.length&&(a.timeout=b[0]),a}},A,B;B=function(a){function b(a){var a=a.split("!"),b=x.length,c=a.pop(),d=a.length,c={url:c,origUrl:c,prefixes:a},e,f,g;for(f=0;f<d;f++)g=a[f].split("="),(e=z[g.shift()])&&(c=e(c,g));for(f=0;f<b;f++)c=x[f](c);return c}function g(a,e,f,g,h){var i=b(a),j=i.autoCallback;i.url.split(".").pop().split("?").shift(),i.bypass||(e&&(e=d(e)?e:e[a]||e[g]||e[a.split("/").pop().split("?")[0]]),i.instead?i.instead(a,e,f,g,h):(y[i.url]?i.noexec=!0:y[i.url]=1,f.load(i.url,i.forceCSS||!i.forceJS&&"css"==i.url.split(".").pop().split("?").shift()?"c":c,i.noexec,i.attrs,i.timeout),(d(e)||d(j))&&f.load(function(){k(),e&&e(i.origUrl,h,g),j&&j(i.origUrl,h,g),y[i.url]=2})))}function h(a,b){function c(a,c){if(a){if(e(a))c||(j=function(){var a=[].slice.call(arguments);k.apply(this,a),l()}),g(a,j,b,0,h);else if(Object(a)===a)for(n in m=function(){var b=0,c;for(c in a)a.hasOwnProperty(c)&&b++;return b}(),a)a.hasOwnProperty(n)&&(!c&&!--m&&(d(j)?j=function(){var a=[].slice.call(arguments);k.apply(this,a),l()}:j[n]=function(a){return function(){var b=[].slice.call(arguments);a&&a.apply(this,b),l()}}(k[n])),g(a[n],j,b,n,h))}else!c&&l()}var h=!!a.test,i=a.load||a.both,j=a.callback||f,k=j,l=a.complete||f,m,n;c(h?a.yep:a.nope,!!i),i&&c(i)}var i,j,l=this.yepnope.loader;if(e(a))g(a,0,l,0);else if(w(a))for(i=0;i<a.length;i++)j=a[i],e(j)?g(j,0,l,0):w(j)?B(j):Object(j)===j&&h(j,l);else Object(a)===a&&h(a,l)},B.addPrefix=function(a,b){z[a]=b},B.addFilter=function(a){x.push(a)},B.errorTimeout=1e4,null==b.readyState&&b.addEventListener&&(b.readyState="loading",b.addEventListener("DOMContentLoaded",A=function(){b.removeEventListener("DOMContentLoaded",A,0),b.readyState="complete"},0)),a.yepnope=k(),a.yepnope.executeStack=h,a.yepnope.injectJs=function(a,c,d,e,i,j){var k=b.createElement("script"),l,o,e=e||B.errorTimeout;k.src=a;for(o in d)k.setAttribute(o,d[o]);c=j?h:c||f,k.onreadystatechange=k.onload=function(){!l&&g(k.readyState)&&(l=1,c(),k.onload=k.onreadystatechange=null)},m(function(){l||(l=1,c(1))},e),i?k.onload():n.parentNode.insertBefore(k,n)},a.yepnope.injectCss=function(a,c,d,e,g,i){var e=b.createElement("link"),j,c=i?h:c||f;e.href=a,e.rel="stylesheet",e.type="text/css";for(j in d)e.setAttribute(j,d[j]);g||(n.parentNode.insertBefore(e,n),m(c,0))}})(this,document); //--><!]]> </script> <script type="text/javascript"> <!--//--><![CDATA[//><!-- yepnope({ test: Modernizr.matchmedia, nope: '/sites/all/libraries/media-match/media.match.min.js' }); //--><!]]> </script> <script type="text/javascript"> <!--//--><![CDATA[//><!-- document.createElement( "picture" ); //--><!]]> </script> <script type="text/javascript"> <!--//--><![CDATA[//><!-- if(typeof window.MathJax === "undefined") window.MathJax = { menuSettings: { zoom: "Click" } }; //--><!]]> </script> <script type="text/javascript" src="/sites/default/files/advagg_js/js__GM3GJPR36rRIz0TRkjC5OQwrioSyN9aoYRivDhCO_AM__qAl84FcCv2jyN22yFGS5Oc85cjd9zKX6p_cFNLGhe-M__FTZ25lEcrtnzSW3JzKpn0j1z_ccWiSdhuJwjpWHa4ec.js" async="async"></script> <script type="text/javascript" defer="defer" async="async" src="//cdn.foxycart.com/iiar.ecommerce.highwire.org/loader.js"></script> <script type="text/javascript" async="async" src="https://scholar.google.com/scholar_js/casa.js"></script> <script type="text/javascript"> <!--//--><![CDATA[//><!-- jQuery.extend(Drupal.settings,{"basePath":"\/","pathPrefix":"","ajaxPageState":{"theme":"jcore_1","theme_token":"ZgKi7Ati6XeQRc4XxoZoWzX0dRuxTeuDeXgWvJSmbXM","jquery_version":"1.8","css":{"modules\/system\/system.base.css":1,"modules\/system\/system.menus.css":1,"modules\/system\/system.messages.css":1,"modules\/system\/system.theme.css":1,"misc\/ui\/jquery.ui.core.css":1,"misc\/ui\/jquery.ui.theme.css":1,"misc\/ui\/jquery.ui.button.css":1,"misc\/ui\/jquery.ui.resizable.css":1,"misc\/ui\/jquery.ui.dialog.css":1,"misc\/ui\/jquery.ui.tooltip.css":1,"misc\/ui\/jquery.ui.accordion.css":1,"sites\/all\/modules\/contrib\/date\/date_api\/date.css":1,"sites\/all\/modules\/contrib\/date\/date_popup\/themes\/datepicker.1.7.css":1,"modules\/field\/theme\/field.css":1,"sites\/all\/modules\/highwire\/highwire\/highwire_draw\/css\/highwire-draw.css":1,"sites\/all\/modules\/highwire\/highwire\/highwire_folders\/highwire_folders.css":1,"sites\/all\/modules\/highwire\/highwire\/highwire_foxycart\/highwire_foxycart.css":1,"sites\/all\/modules\/highwire\/highwire\/highwire_responsive\/css\/highwire-responsive.css":1,"sites\/all\/modules\/highwire\/highwire\/highwire_saved_searches\/highwire_saved_searches.css":1,"sites\/all\/modules\/highwire\/highwire\/highwire_user\/highwire_user.css":1,"modules\/node\/node.css":1,"sites\/all\/modules\/contrib\/picture\/picture_wysiwyg.css":1,"modules\/search\/search.css":1,"modules\/user\/user.css":1,"sites\/all\/modules\/contrib\/views\/css\/views.css":1,"sites\/all\/modules\/contrib\/ckeditor\/css\/ckeditor.css":1,"sites\/all\/modules\/contrib\/colorbox\/styles\/default\/colorbox_style.css":1,"sites\/all\/modules\/contrib\/ctools\/css\/ctools.css":1,"sites\/all\/modules\/contrib\/foxycart\/foxycart.css":1,"sites\/all\/modules\/highwire\/highwire\/highwire.style.highwire.css":1,"sites\/all\/modules\/highwire\/highwire\/css\/nlm-elements.css":1,"sites\/all\/modules\/contrib\/panels\/css\/panels.css":1,"public:\/\/ctools\/css\/263bfdb18936424f0ade19d6bd885f37.css":1,"sites\/all\/modules\/contrib\/panels_ajax_tab\/css\/panels_ajax_tab.css":1,"sites\/all\/modules\/highwire\/highwire\/highwire.style.markup.css":1,"\/\/cdn.jsdelivr.net\/qtip2\/2.2.1\/jquery.qtip.min.css":1,"sites\/all\/modules\/highwire\/highwire\/plugins\/layouts\/highwire_2col_stacked\/highwire-2col-stacked.css":1,"sites\/all\/modules\/contrib\/forward\/forward.css":1,"sites\/all\/modules\/highwire\/highwire\/plugins\/content_types\/css\/highwire_share_link.css":1,"sites\/all\/modules\/highwire\/highwire\/plugins\/content_types\/css\/highwire_copy_permalink.css":1,"sites\/all\/modules\/highwire\/highwire\/plugins\/content_types\/css\/highwire_reports_feed.css":1,"sites\/all\/modules\/highwire\/highwire\/css\/highwire-article-citation-list.css":1,"sites\/all\/modules\/highwire\/highwire\/plugins\/content_types\/css\/highwire_corrections.css":1,"sites\/all\/modules\/highwire\/highwire\/highwire_responsive\/plugins\/styles\/highwire_responsive_toggle\/highwire_responsive_toggle.css.less":1,"sites\/all\/modules\/contrib\/nice_menus\/css\/nice_menus.css":1,"sites\/all\/modules\/contrib\/nice_menus\/css\/nice_menus_default.css":1,"sites\/all\/modules\/contrib\/panels\/plugins\/layouts\/onecol\/onecol.css":1,"sites\/all\/modules\/contrib\/eu_cookie_compliance\/css\/eu_cookie_compliance.css":1,"sites\/all\/modules\/highwire\/highwire\/css\/highwire.gtranslate.css":1,"sites\/all\/themes\/highwire\/jcore_1\/css\/userbar-dropdown-menu.css":1,"sites\/all\/modules\/highwire\/highwire\/highwire_theme_tools\/css\/font-hwicons.css":1,"sites\/all\/modules\/highwire\/highwire\/highwire_theme_tools\/css\/font-hwicons-glyphs.css":1,"sites\/all\/modules\/highwire\/highwire\/plugins\/content_types\/css\/highwire_citing_links.css":1,"sites\/all\/themes\/highwire\/jcore_1\/eu_cookie_compliance.css":1,"sites\/all\/themes\/highwire\/jcore_1\/css\/font-awesome-ie7.css":1,"sites\/all\/themes\/contrib\/omega\/alpha\/css\/alpha-reset.css":1,"sites\/all\/themes\/contrib\/omega\/alpha\/css\/alpha-mobile.css":1,"sites\/all\/themes\/contrib\/omega\/alpha\/css\/alpha-alpha.css":1,"sites\/all\/themes\/contrib\/omega\/omega\/css\/formalize.css":1,"sites\/all\/themes\/contrib\/omega\/omega\/css\/omega-text.css":1,"sites\/all\/themes\/contrib\/omega\/omega\/css\/omega-branding.css":1,"sites\/all\/themes\/contrib\/omega\/omega\/css\/omega-menu.css":1,"sites\/all\/themes\/contrib\/omega\/omega\/css\/omega-forms.css":1,"sites\/all\/modules\/highwire\/highwire\/css\/highwire-forms.css":1,"sites\/all\/themes\/highwire\/jcore_1\/css\/mobile-reset.css":1,"sites\/all\/themes\/highwire\/jcore_1\/css\/font-awesome.css":1,"sites\/all\/themes\/highwire\/jcore_1\/css\/forms.css":1,"sites\/all\/themes\/highwire\/jcore_1\/css\/global.css":1,"sites\/all\/themes\/highwire\/jcore_1\/css\/jquery-ui-elements.css":1,"sites\/all\/themes\/highwire\/jcore_1\/css\/text.css":1,"sites\/all\/themes\/highwire\/jcore_1\/css\/eletters.css":1,"sites\/all\/themes\/highwire\/jcore_1\/css\/colors.css.less":1,"ie::normal::sites\/all\/themes\/highwire\/jcore_1\/css\/jcore-1-jcore-default.css":1,"ie::normal::sites\/all\/themes\/highwire\/jcore_1\/css\/jcore-1-jcore-default-normal.css":1,"ie::normal::sites\/all\/themes\/highwire\/jcore_1\/css\/grid\/jcore_default\/normal\/jcore-default-normal-30.css":1,"narrow::sites\/all\/themes\/highwire\/jcore_1\/css\/jcore-1-jcore-default.css":1,"narrow::sites\/all\/themes\/highwire\/jcore_1\/css\/jcore-1-jcore-default-narrow.css":1,"sites\/all\/themes\/highwire\/jcore_1\/css\/grid\/jcore_default\/narrow\/jcore-default-narrow-30.css":1,"normal::sites\/all\/themes\/highwire\/jcore_1\/css\/jcore-1-jcore-default.css":1,"normal::sites\/all\/themes\/highwire\/jcore_1\/css\/jcore-1-jcore-default-normal.css":1,"sites\/all\/themes\/highwire\/jcore_1\/css\/grid\/jcore_default\/normal\/jcore-default-normal-30.css":1,"wide::sites\/all\/themes\/highwire\/jcore_1\/css\/jcore-1-jcore-default.css":1,"wide::sites\/all\/themes\/highwire\/jcore_1\/css\/jcore-1-jcore-default-wide.css":1,"sites\/all\/themes\/highwire\/jcore_1\/css\/grid\/jcore_default\/wide\/jcore-default-wide-30.css":1,"sites\/all\/modules\/shared\/jnl_iiar_styles\/css\/jnl_iiar_styles.css.less":1},"js":{"sites\/all\/libraries\/enquire.js\/enquire.min.js":1,"sites\/all\/modules\/highwire\/highwire\/plugins\/content_types\/js\/highwire_panels_ajax_tab.js":1,"sites\/all\/modules\/highwire\/highwire\/plugins\/highwire_markup_process\/js\/highwire_google_scholar_sprinkle.js":1,"sites\/all\/modules\/highwire\/highwire\/plugins\/highwire_markup_process\/js\/highwire_openurl.js":1,"sites\/all\/modules\/highwire\/highwire\/plugins\/highwire_markup_process\/js\/highwire_tables.js":1,"sites\/all\/libraries\/lazysizes\/lazysizes.min.js":1,"sites\/all\/modules\/highwire\/highwire\/plugins\/highwire_markup_process\/js\/highwire_figures.js":1,"sites\/all\/modules\/highwire\/highwire\/highwire_user\/plugins\/content_types\/js\/highwire_user_salutation.js":1,"sites\/all\/modules\/highwire\/highwire\/highwire_foxycart\/highwire_foxycart.js":1,"sites\/all\/modules\/contrib\/eu_cookie_compliance\/js\/eu_cookie_compliance.js":1,"sites\/all\/libraries\/modernizr\/modernizr.min.js":1,"sites\/all\/modules\/contrib\/jquery_update\/replace\/jquery\/1.8\/jquery.min.js":1,"misc\/jquery-extend-3.4.0.js":1,"misc\/jquery.once.js":1,"misc\/drupal.js":1,"sites\/all\/modules\/contrib\/jquery_update\/replace\/ui\/ui\/minified\/jquery.ui.core.min.js":1,"sites\/all\/modules\/contrib\/jquery_update\/replace\/ui\/ui\/minified\/jquery.ui.widget.min.js":1,"sites\/all\/modules\/contrib\/jquery_update\/replace\/ui\/external\/jquery.cookie.js":1,"sites\/all\/modules\/contrib\/jquery_update\/replace\/misc\/jquery.form.min.js":1,"sites\/all\/modules\/contrib\/jquery_update\/replace\/ui\/ui\/minified\/jquery.ui.button.min.js":1,"sites\/all\/modules\/contrib\/jquery_update\/replace\/ui\/ui\/minified\/jquery.ui.mouse.min.js":1,"sites\/all\/modules\/contrib\/jquery_update\/replace\/ui\/ui\/minified\/jquery.ui.draggable.min.js":1,"sites\/all\/modules\/contrib\/jquery_update\/replace\/ui\/ui\/minified\/jquery.ui.position.min.js":1,"sites\/all\/modules\/contrib\/jquery_update\/replace\/ui\/ui\/minified\/jquery.ui.resizable.min.js":1,"sites\/all\/modules\/contrib\/jquery_update\/replace\/ui\/ui\/minified\/jquery.ui.dialog.min.js":1,"sites\/all\/modules\/contrib\/jquery_update\/replace\/ui\/ui\/minified\/jquery.ui.tooltip.min.js":1,"sites\/all\/modules\/contrib\/jquery_update\/replace\/ui\/ui\/minified\/jquery.ui.accordion.min.js":1,"sites\/all\/libraries\/jquery.bgiframe\/jquery.bgiframe.js":1,"sites\/all\/libraries\/jquery.hoverIntent\/jquery.hoverIntent.js":1,"sites\/all\/libraries\/superfish\/superfish.js":1,"sites\/all\/modules\/contrib\/nice_menus\/js\/nice_menus.js":1,"misc\/ajax.js":1,"sites\/all\/modules\/contrib\/jquery_update\/js\/jquery_update.js":1,"sites\/all\/modules\/highwire\/highwire\/js\/highwire.equal-heights.js":1,"sites\/all\/modules\/highwire\/highwire\/js\/highwire.panels-ajax-tab.js":1,"sites\/all\/libraries\/colorbox\/jquery.colorbox-min.js":1,"sites\/all\/modules\/contrib\/colorbox\/js\/colorbox.js":1,"sites\/all\/modules\/contrib\/colorbox\/styles\/default\/colorbox_style.js":1,"sites\/all\/modules\/contrib\/foxycart\/foxycart.js":1,"sites\/all\/modules\/highwire\/highwire\/highwire_log\/highwire_log.js":1,"sites\/all\/modules\/highwire\/highwire\/highwire_user\/js\/highwire_user_meta.js":1,"sites\/all\/modules\/contrib\/panels_ajax_tab\/js\/panels_ajax_tab.js":1,"sites\/all\/modules\/highwire\/highwire\/plugins\/highwire_markup_process\/js\/highwire_at_symbol.js":1,"\/\/cdn.jsdelivr.net\/qtip2\/2.2.1\/jquery.qtip.min.js":1,"sites\/all\/modules\/highwire\/highwire\/plugins\/highwire_markup_process\/js\/highwire_article_reference_popup.js":1,"misc\/progress.js":1,"sites\/all\/modules\/contrib\/captcha\/captcha.js":1,"misc\/textarea.js":1,"sites\/all\/modules\/highwire\/highwire\/highwire_citation\/plugins\/content_types\/js\/highwire_citation_export.js":1,"sites\/all\/modules\/highwire\/highwire\/plugins\/content_types\/js\/minipanel_dialog_link.js":1,"sites\/all\/modules\/highwire\/highwire\/plugins\/content_types\/js\/highwire_share_dialog.js":1,"sites\/all\/modules\/highwire\/highwire\/plugins\/content_types\/js\/clipboard.min.js":1,"sites\/all\/modules\/highwire\/highwire\/plugins\/content_types\/js\/highwire_clipboard.js":1,"sites\/all\/modules\/contrib\/service_links\/js\/twitter_button.js":1,"sites\/all\/modules\/contrib\/service_links\/js\/facebook_like.js":1,"sites\/all\/modules\/contrib\/service_links\/js\/google_plus_one.js":1,"sites\/all\/modules\/highwire\/highwire\/highwire_search\/plugins\/content_types\/js\/highwire_search_similar_articles.js":1,"sites\/all\/modules\/contrib\/panels_accordion\/js\/panels_accordion.js":1,"sites\/all\/modules\/highwire\/highwire\/highwire_responsive\/plugins\/styles\/highwire_responsive_toggle\/highwire_responsive_toggle.js":1,"sites\/all\/modules\/highwire\/highwire\/js\/highwire.gtranslate.js":1,"sites\/all\/modules\/highwire\/highwire\/plugins\/content_types\/js\/highwire_article_nav.js":1,"sites\/all\/modules\/highwire\/highwire\/plugins\/content_types\/js\/highwire_nav_float.js":1,"sites\/all\/modules\/highwire\/highwire\/js\/highwire.article-citation-access.js":1,"sites\/all\/modules\/highwire\/highwire\/js\/highwire.article-citation-author-tooltip.js":1,"sites\/all\/themes\/highwire\/jcore_1\/js\/theme-scripts.js":1,"sites\/all\/themes\/contrib\/omega\/omega\/js\/jquery.formalize.js":1,"sites\/all\/themes\/contrib\/omega\/omega\/js\/omega-mediaqueries.js":1,"sites\/all\/themes\/contrib\/omega\/omega\/js\/omega-equalheights.js":1,"sites\/all\/modules\/highwire\/highwire\/highwire_responsive\/js\/highwire-mediaqueries.js":1,"sites\/all\/modules\/contrib\/picture\/picturefill2\/picturefill.min.js":1,"sites\/all\/modules\/contrib\/picture\/picture.min.js":1,"\/\/cdn.foxycart.com\/iiar.ecommerce.highwire.org\/loader.js":1,"https:\/\/scholar.google.com\/scholar_js\/casa.js":1}},"colorbox":{"opacity":"0.85","current":"{current} of {total}","previous":"\u00ab Prev","next":"Next \u00bb","close":"Close","maxWidth":"98%","maxHeight":"98%","fixed":true,"mobiledetect":true,"mobiledevicewidth":"480px"},"highwire":{"nid":"83129","apath":"\/anticanres\/45\/2\/639.atom","pisa":"anticanres;45\/2\/639","ac":{"\/anticanres\/45\/2\/639.atom":{"access":{"full":true},"pisa_id":"","apath":"\/anticanres\/45\/2\/639.atom","jcode":"anticanres"},"anticanres;45\/2\/639":{"access":{"full":true},"pisa_id":"anticanres;45\/2\/639","apath":"","jcode":"anticanres"}},"processed":["highwire_math"],"markup":[{"requested":"long","variant":"full-text","view":"full","pisa":"anticanres;45\/2\/639"},{"requested":"full-text","variant":"full-text","view":"full","pisa":"anticanres;45\/2\/639"},{"requested":"full-text","variant":"full-text","view":"full","pisa":"anticanres;45\/2\/639"}],"modal_window_width":"560","share_modal_width":"560","share_modal_title":"Share this Article"},"user_uid":0,"customer_email":"","cartstack_siteid":"","foxycart_subdomain":"iiar.ecommerce.highwire.org","foxycart_always_show_cart_link":1,"hw_fc_cookie_domain":".iiarjournals.org","highwire_panel_tabs":[{"panel_name":"jnl_iiar_tab_pdf","panel_ajax_tab":"jnl_iiar_tab_pdf"}],"panel_ajax_tab":{"path":"sites\/all\/modules\/contrib\/panels_ajax_tab"},"instances":"{\u0022highwire_abstract_tooltip\u0022:{\u0022content\u0022:{\u0022text\u0022:\u0022\u0022},\u0022style\u0022:{\u0022tip\u0022:{\u0022width\u0022:20,\u0022height\u0022:20,\u0022border\u0022:1,\u0022offset\u0022:0,\u0022corner\u0022:true},\u0022classes\u0022:\u0022qtip-custom hw-tooltip hw-abstract-tooltip qtip-shadow qtip-rounded\u0022,\u0022classes_custom\u0022:\u0022hw-tooltip hw-abstract-tooltip\u0022},\u0022position\u0022:{\u0022at\u0022:\u0022right center\u0022,\u0022my\u0022:\u0022left center\u0022,\u0022viewport\u0022:true,\u0022adjust\u0022:{\u0022method\u0022:\u0022shift\u0022}},\u0022show\u0022:{\u0022event\u0022:\u0022mouseenter click \u0022,\u0022solo\u0022:true},\u0022hide\u0022:{\u0022event\u0022:\u0022mouseleave \u0022,\u0022fixed\u0022:1,\u0022delay\u0022:\u0022100\u0022}},\u0022highwire_author_tooltip\u0022:{\u0022content\u0022:{\u0022text\u0022:\u0022\u0022},\u0022style\u0022:{\u0022tip\u0022:{\u0022width\u0022:15,\u0022height\u0022:15,\u0022border\u0022:1,\u0022offset\u0022:0,\u0022corner\u0022:true},\u0022classes\u0022:\u0022qtip-custom hw-tooltip hw-author-tooltip qtip-shadow qtip-rounded\u0022,\u0022classes_custom\u0022:\u0022hw-tooltip hw-author-tooltip\u0022},\u0022position\u0022:{\u0022at\u0022:\u0022top center\u0022,\u0022my\u0022:\u0022bottom center\u0022,\u0022viewport\u0022:true,\u0022adjust\u0022:{\u0022method\u0022:\u0022\u0022}},\u0022show\u0022:{\u0022event\u0022:\u0022mouseenter \u0022,\u0022solo\u0022:true},\u0022hide\u0022:{\u0022event\u0022:\u0022mouseleave \u0022,\u0022fixed\u0022:1,\u0022delay\u0022:\u0022100\u0022}},\u0022highwire_reflinks_tooltip\u0022:{\u0022content\u0022:{\u0022text\u0022:\u0022\u0022},\u0022style\u0022:{\u0022tip\u0022:{\u0022width\u0022:15,\u0022height\u0022:15,\u0022border\u0022:1,\u0022mimic\u0022:\u0022top center\u0022,\u0022offset\u0022:0,\u0022corner\u0022:true},\u0022classes\u0022:\u0022qtip-custom hw-tooltip hw-ref-link-tooltip qtip-shadow qtip-rounded\u0022,\u0022classes_custom\u0022:\u0022hw-tooltip hw-ref-link-tooltip\u0022},\u0022position\u0022:{\u0022at\u0022:\u0022bottom left\u0022,\u0022my\u0022:\u0022top left\u0022,\u0022viewport\u0022:true,\u0022adjust\u0022:{\u0022method\u0022:\u0022flip\u0022}},\u0022show\u0022:{\u0022event\u0022:\u0022mouseenter \u0022,\u0022solo\u0022:true},\u0022hide\u0022:{\u0022event\u0022:\u0022mouseleave \u0022,\u0022fixed\u0022:1,\u0022delay\u0022:\u0022100\u0022}}}","qtipDebug":"{\u0022leaveElement\u0022:0}","ajax":{"edit-submit--3":{"callback":"highwire_alerts_login_form_submit","wrapper":"alerts-form-wrapper","event":"click","url":"\/system\/ajax","submit":{"_triggering_element_name":"op","_triggering_element_value":"Submit"}}},"urlIsAjaxTrusted":{"\/system\/ajax":true,"\/content\/45\/2\/639":true},"ws_fl":{"width":100,"height":21},"ws_gpo":{"size":"","annotation":"","lang":"","callback":"","width":300},"highwire_search_similar_articles":{"highwire-search-similar-articles-list-1":{"conf":{"context":"requiredcontext_entity:node_1","override_title":1,"override_title_text":"\u003Ci class=\u0022icon-caret-right\u0022\u003E\u003C\/i\u003E Similar Articles","number_per_page":"5","show_pager":0,"more_link_path":"similar\/articles","more_link":1,"empty_message":"No similar articles are available.","citation_style":"jcore_standard","title_type":"prefer_short","title_as_link":0,"display_subtitle":0,"choose_pubdate":"ppubdate","display_markup_snippet":"","display_original_link":0,"display_access_indicator":0,"display_cme_link":0,"display_access_indicator_text":0,"display_highlight_image":"0","display_variants":0,"display_supplements":0,"display_abstract_tooltip":0,"display_author_tooltip":0,"override_title_heading":"h2","citation_settings_source":"citation_manager","citation_manager_wrapper":{"citation_manager_citation":"jcore_list_title_only"},"corpus_config_wrapper":{"corpus_config_citation_context":[]},"cache_enabled":1,"cache_time":"600","short_title_options":{"char_count":"50","add_ellipsis":0},"access_indicator_settings":{"open_access":{"icon":"icon-unlock","title":"Open Access"},"user_access":{"icon":"icon-ok-sign","title":"You have access"},"no_access":{"icon":"icon-lock","title":"Restricted access"}},"pdf_download":{"display_pdf_download":0,"pdf_download_icon":"icon-cloud-download","pdf_download_text":"PDF"},"include_on_behalf":1,"show_mark_citation":0,"display_infotrieve_link":0,"infotrieve_link_settings":{"icon":"icon-usd","link_caption":"Order full text via Infotrieve"},"highlight_image_style":"","featured_image_variant":"large","featured_image_click_image":"colorbox","display_google_scholar_tooltip":1,"display_pubmed_tooltip":1,"display_advanced_search_tooltip":1,"display_author_landing_page_tooltip":1,"display_orcid_tooltip":0,"display_ads_search_tooltip":0,"display_agricola_tooltip":0,"author_site_search_path":"","display_translations":0,"display_translations_text":"","display_translations_text_icon":"","bundle_overrides_checkboxes":{"highwire_book_fragment":{"selector":0},"highwire_news_story":{"selector":0},"highwire_book_edition":{"selector":0},"highwire_article":{"selector":0},"highwire_issue":{"selector":0},"highwire_comment":{"selector":0},"highwire_fragment":{"selector":0},"highwire_book_section":{"selector":0},"highwire_journal":{"selector":0}},"bundle_overrides":{"highwire_book_fragment":{"selector":0,"citation_style":"jcore_title_and_author","cache_enabled":1,"cache_time":"600","title_type":"full","short_title_options":{"char_count":"50","add_ellipsis":0},"title_as_link":0,"display_subtitle":0,"choose_pubdate":"ppubdate","display_markup_snippet":"","highlight_image_toggle":0,"display_original_link":0,"display_access_indicator":"0","access_indicator_settings":{"open_access":{"icon":"icon-unlock","title":"Open Access"},"user_access":{"icon":"icon-ok-sign","title":"You have access"},"no_access":{"icon":"icon-lock","title":"Restricted access"}},"display_variants":0,"display_supplements":0,"pdf_download":{"display_pdf_download":0,"pdf_download_icon":"icon-cloud-download","pdf_download_text":"PDF"},"include_on_behalf":1,"cpath_prefix":"\/content","show_mark_citation":0,"display_infotrieve_link":0,"infotrieve_link_settings":{"icon":"icon-usd","link_caption":"Order full text via Infotrieve"},"display_highlight_image":0,"highlight_image_style":"thumbnail","display_fragment_caption":1,"display_parent_citation":1,"parent_citation_type":"highwire_book_section","parent_citation_settings":{"citation_style":"folio_book_sections_standard","cache_enabled":1,"cache_time":"600","title_type":"full","short_title_options":{"char_count":"50","add_ellipsis":0},"title_as_link":0,"display_subtitle":0,"choose_pubdate":"ppubdate","display_markup_snippet":"","highlight_image_toggle":0,"display_original_link":0,"display_access_indicator":0,"access_indicator_settings":{"open_access":{"icon":"icon-unlock","title":"Open Access"},"user_access":{"icon":"icon-ok-sign","title":"You have access"},"no_access":{"icon":"icon-lock","title":"Restricted access"}},"display_variants":0,"display_supplements":0,"pdf_download":{"display_pdf_download":0,"pdf_download_icon":"icon-cloud-download","pdf_download_text":"PDF"},"include_on_behalf":1,"cpath_prefix":"\/content","show_mark_citation":0,"display_infotrieve_link":0,"infotrieve_link_settings":{"icon":"icon-usd","link_caption":"Order full text via Infotrieve"},"display_highlight_image":0,"highlight_image_style":"","display_abstract_tooltip":0,"display_author_tooltip":0,"display_google_scholar_tooltip":1,"display_pubmed_tooltip":1,"display_advanced_search_tooltip":1,"display_author_landing_page_tooltip":0,"author_site_search_path":"search\/"}},"highwire_news_story":{"selector":0,"citation_style":"mla","cache_enabled":1,"cache_time":"600","title_type":"full","short_title_options":{"char_count":"50","add_ellipsis":0},"title_as_link":0,"display_subtitle":0,"choose_pubdate":"ppubdate","display_markup_snippet":"","highlight_image_toggle":0,"display_original_link":0,"display_access_indicator":0,"access_indicator_settings":{"open_access":{"icon":"icon-unlock","title":"Open Access"},"user_access":{"icon":"icon-ok-sign","title":"You have access"},"no_access":{"icon":"icon-lock","title":"Restricted access"}},"display_variants":0,"display_supplements":0,"pdf_download":{"display_pdf_download":0,"pdf_download_icon":"icon-cloud-download","pdf_download_text":"PDF"},"include_on_behalf":1,"cpath_prefix":"\/content","show_mark_citation":0,"display_infotrieve_link":0,"infotrieve_link_settings":{"icon":"icon-usd","link_caption":"Order full text via Infotrieve"},"display_highlight_image":"0","highlight_image_style":"","featured_image_click_image":"nothing","display_author_tooltip":0,"display_google_scholar_tooltip":0,"display_pubmed_tooltip":0,"display_advanced_search_tooltip":0},"highwire_book_edition":{"selector":0,"citation_style":"folio_books_standard","cache_enabled":1,"cache_time":"600","title_type":"full","short_title_options":{"char_count":"50","add_ellipsis":0},"title_as_link":0,"display_subtitle":0,"choose_pubdate":"ppubdate","display_markup_snippet":"","highlight_image_toggle":0,"display_original_link":0,"display_access_indicator":0,"access_indicator_settings":{"open_access":{"icon":"icon-unlock","title":"Open Access"},"user_access":{"icon":"icon-ok-sign","title":"You have access"},"no_access":{"icon":"icon-lock","title":"Restricted access"}},"display_variants":0,"display_supplements":0,"pdf_download":{"display_pdf_download":0,"pdf_download_icon":"icon-cloud-download","pdf_download_text":"PDF"},"include_on_behalf":1,"cpath_prefix":"\/content","show_mark_citation":0,"display_infotrieve_link":0,"infotrieve_link_settings":{"icon":"icon-usd","link_caption":"Order full text via Infotrieve"},"display_highlight_image":0,"highlight_image_style":"","display_author_tooltip":0,"display_google_scholar_tooltip":1,"display_pubmed_tooltip":1,"display_advanced_search_tooltip":1,"display_author_landing_page_tooltip":1,"display_orcid_tooltip":1,"author_site_search_path":"search\/"},"highwire_article":{"selector":0,"citation_style":"mla","cache_enabled":1,"cache_time":"600","title_type":"full","short_title_options":{"char_count":"50","add_ellipsis":0},"title_as_link":0,"display_subtitle":0,"choose_pubdate":"ppubdate","display_markup_snippet":"","highlight_image_toggle":0,"display_original_link":0,"display_access_indicator":0,"access_indicator_settings":{"open_access":{"icon":"icon-unlock","title":"Open Access"},"user_access":{"icon":"icon-ok-sign","title":"You have access"},"no_access":{"icon":"icon-lock","title":"Restricted access"}},"display_variants":0,"display_supplements":0,"pdf_download":{"display_pdf_download":0,"pdf_download_icon":"icon-cloud-download","pdf_download_text":"PDF"},"include_on_behalf":0,"cpath_prefix":"\/content","show_mark_citation":0,"display_infotrieve_link":0,"infotrieve_link_settings":{"icon":"icon-usd","link_caption":"Order full text via Infotrieve"},"display_highlight_image":"0","highlight_image_style":"","featured_image_variant":"large","featured_image_click_image":"nothing","display_cme_link":0,"display_abstract_tooltip":0,"display_author_tooltip":0,"display_google_scholar_tooltip":1,"display_pubmed_tooltip":1,"display_advanced_search_tooltip":1,"display_author_landing_page_tooltip":1,"display_orcid_tooltip":1,"display_ads_search_tooltip":0,"display_agricola_tooltip":0,"author_site_search_path":"search\/","display_translations":0,"display_translations_text":"Translations Available","display_translations_text_icon":"icon-globe"},"highwire_issue":{"selector":0,"citation_style":"mla","cache_enabled":1,"cache_time":"600","title_type":"full","short_title_options":{"char_count":"50","add_ellipsis":0},"title_as_link":0,"display_subtitle":0,"choose_pubdate":"ppubdate","display_markup_snippet":"","highlight_image_toggle":0,"display_original_link":0,"display_access_indicator":0,"access_indicator_settings":{"open_access":{"icon":"icon-unlock","title":"Open Access"},"user_access":{"icon":"icon-ok-sign","title":"You have access"},"no_access":{"icon":"icon-lock","title":"Restricted access"}},"display_variants":0,"display_supplements":0,"pdf_download":{"display_pdf_download":0,"pdf_download_icon":"icon-cloud-download","pdf_download_text":"PDF"},"include_on_behalf":1,"cpath_prefix":"\/content","show_mark_citation":0,"display_infotrieve_link":0,"infotrieve_link_settings":{"icon":"icon-usd","link_caption":"Order full text via Infotrieve"},"display_highlight_image":0,"highlight_image_style":"","featured_image_click_image":"nothing","display_author_tooltip":0,"display_google_scholar_tooltip":1,"display_pubmed_tooltip":1,"display_advanced_search_tooltip":1,"display_author_landing_page_tooltip":0,"display_orcid_tooltip":1,"author_site_search_path":"search\/"},"highwire_comment":{"selector":0,"citation_style":"highwire_comment","show_title":0,"title_as_link":0,"title_as_link_type":"tab_view","author_format_type":"fullname","author_format_custom":"","author_list_separator":", ","date_format":"(j F Y)","display_comment_body":1,"display_attachment":1,"display_conflict_of_interest":1},"highwire_fragment":{"selector":0,"citation_style":"jcore_title_and_author","cache_enabled":1,"cache_time":"600","title_type":"full","short_title_options":{"char_count":"50","add_ellipsis":0},"title_as_link":0,"display_subtitle":0,"choose_pubdate":"ppubdate","display_markup_snippet":"","highlight_image_toggle":0,"display_original_link":0,"display_access_indicator":"0","access_indicator_settings":{"open_access":{"icon":"icon-unlock","title":"Open Access"},"user_access":{"icon":"icon-ok-sign","title":"You have access"},"no_access":{"icon":"icon-lock","title":"Restricted access"}},"display_variants":0,"display_supplements":0,"pdf_download":{"display_pdf_download":0,"pdf_download_icon":"icon-cloud-download","pdf_download_text":"PDF"},"include_on_behalf":1,"cpath_prefix":"\/content","show_mark_citation":0,"display_infotrieve_link":0,"infotrieve_link_settings":{"icon":"icon-usd","link_caption":"Order full text via Infotrieve"},"display_highlight_image":0,"highlight_image_style":"","display_fragment_caption":1,"fragment_image_settings":{"fragment_image_variant":"medium","fragment_click_image":"colorbox","show_download_links":1},"display_parent_citation":1,"parent_citation_type":"highwire_article","parent_citation_settings":{"citation_style":"mla","cache_enabled":1,"cache_time":"600","title_type":"full","short_title_options":{"char_count":"50","add_ellipsis":0},"title_as_link":0,"display_subtitle":0,"choose_pubdate":"ppubdate","display_markup_snippet":"","highlight_image_toggle":0,"display_original_link":0,"display_access_indicator":0,"access_indicator_settings":{"open_access":{"icon":"icon-unlock","title":"Open Access"},"user_access":{"icon":"icon-ok-sign","title":"You have access"},"no_access":{"icon":"icon-lock","title":"Restricted access"}},"display_variants":0,"display_supplements":0,"pdf_download":{"display_pdf_download":0,"pdf_download_icon":"icon-cloud-download","pdf_download_text":"PDF"},"include_on_behalf":0,"cpath_prefix":"\/content","show_mark_citation":0,"display_infotrieve_link":0,"infotrieve_link_settings":{"icon":"icon-usd","link_caption":"Order full text via Infotrieve"},"display_highlight_image":"0","highlight_image_style":"","featured_image_variant":"large","featured_image_click_image":"nothing","display_cme_link":0,"display_abstract_tooltip":0,"display_author_tooltip":0,"display_google_scholar_tooltip":1,"display_pubmed_tooltip":1,"display_advanced_search_tooltip":1,"display_author_landing_page_tooltip":1,"display_orcid_tooltip":1,"display_ads_search_tooltip":0,"display_agricola_tooltip":0,"author_site_search_path":"search\/","display_translations":0,"display_translations_text":"Translations Available","display_translations_text_icon":"icon-globe"}},"highwire_book_section":{"selector":0,"citation_style":"folio_book_sections_standard","cache_enabled":1,"cache_time":"600","title_type":"full","short_title_options":{"char_count":"50","add_ellipsis":0},"title_as_link":0,"display_subtitle":0,"choose_pubdate":"ppubdate","display_markup_snippet":"","highlight_image_toggle":0,"display_original_link":0,"display_access_indicator":0,"access_indicator_settings":{"open_access":{"icon":"icon-unlock","title":"Open Access"},"user_access":{"icon":"icon-ok-sign","title":"You have access"},"no_access":{"icon":"icon-lock","title":"Restricted access"}},"display_variants":0,"display_supplements":0,"pdf_download":{"display_pdf_download":0,"pdf_download_icon":"icon-cloud-download","pdf_download_text":"PDF"},"include_on_behalf":1,"cpath_prefix":"\/content","show_mark_citation":0,"display_infotrieve_link":0,"infotrieve_link_settings":{"icon":"icon-usd","link_caption":"Order full text via Infotrieve"},"display_highlight_image":0,"highlight_image_style":"","display_abstract_tooltip":0,"display_author_tooltip":0,"display_google_scholar_tooltip":1,"display_pubmed_tooltip":1,"display_advanced_search_tooltip":1,"display_author_landing_page_tooltip":0,"author_site_search_path":"search\/"},"highwire_journal":{"selector":0,"citation_style":"mla","cache_enabled":1,"cache_time":"600","title_type":"full","short_title_options":{"char_count":"50","add_ellipsis":0},"title_as_link":0,"display_subtitle":0,"choose_pubdate":"ppubdate","display_markup_snippet":"","highlight_image_toggle":0,"display_original_link":0,"display_access_indicator":0,"access_indicator_settings":{"open_access":{"icon":"icon-unlock","title":"Open Access"},"user_access":{"icon":"icon-ok-sign","title":"You have access"},"no_access":{"icon":"icon-lock","title":"Restricted access"}},"display_variants":0,"display_supplements":0,"pdf_download":{"display_pdf_download":0,"pdf_download_icon":"icon-cloud-download","pdf_download_text":"PDF"},"include_on_behalf":1,"cpath_prefix":"\/content","show_mark_citation":0,"display_infotrieve_link":0,"infotrieve_link_settings":{"icon":"icon-usd","link_caption":"Order full text via Infotrieve"},"display_highlight_image":0,"highlight_image_style":"","display_author_tooltip":0,"display_google_scholar_tooltip":1,"display_pubmed_tooltip":1,"display_advanced_search_tooltip":1,"display_author_landing_page_tooltip":0,"display_orcid_tooltip":1,"author_site_search_path":"search\/"}},"cpath_prefix":"\/content","ajax_loading_icon_classes":"icon-spinner icon-spin icon-2x","ajax_loading_text":"","highlight_image_toggle":0,"more_link_label":"See more","url_parameters":{"q":"node\/83129"}},"nid":"83129"}},"panels_accordion":{"highwire_article_accordion_container":{"heightStyle":"content","autoHeight":false,"collapsible":0,"region_accordion_id":"highwire_article_accordion_container","active":0,"animated":"slide"}},"color":{"logo":"https:\/\/ar.iiarjournals.org\/sites\/default\/files\/ar-700_wide_0.png"},"HighWireFoxycart":{"link_text":"Add to Cart (%short-price)","link_icon":""},"nice_menus_options":{"delay":800,"speed":"fast"},"eu_cookie_compliance":{"popup_enabled":true,"popup_agreed_enabled":false,"popup_hide_agreed":false,"popup_clicking_confirmation":true,"popup_scrolling_confirmation":false,"popup_html_info":"\u003Cdiv\u003E\n \u003Cdiv class=\u0022popup-content info\u0022\u003E\n \u003Cdiv id=\u0022popup-text\u0022\u003E\n \u003Ch2\u003EWe use cookies on this site to enhance your user experience\u003C\/h2\u003E\u003Cp\u003EBy clicking any link on this page you are giving your consent for us to set cookies.\u003C\/p\u003E \u003C\/div\u003E\n \u003Cdiv id=\u0022popup-buttons\u0022\u003E\n \u003Cbutton type=\u0022button\u0022 role=\u0022dialog\u0022 aria-labelledby=\u0022OK, I agree\u0022\n class=\u0022agree-button eu-cookie-compliance-default-button\u0022\u003EOK, I agree\u003C\/button\u003E\n \u003Cbutton type=\u0022button\u0022 role=\u0022dialog\u0022 aria-labelledby=\u0022More info\u0022\n class=\u0022find-more-button eu-cookie-compliance-more-button\u0022\u003EMore info\u003C\/button\u003E\n \u003C\/div\u003E\n \u003C\/div\u003E\n\u003C\/div\u003E","use_mobile_message":false,"mobile_popup_html_info":"\u003Cdiv\u003E\n \u003Cdiv class=\u0022popup-content info\u0022\u003E\n \u003Cdiv id=\u0022popup-text\u0022\u003E\n \u003C\/div\u003E\n \u003Cdiv id=\u0022popup-buttons\u0022\u003E\n \u003Cbutton type=\u0022button\u0022 role=\u0022dialog\u0022 aria-labelledby=\u0022OK, I agree\u0022\n class=\u0022agree-button eu-cookie-compliance-default-button\u0022\u003EOK, I agree\u003C\/button\u003E\n \u003Cbutton type=\u0022button\u0022 role=\u0022dialog\u0022 aria-labelledby=\u0022More info\u0022\n class=\u0022find-more-button eu-cookie-compliance-more-button\u0022\u003EMore info\u003C\/button\u003E\n \u003C\/div\u003E\n \u003C\/div\u003E\n\u003C\/div\u003E","mobile_breakpoint":"768","popup_html_agreed":"\u003Cdiv\u003E\n \u003Cdiv class=\u0022popup-content agreed\u0022\u003E\n \u003Cdiv id=\u0022popup-text\u0022\u003E\n \u003Ch2\u003EThank you for accepting cookies\u003C\/h2\u003E\u003Cp\u003EYou can now hide this message or find out more about cookies.\u003C\/p\u003E \u003C\/div\u003E\n \u003Cdiv id=\u0022popup-buttons\u0022\u003E\n \u003Cbutton type=\u0022button\u0022 class=\u0022hide-popup-button eu-cookie-compliance-hide-button\u0022\u003EHide\u003C\/button\u003E\n \u003Cbutton type=\u0022button\u0022 class=\u0022find-more-button eu-cookie-compliance-more-button-thank-you\u0022 \u003EMore info\u003C\/button\u003E\n \u003C\/div\u003E\n \u003C\/div\u003E\n\u003C\/div\u003E","popup_use_bare_css":false,"popup_height":"auto","popup_width":"100%","popup_delay":1000,"popup_link":"\/help\/cookie-policy","popup_link_new_window":1,"popup_position":null,"popup_language":"en","store_consent":false,"better_support_for_screen_readers":0,"reload_page":0,"domain":"","popup_eu_only_js":0,"cookie_lifetime":365,"cookie_session":false,"disagree_do_not_show_popup":0,"method":"default","whitelisted_cookies":"","withdraw_markup":"\u003Cbutton type=\u0022button\u0022 class=\u0022eu-cookie-withdraw-tab\u0022\u003EPrivacy settings\u003C\/button\u003E\n\u003Cdiv class=\u0022eu-cookie-withdraw-banner\u0022\u003E\n \u003Cdiv class=\u0022popup-content info\u0022\u003E\n \u003Cdiv id=\u0022popup-text\u0022\u003E\n \u003Ch2\u003EWe use cookies on this site to enhance your user experience\u003C\/h2\u003E\u003Cp\u003EYou have given your consent for us to set cookies.\u003C\/p\u003E \u003C\/div\u003E\n \u003Cdiv id=\u0022popup-buttons\u0022\u003E\n \u003Cbutton type=\u0022button\u0022 class=\u0022eu-cookie-withdraw-button\u0022\u003EWithdraw consent\u003C\/button\u003E\n \u003C\/div\u003E\n \u003C\/div\u003E\n\u003C\/div\u003E\n","withdraw_enabled":false},"highwireResponsive":{"enquire_enabled":1,"breakpoints_configured":1,"breakpoints":{"zero":"all and (min-width: 0px)","xsmall":"all and (min-width: 380px)","narrow":"all and (min-width: 768px) and (min-device-width: 768px), (max-device-width: 800px) and (min-width: 768px) and (orientation:landscape)","normal":"all and (min-width: 980px) and (min-device-width: 980px), all and (max-device-width: 1024px) and (min-width: 1024px) and (orientation:landscape)","wide":"all and (min-width: 1220px)"}},"omega":{"layouts":{"primary":"normal","order":["narrow","normal","wide"],"queries":{"narrow":"all and (min-width: 768px) and (min-device-width: 768px), (max-device-width: 800px) and (min-width: 768px) and (orientation:landscape)","normal":"all and (min-width: 980px) and (min-device-width: 980px), all and (max-device-width: 1024px) and (min-width: 1024px) and (orientation:landscape)","wide":"all and (min-width: 1220px)"}}}}); //--><!]]> </script> <!--[if lt IE 9]><script src="http://html5shiv.googlecode.com/svn/trunk/html5.js"></script><![endif]--> </head> <body class="html not-front not-logged-in page-node page-node- page-node-83129 node-type-highwire-article context-content hw-default-jcode-anticanres hw-article-type-research-article hw-article-category-clinical-studies"> <div id="skip-link"> <a href="#main-content" class="element-invisible element-focusable">Skip to main content</a> </div> <div class="page clearfix page-box-shadows footer-borders panels-page panels-layout-jcore_2col" id="page"> <header id="section-header" class="section section-header"> <div id="zone-superheader-wrapper" class="zone-wrapper zone-superheader-wrapper clearfix mobile-only print-hidden"> <div id="zone-superheader" class="zone zone-superheader clearfix mobile-only print-hidden container-30"> <div class="grid-30 region region-superheader" id="region-superheader"> <div class="region-inner region-superheader-inner"> <div class="block block-panels-mini block-responsive-menu block-panels-mini-responsive-menu odd block-without-title" id="block-panels-mini-responsive-menu"> <div class="block-inner clearfix"> <div class="content clearfix"> <div class="panel-display panel-1col clearfix" id="mini-panel-responsive_menu"> <div class="panel-panel panel-col"> <div><div id="unique-id3" class="highwire-responsive-toggle-group"><div class="panel-pane pane-panels-mini pane-responsive-menu-main-menu" > <h2 class="pane-title"><span class="icon-reorder"></span><span class="element-invisible">Main menu</span></h2> <div class="pane-content"> <div class="panel-display panel-1col clearfix" id="mini-panel-responsive_menu_main_menu"> <div class="panel-panel panel-col"> <div><div class="panel-pane pane-menu-tree pane-main-menu" > <div class="pane-content"> <div class="menu-block-wrapper menu-block-ctools-main-menu-1 menu-name-main-menu parent-mlid-main-menu:0 menu-level-1"> <nav class="menubar-nav"><ul class="menu" role="menu"><li class="first leaf menu-mlid-734" role="menuitem"><a href="/" class="" data-icon-position="" data-hide-link-title="0">Home</a></li> <li class="expanded active-trail menu-mlid-736" role="menuitem"><a href="/content/current" data-hide-link-title="0" class="active active-trail" data-icon-position="">Current Issue</a></li> <li class="leaf menu-mlid-738" role="menuitem"><a href="/content/by/year" class="" data-icon-position="" data-hide-link-title="0">Archive</a></li> <li class="expanded menu-mlid-739" role="menuitem"><a href="/content/instructions-authors" data-hide-link-title="0" class="" data-icon-position="">Info for</a><nav class="menubar-nav"><ul class="menu" role="menu"><li class="first leaf menu-mlid-740" role="menuitem"><a href="/content/instructions-authors" class="" data-icon-position="" data-hide-link-title="0">Authors</a></li> <li class="leaf menu-mlid-1535" role="menuitem"><a href="/page/https%3A//ar.iiarjournals.org/content/editorial-policies-2024" data-hide-link-title="0" class="" data-icon-position="">Editorial Policies</a></li> <li class="leaf menu-mlid-742" role="menuitem"><a href="/content/subscriptions" data-hide-link-title="0" class="" data-icon-position="">Subscribers</a></li> <li class="leaf menu-mlid-744" role="menuitem"><a href="/content/information-advertisers" data-hide-link-title="0" class="" data-icon-position="">Advertisers</a></li> <li class="leaf menu-mlid-749" role="menuitem"><a href="/node/61603/" data-hide-link-title="0" class="" data-icon-position="">Editorial Board</a></li> <li class="last leaf menu-mlid-1699" role="menuitem"><a href="/content/special-issues-2025" data-hide-link-title="0" class="" data-icon-position="">Special Issues 2025</a></li> </ul></nav></li> <li class="leaf menu-mlid-1698" role="menuitem"><a href="/content/journal-metrics" data-hide-link-title="0" class="" data-icon-position="">Journal Metrics</a></li> <li class="expanded menu-mlid-1328" role="menuitem"><a href="/feedback" data-hide-link-title="0" title="Other Publications" class="" data-icon-position="">Other Publications</a><nav class="menubar-nav"><ul class="menu" role="menu"><li class="first leaf menu-mlid-1329" role="menuitem"><a href="//iv.iiarjournals.org/" data-hide-link-title="0" title="In Vivo" class="" data-icon-position="">In Vivo</a></li> <li class="leaf menu-mlid-1330" role="menuitem"><a href="//cgp.iiarjournals.org/" data-hide-link-title="0" title="Cancer Genomics & Proteomics" class="" data-icon-position="">Cancer Genomics & Proteomics</a></li> <li class="last leaf menu-mlid-1446" role="menuitem"><a href="http://www.cancerdiagnosisprognosis.org/" data-hide-link-title="0" target="_blank" class="" data-icon-position="">Cancer Diagnosis & Prognosis</a></li> </ul></nav></li> <li class="expanded menu-mlid-750" role="menuitem"><a href="/content/advertising" class="" data-icon-position="" data-hide-link-title="0">More</a><nav class="menubar-nav"><ul class="menu" role="menu"><li class="first leaf menu-mlid-1331" role="menuitem"><a href="https://iiar-anticancer.org/" data-hide-link-title="0" title="IIAR" class="" data-icon-position="">IIAR</a></li> <li class="leaf menu-mlid-1327" role="menuitem"><a href="http://www.iiar-anticancer.org/conference/" data-hide-link-title="0" title="Conferences" class="" data-icon-position="">Conferences</a></li> <li class="last leaf menu-mlid-1326" role="menuitem"><a href="/help/email-alert-change-email" data-hide-link-title="0" title="2008 Nobel Laureates" class="" data-icon-position="">2008 Nobel Laureates</a></li> </ul></nav></li> <li class="last expanded menu-mlid-746" role="menuitem"><a href="/content/general-policy" data-hide-link-title="0" class="" data-icon-position="">About Us</a><nav class="menubar-nav"><ul class="menu" role="menu"><li class="first leaf menu-mlid-747" role="menuitem"><a href="/content/general-policy" data-hide-link-title="0" class="" data-icon-position="">General Policy</a></li> <li class="last leaf menu-mlid-753" role="menuitem"><a href="/feedback" data-hide-link-title="0" title="Contact us" class="" data-icon-position="">Contact</a></li> </ul></nav></li> </ul></nav></div> </div> </div> <div class="panel-separator"></div><div class="panel-pane pane-menu-tree pane-umbrella-menu" > <div class="pane-content"> <div class="menu-block-wrapper menu-block-ctools-umbrella-menu-1 menu-name-umbrella-menu parent-mlid-umbrella-menu:0 menu-level-1"> <nav class="menubar-nav"><ul class="menu" role="menu"><li class="first last expanded menu-mlid-728" role="menuitem"><a href="/" class="" data-icon-position="" data-hide-link-title="0">Other Publications</a><nav class="menubar-nav"><ul class="menu" role="menu"><li class="first leaf menu-mlid-729" role="menuitem"><a href="/" data-hide-link-title="0" class="" data-icon-position="">Anticancer Research</a></li> <li class="leaf menu-mlid-1384" role="menuitem"><a href="//iv.iiarjournals.org/" data-hide-link-title="0" class="" data-icon-position="">In Vivo</a></li> <li class="last leaf menu-mlid-1385" role="menuitem"><a href="//cgp.iiarjournals.org/" data-hide-link-title="0" class="" data-icon-position="">Cancer Genomics & Proteomics</a></li> </ul></nav></li> </ul></nav></div> </div> </div> </div> </div> </div> </div> </div> <div class="panel-pane pane-panels-mini pane-responsive-menu-user-menu" > <h2 class="pane-title"><span class="icon-gear"></span><span class="element-invisible">User menu</span></h2> <div class="pane-content"> <div class="panel-display panel-1col clearfix" id="mini-panel-responsive_menu_user_menu"> <div class="panel-panel panel-col"> <div><div class="panel-pane pane-menu-tree pane-user-menu" > <div class="pane-content"> <div class="menu-block-wrapper menu-block-ctools-user-menu-1 menu-name-user-menu parent-mlid-user-menu:0 menu-level-1"> <nav class="menubar-nav"><ul class="menu" role="menu"><li class="first leaf menu-mlid-762" role="menuitem"><a href="/user/register" class="" data-icon-position="" data-hide-link-title="0">Register</a></li> <li class="leaf menu-mlid-763" role="menuitem"><a href="/" class="" data-icon-position="" data-hide-link-title="0">Subscribe</a></li> <li class="leaf menu-mlid-764" role="menuitem"><a href="/alerts" class="" data-icon-position="" data-hide-link-title="0">My alerts</a></li> <li class="leaf menu-mlid-765" role="menuitem"><a href="/user/login?destination=/content/45/2/639" class="" data-icon-position="" data-hide-link-title="0">Log in</a></li> <li class="last leaf menu-mlid-1250" role="menuitem"><a href="/cart" class="link-icon-only link-icon"><span class="icon-shopping-cart"></span> <span class="title element-invisible">My Cart</span></a></li> </ul></nav></div> </div> </div> <div class="panel-separator"></div><div class="panel-pane pane-highwire-user-identities" > <div class="pane-content"> <div class="highwire-user-message" data-separator="|"><span class="highwire-user-institution" data-id-type="institution" data-identity="a%3A2%3A%7Bs%3A4%3A%22show%22%3Bi%3A1%3Bs%3A7%3A%22message%22%3Bs%3A50%3A%22Institution%3A%20%5Bidentity%3Ainstitutional_display_name%5D%22%3B%7D"></span></div> </div> </div> </div> </div> </div> </div> </div> <div class="panel-pane pane-panels-mini pane-responsive-menu-search" > <h2 class="pane-title"><span class="icon-search"></span><span class="element-invisible">Search</span></h2> <div class="pane-content"> <div class="panel-display panel-1col clearfix" id="mini-panel-responsive_menu_search"> <div class="panel-panel panel-col"> <div><div class="panel-pane pane-highwire-seach-qsearch-nocontext" > <div class="pane-content"> <form class="highwire-quicksearch button-style-mini button-style-mini" action="/content/45/2/639" method="post" id="highwire-search-qsearch-nocontext-form" accept-charset="UTF-8"><div><div class="form-item form-item-label-invisible form-type-textfield form-item-keywords"> <label class="element-invisible" for="quick_search_header_keywords_2137396919">Search for this keyword </label> <input placeholder="Search..." type="text" id="quick_search_header_keywords_2137396919" name="keywords" value="" size="60" maxlength="128" class="form-text" /> </div> <div class="button-wrapper button-mini"><span class="icon-search"></span><input data-icon-only="1" data-font-icon="icon-search" data-icon-position="after" type="submit" id="quick_search_header_submit_116865498" name="op" value="Search" class="form-submit" /></div><input type="hidden" name="form_build_id" value="form-M-CnXr-Iu_qDiWzszaN7MWgiQyLtG1TAZaKJgMKVGHI" /> <input type="hidden" name="form_id" value="highwire_search_qsearch_nocontext_form" /> </div></form> </div> </div> <div class="panel-separator"></div><div class="panel-pane pane-custom pane-1 highwire-responsive-advanced-search-link pane-menu-tree" > <div class="pane-content"> <ul class="menu"> <li><a href="/search" title="Advanced search">Advanced search</a></li> </ul> </div> </div> </div> </div> </div> </div> </div> </div></div> </div> </div> </div> </div> </div><div class="block block-panels-mini block-hw-small-logo block-panels-mini-hw-small-logo even block-without-title" id="block-panels-mini-hw-small-logo"> <div class="block-inner clearfix"> <div class="content clearfix"> <div class="panel-display panel-1col clearfix" id="mini-panel-hw_small_logo"> <div class="panel-panel panel-col"> <div><div class="panel-pane pane-small-logo" > <div class="pane-content"> <a href="/" class="" data-icon-position="" data-hide-link-title="0"><img src="https://ar.iiarjournals.org/sites/default/files/ar-350_wide.png" alt="Anticancer Research" title="Anticancer Research" /></a> </div> </div> </div> </div> </div> </div> </div> </div> </div> </div> </div> </div><div id="zone-user-wrapper" class="zone-wrapper zone-user-wrapper clearfix zone-wrapper-twotone-bg mobile-hidden print-hidden"> <div id="zone-user" class="zone zone-user clearfix equal-height-container zone-twotone-bg mobile-hidden print-hidden container-30"> <div class="twotone-bg-region twotone-bg-region-first"></div> <div class="twotone-bg-region twotone-bg-region-second"></div> <div class="grid-10 region region-user-first equal-height-element" id="region-user-first"> <div class="region-inner region-user-first-inner"> <div class="block block-nice-menus block-2 block-nice-menus-2 odd block-without-title" id="block-nice-menus-2"> <div class="block-inner clearfix"> <div class="content clearfix user-menu-dropdown"> <nav class="menubar-nav"><ul class="nice-menu nice-menu-down nice-menu-umbrella-menu" id="nice-menu-2" role="menu"><li class="menu-728 menuparent menu-path-front first odd last" role="menuitem"><a href="/" class="" data-icon-position="" data-hide-link-title="0">Other Publications</a><ul role="menu"><li class="menu-729 menu-path-front first odd " role="menuitem"><a href="/" data-hide-link-title="0" class="" data-icon-position="">Anticancer Research</a></li> <li class="menu-1384 menu-path---iviiarjournalsorg- even " role="menuitem"><a href="//iv.iiarjournals.org/" data-hide-link-title="0" class="" data-icon-position="">In Vivo</a></li> <li class="menu-1385 menu-path---cgpiiarjournalsorg- odd last" role="menuitem"><a href="//cgp.iiarjournals.org/" data-hide-link-title="0" class="" data-icon-position="">Cancer Genomics & Proteomics</a></li> </ul></li> </ul></nav> </div> </div> </div> </div> </div><div class="grid-20 region region-user-second equal-height-element" id="region-user-second"> <div class="region-inner region-user-second-inner"> <div class="block block-panels-mini highwire-uid-string block-jnl-iiar-uid-strng block-panels-mini-jnl-iiar-uid-strng odd block-without-title" id="block-panels-mini-jnl-iiar-uid-strng"> <div class="block-inner clearfix"> <div class="content clearfix"> <div class="panel-display panel-1col clearfix" id="mini-panel-jnl_iiar_uid_strng"> <div class="panel-panel panel-col"> <div><div class="panel-pane pane-highwire-user-identities" > <div class="pane-content"> <div class="highwire-user-message" data-separator=" | "><span class="highwire-user-institution" data-id-type="institution" data-identity="a%3A2%3A%7Bs%3A4%3A%22show%22%3Bi%3A1%3Bs%3A7%3A%22message%22%3Bs%3A85%3A%22%3Cspan%20class%3D%22narrow-hidden%22%3EInstitution%3A%20%3C%2Fspan%3E%5Bidentity%3Ainstitutional_display_name%5D%22%3B%7D"></span></div> </div> </div> <div class="panel-pane pane-block pane-system-user-menu links inline pane-system" > <div class="pane-content"> <nav class="menubar-nav"><ul class="menu" role="menu"><li class="first leaf" role="menuitem"><a href="/user/register" class="" data-icon-position="" data-hide-link-title="0">Register</a></li> <li class="leaf" role="menuitem"><a href="/" class="" data-icon-position="" data-hide-link-title="0">Subscribe</a></li> <li class="leaf" role="menuitem"><a href="/alerts" class="" data-icon-position="" data-hide-link-title="0">My alerts</a></li> <li class="leaf" role="menuitem"><a href="/user/login?destination=/content/45/2/639" class="" data-icon-position="" data-hide-link-title="0">Log in</a></li> <li class="last leaf" role="menuitem"><a href="/cart" class="link-icon-only link-icon"><span class="icon-shopping-cart"></span> <span class="title element-invisible">My Cart</span></a></li> </ul></nav> </div> </div> </div> </div> </div> </div> </div> </div> </div> </div> </div> </div> <div id="zone-branding" class="zone zone-branding clearfix mobile-hidden print-display-block container-30"> <div class="grid-19 prefix-1 region region-branding print-display-block" id="region-branding"> <div class="region-inner region-branding-inner"> <div class="branding-data clearfix"> <div class="logo-img"> <a href="/" rel="home" class="" data-icon-position="" data-hide-link-title="0"><img alt="Anticancer Research" src="https://ar.iiarjournals.org/sites/default/files/ar-700_wide_0.png" /></a> </div> </div> </div> </div><div class="grid-9 suffix-1 region region-branding-second print-hidden" id="region-branding-second"> <div class="region-inner region-branding-second-inner"> <div class="block block-panels-mini block-jnl-iiar-search-box block-panels-mini-jnl-iiar-search-box odd block-without-title" id="block-panels-mini-jnl-iiar-search-box"> <div class="block-inner clearfix"> <div class="content clearfix"> <div class="panel-display panel-1col clearfix" id="mini-panel-jnl_iiar_search_box"> <div class="panel-panel panel-col"> <div><div class="panel-pane pane-highwire-seach-quicksearch no-margin-bottom" > <div class="pane-content"> <form class="highwire-quicksearch button-style-mini button-style-mini" action="/content/45/2/639" method="post" id="highwire-search-quicksearch-form-0" accept-charset="UTF-8"><div><div class="form-item form-item-label-invisible form-type-textfield form-item-keywords"> <label class="element-invisible" for="search_rightsidebar_keywords_1428629998">Search for this keyword </label> <input placeholder="search" type="text" id="search_rightsidebar_keywords_1428629998" name="keywords" value="" size="60" maxlength="128" class="form-text" /> </div> <div class="button-wrapper button-mini"><span class="icon-search"></span><input data-icon-only="1" data-font-icon="icon-search" data-icon-position="after" type="submit" id="search_rightsidebar_submit_73937182" name="op" value="Search" class="form-submit" /></div><input type="hidden" name="form_build_id" value="form-Q5a88BIkhYHEgQlqcfL4-Hha596BY5sMh8gWAwSA610" /> <input type="hidden" name="form_id" value="highwire_search_quicksearch_form_0" /> </div></form> </div> </div> <div class="panel-separator"></div><div class="panel-pane pane-custom pane-2" > <div class="pane-content"> <p><a href="/search">Advanced Search</a></p> </div> </div> </div> </div> </div> </div> </div> </div> </div> </div> </div> <div id="zone-menu" class="zone zone-menu clearfix mobile-hidden container-30"> <div class="grid-28 suffix-1 prefix-1 region region-menu main-menu-active-caret" id="region-menu"> <div class="region-inner region-menu-inner region-menu-bg-opaque"> <div class="block block-nice-menus block-1 block-nice-menus-1 odd block-without-title" id="block-nice-menus-1"> <div class="block-inner clearfix"> <div class="content clearfix"> <nav class="menubar-nav"><ul class="nice-menu nice-menu-down nice-menu-main-menu" id="nice-menu-1" role="menu"><li class="menu-734 menu-path-front first odd " role="menuitem"><a href="/" class="" data-icon-position="" data-hide-link-title="0">Home</a></li> <li class="menu-736 menu-path-content-current active-trail even " role="menuitem"><a href="/content/current" data-hide-link-title="0" class="active" data-icon-position="">Current Issue</a></li> <li class="menu-738 menu-path-content-by-year odd " role="menuitem"><a href="/content/by/year" class="" data-icon-position="" data-hide-link-title="0">Archive</a></li> <li class="menu-739 menuparent menu-path-node-1 even " role="menuitem"><a href="/content/instructions-authors" data-hide-link-title="0" class="" data-icon-position="">Info for</a><ul role="menu"><li class="menu-740 menu-path-node-1 first odd " role="menuitem"><a href="/content/instructions-authors" class="" data-icon-position="" data-hide-link-title="0">Authors</a></li> <li class="menu-1535 menu-path-node-75276 even " role="menuitem"><a href="/page/https%3A//ar.iiarjournals.org/content/editorial-policies-2024" data-hide-link-title="0" class="" data-icon-position="">Editorial Policies</a></li> <li class="menu-742 menu-path-node-3 odd " role="menuitem"><a href="/content/subscriptions" data-hide-link-title="0" class="" data-icon-position="">Subscribers</a></li> <li class="menu-744 menu-path-node-5 even " role="menuitem"><a href="/content/information-advertisers" data-hide-link-title="0" class="" data-icon-position="">Advertisers</a></li> <li class="menu-749 menu-path-node-61603- odd " role="menuitem"><a href="/node/61603/" data-hide-link-title="0" class="" data-icon-position="">Editorial Board</a></li> <li class="menu-1699 menu-path-node-81984 even last" role="menuitem"><a href="/content/special-issues-2025" data-hide-link-title="0" class="" data-icon-position="">Special Issues 2025</a></li> </ul></li> <li class="menu-1698 menu-path-node-81243 odd " role="menuitem"><a href="/content/journal-metrics" data-hide-link-title="0" class="" data-icon-position="">Journal Metrics</a></li> <li class="menu-1328 menuparent menu-path-node-10 even " role="menuitem"><a href="/feedback" data-hide-link-title="0" title="Other Publications" class="" data-icon-position="">Other Publications</a><ul role="menu"><li class="menu-1329 menu-path---iviiarjournalsorg- first odd " role="menuitem"><a href="//iv.iiarjournals.org/" data-hide-link-title="0" title="In Vivo" class="" data-icon-position="">In Vivo</a></li> <li class="menu-1330 menu-path---cgpiiarjournalsorg- even " role="menuitem"><a href="//cgp.iiarjournals.org/" data-hide-link-title="0" title="Cancer Genomics & Proteomics" class="" data-icon-position="">Cancer Genomics & Proteomics</a></li> <li class="menu-1446 menu-path-cancerdiagnosisprognosisorg- odd last" role="menuitem"><a href="http://www.cancerdiagnosisprognosis.org/" data-hide-link-title="0" target="_blank" class="" data-icon-position="">Cancer Diagnosis & Prognosis</a></li> </ul></li> <li class="menu-750 menuparent menu-path-node-9 odd " role="menuitem"><a href="/content/advertising" class="" data-icon-position="" data-hide-link-title="0">More</a><ul role="menu"><li class="menu-1331 menu-path-siiar-anticancerorg- first odd " role="menuitem"><a href="https://iiar-anticancer.org/" data-hide-link-title="0" title="IIAR" class="" data-icon-position="">IIAR</a></li> <li class="menu-1327 menu-path-iiar-anticancerorg-conference- even " role="menuitem"><a href="http://www.iiar-anticancer.org/conference/" data-hide-link-title="0" title="Conferences" class="" data-icon-position="">Conferences</a></li> <li class="menu-1326 menu-path-node-12 odd last" role="menuitem"><a href="/help/email-alert-change-email" data-hide-link-title="0" title="2008 Nobel Laureates" class="" data-icon-position="">2008 Nobel Laureates</a></li> </ul></li> <li class="menu-746 menuparent menu-path-node-7 even last" role="menuitem"><a href="/content/general-policy" data-hide-link-title="0" class="" data-icon-position="">About Us</a><ul role="menu"><li class="menu-747 menu-path-node-7 first odd " role="menuitem"><a href="/content/general-policy" data-hide-link-title="0" class="" data-icon-position="">General Policy</a></li> <li class="menu-753 menu-path-node-10 even last" role="menuitem"><a href="/feedback" data-hide-link-title="0" title="Contact us" class="" data-icon-position="">Contact</a></li> </ul></li> </ul></nav> </div> </div> </div><div class="block block-menu text-right block-menu-social-media block-menu-menu-social-media even block-without-title" id="block-menu-menu-social-media"> <div class="block-inner clearfix"> <div class="content clearfix"> <nav class="menubar-nav"><ul class="menu" role="menu"><li class="first leaf" role="menuitem"><a href="https://www.facebook.com/Anticancer-Research-115717456498174" target="_blank" class="link-icon-only link-icon"><span class="icon-facebook-sign icon-2x"></span> <span class="title element-invisible">Visit us on Facebook</span></a></li> <li class="last leaf" role="menuitem"><a href="https://www.linkedin.com/company/28898783/admin/" target="_blank" class="link-icon-only link-icon"><span class="icon-linkedin-sign icon-2x"></span> <span class="title element-invisible">Follow us on Linkedin</span></a></li> </ul></nav> </div> </div> </div> </div> </div> </div> <div id="zone-header" class="zone zone-header clearfix container-30"> </div> </header> <section id="section-content" class="section section-content"> <div id="zone-content" class="zone zone-content clearfix container-30"> <div class="grid-28 suffix-1 prefix-1 region region-content" id="region-content"> <div class="region-inner region-content-inner"> <a id="main-content"></a> <div class="block block-system block-main block-system-main odd block-without-title" id="block-system-main"> <div class="block-inner clearfix"> <div class="content clearfix"> <div class="panel-display panels-960-layout jcore-2col-layout" > <div class="panel-row-wrapper panel-row-first clearfix"> <div class="top-wrapper"> <div class="panel-panel panel-region-top"> <div class="inside"><div class="panel-pane pane-highwire-article-citation" > <div class="pane-content"> <div class="highwire-article-citation highwire-citation-type-highwire-article node83129--5" data-node-nid="83129" id="top-node-83129--6530904863" data-pisa="anticanres;45/2/639" data-pisa-master="anticanres;45/2/639" data-apath="/anticanres/45/2/639.atom" data-hw-author-tooltip-instance="highwire_author_tooltip"><div class="highwire-cite highwire-cite-highwire-article highwire-citation-jcore-article-title-complete clearfix has-author-tooltip highwire-citation-highwire-article-top-a"> <div class="highwire-cite-overline"><span class="highwire-cite-metadata-article-type highwire-cite-metadata">Research Article</span><span class="separator-pipe"></span><span class="highwire-cite-metadata-art-cat highwire-cite-metadata"><span class="wrapper">Clinical Studies</span></span></div> <div class="highwire-cite-access"><span class="highwire-citation-access"><i class="highwire-access-icon highwire-access-icon-open-access open-access hw-icon-open-access" title="Open Access" aria-hidden="true"></i><span class="element-invisible highwire-access-icon highwire-access-icon-open-access" style="">Open Access</span></span></div> <h1 class="highwire-cite-title" id="page-title">Efficacy of Second-line Nivolumab <em>Versus</em> Tyrosine Kinase Inhibitors for Renal Cell Carcinoma With Bone Metastases</h1> <div class="highwire-cite-authors"><span class="highwire-citation-authors"><span class="highwire-citation-author first" data-delta="0">GAKU YAMAMICHI</span>, <span class="highwire-citation-author" data-delta="1">TAIGO KATO</span>, <span class="highwire-citation-author" data-delta="2">AKIHIRO YOSHIMURA</span>, <span class="highwire-citation-author" data-delta="3">MASARU TANI</span>, <span class="highwire-citation-author" data-delta="4">YUKI HORIBE</span>, <span class="highwire-citation-author" data-delta="5">YUTONG LIU</span>, <span class="highwire-citation-author" data-delta="6">NESRINE SASSI</span>, <span class="highwire-citation-author" data-delta="7">YOHEI OKUDA</span>, <span class="highwire-citation-author" data-delta="8">TOSHIKI OKA</span>, <span class="highwire-citation-author" data-delta="9">TOSHIHIRO UEMURA</span>, <span class="highwire-citation-author" data-delta="10">AKINARU YAMAMOTO</span>, <span class="highwire-citation-author" data-delta="11">YU ISHIZUYA</span>, <span class="highwire-citation-author" data-delta="12">TAKUJI HAYASHI</span>, <span class="highwire-citation-author" data-delta="13">YOSHIYUKI YAMAMOTO</span>, <span class="highwire-citation-author" data-delta="14">KOJI HATANO</span>, <span class="highwire-citation-author" data-delta="15">ATSUNARI KAWASHIMA</span>, <span class="highwire-citation-author" data-delta="16">TETSUYA TAKAO</span>, <span class="highwire-citation-author" data-delta="17">KENSAKU NISHIMURA</span>, <span class="highwire-citation-author" data-delta="18">SHINGO TAKADA</span>, <span class="highwire-citation-author" data-delta="19">MASAO TSUJIHATA</span> and <span class="highwire-citation-author" data-delta="20">NORIO NONOMURA</span></span></div> <div class="highwire-cite-metadata"><span class="highwire-cite-metadata-journal highwire-cite-metadata">Anticancer Research </span><span class="highwire-cite-metadata-date highwire-cite-metadata">February 2025, </span><span class="highwire-cite-metadata-volume highwire-cite-metadata">45 </span><span class="highwire-cite-metadata-issue highwire-cite-metadata">(2) </span><span class="highwire-cite-metadata-pages highwire-cite-metadata">639-650; </span><span class="highwire-cite-metadata-doi highwire-cite-metadata">DOI: https://doi.org/10.21873/anticanres.17451 </span></div> <div class="highwire-cite-extras"><span class="highwire-foxycart-add-to-cart-ahah highwire-foxycart-add-to-cart-ahah" data-text="Add to Cart (%short-price)" data-apath="/anticanres/45/2/639.atom" data-type="link" data-font-icon="" data-parent-id="83103"></span></div> </div> <div id="hw-article-author-popups-top-node-83129--6530904863" style="display: none;"><div class="author-tooltip-0"><div class="author-tooltip-name">GAKU YAMAMICHI </div><div class="author-tooltip-affiliation"><span class="author-tooltip-text"><div class='author-affiliation'><span class='nlm-sup'>1</span>Department of Urology, Osaka University Graduate School of Medicine, Osaka, Japan</div></span></div><ul class="author-tooltip-find-more"><li class="author-tooltip-gs-link first"><a href="/lookup/google-scholar?link_type=googlescholar&gs_type=author&author%5B0%5D=GAKU%2BYAMAMICHI%2B" target="_blank" class="" data-icon-position="" data-hide-link-title="0">Find this author on Google Scholar</a></li><li class="author-tooltip-pubmed-link"><a href="/lookup/external-ref?access_num=YAMAMICHI%20G&link_type=AUTHORSEARCH" target="_blank" class="" data-icon-position="" data-hide-link-title="0">Find this author on PubMed</a></li><li class="author-site-search-link last"><a href="/search/author1%3AGAKU%2BYAMAMICHI%2B" rel="nofollow" class="" data-icon-position="" data-hide-link-title="0">Search for this author on this site</a></li></ul></div><div class="author-tooltip-1"><div class="author-tooltip-name">TAIGO KATO </div><div class="author-tooltip-affiliation"><span class="author-tooltip-text"><div class='author-affiliation'><span class='nlm-sup'>1</span>Department of Urology, Osaka University Graduate School of Medicine, Osaka, Japan</div></span></div><ul class="author-tooltip-find-more"><li class="author-tooltip-gs-link first"><a href="/lookup/google-scholar?link_type=googlescholar&gs_type=author&author%5B0%5D=TAIGO%2BKATO%2B" target="_blank" class="" data-icon-position="" data-hide-link-title="0">Find this author on Google Scholar</a></li><li class="author-tooltip-pubmed-link"><a href="/lookup/external-ref?access_num=KATO%20T&link_type=AUTHORSEARCH" target="_blank" class="" data-icon-position="" data-hide-link-title="0">Find this author on PubMed</a></li><li class="author-site-search-link"><a href="/search/author1%3ATAIGO%2BKATO%2B" rel="nofollow" class="" data-icon-position="" data-hide-link-title="0">Search for this author on this site</a></li><li class="author-corresp-email-link last"><span>For correspondence: <a href="mailto:kato@uro.med.osaka-u.ac.jp" class="" data-icon-position="" data-hide-link-title="0">kato@uro.med.osaka-u.ac.jp</a></span></li></ul></div><div class="author-tooltip-2"><div class="author-tooltip-name">AKIHIRO YOSHIMURA </div><div class="author-tooltip-affiliation"><span class="author-tooltip-text"><div class='author-affiliation'><span class='nlm-sup'>1</span>Department of Urology, Osaka University Graduate School of Medicine, Osaka, Japan</div></span></div><ul class="author-tooltip-find-more"><li class="author-tooltip-gs-link first"><a href="/lookup/google-scholar?link_type=googlescholar&gs_type=author&author%5B0%5D=AKIHIRO%2BYOSHIMURA%2B" target="_blank" class="" data-icon-position="" data-hide-link-title="0">Find this author on Google Scholar</a></li><li class="author-tooltip-pubmed-link"><a href="/lookup/external-ref?access_num=YOSHIMURA%20A&link_type=AUTHORSEARCH" target="_blank" class="" data-icon-position="" data-hide-link-title="0">Find this author on PubMed</a></li><li class="author-site-search-link last"><a href="/search/author1%3AAKIHIRO%2BYOSHIMURA%2B" rel="nofollow" class="" data-icon-position="" data-hide-link-title="0">Search for this author on this site</a></li></ul></div><div class="author-tooltip-3"><div class="author-tooltip-name">MASARU TANI </div><div class="author-tooltip-affiliation"><span class="author-tooltip-text"><div class='author-affiliation'><span class='nlm-sup'>1</span>Department of Urology, Osaka University Graduate School of Medicine, Osaka, Japan</div></span></div><ul class="author-tooltip-find-more"><li class="author-tooltip-gs-link first"><a href="/lookup/google-scholar?link_type=googlescholar&gs_type=author&author%5B0%5D=MASARU%2BTANI%2B" target="_blank" class="" data-icon-position="" data-hide-link-title="0">Find this author on Google Scholar</a></li><li class="author-tooltip-pubmed-link"><a href="/lookup/external-ref?access_num=TANI%20M&link_type=AUTHORSEARCH" target="_blank" class="" data-icon-position="" data-hide-link-title="0">Find this author on PubMed</a></li><li class="author-site-search-link last"><a href="/search/author1%3AMASARU%2BTANI%2B" rel="nofollow" class="" data-icon-position="" data-hide-link-title="0">Search for this author on this site</a></li></ul></div><div class="author-tooltip-4"><div class="author-tooltip-name">YUKI HORIBE </div><div class="author-tooltip-affiliation"><span class="author-tooltip-text"><div class='author-affiliation'><span class='nlm-sup'>1</span>Department of Urology, Osaka University Graduate School of Medicine, Osaka, Japan</div></span></div><ul class="author-tooltip-find-more"><li class="author-tooltip-gs-link first"><a href="/lookup/google-scholar?link_type=googlescholar&gs_type=author&author%5B0%5D=YUKI%2BHORIBE%2B" target="_blank" class="" data-icon-position="" data-hide-link-title="0">Find this author on Google Scholar</a></li><li class="author-tooltip-pubmed-link"><a href="/lookup/external-ref?access_num=HORIBE%20Y&link_type=AUTHORSEARCH" target="_blank" class="" data-icon-position="" data-hide-link-title="0">Find this author on PubMed</a></li><li class="author-site-search-link last"><a href="/search/author1%3AYUKI%2BHORIBE%2B" rel="nofollow" class="" data-icon-position="" data-hide-link-title="0">Search for this author on this site</a></li></ul></div><div class="author-tooltip-5"><div class="author-tooltip-name">YUTONG LIU </div><div class="author-tooltip-affiliation"><span class="author-tooltip-text"><div class='author-affiliation'><span class='nlm-sup'>1</span>Department of Urology, Osaka University Graduate School of Medicine, Osaka, Japan</div></span></div><ul class="author-tooltip-find-more"><li class="author-tooltip-gs-link first"><a href="/lookup/google-scholar?link_type=googlescholar&gs_type=author&author%5B0%5D=YUTONG%2BLIU%2B" target="_blank" class="" data-icon-position="" data-hide-link-title="0">Find this author on Google Scholar</a></li><li class="author-tooltip-pubmed-link"><a href="/lookup/external-ref?access_num=LIU%20Y&link_type=AUTHORSEARCH" target="_blank" class="" data-icon-position="" data-hide-link-title="0">Find this author on PubMed</a></li><li class="author-site-search-link last"><a href="/search/author1%3AYUTONG%2BLIU%2B" rel="nofollow" class="" data-icon-position="" data-hide-link-title="0">Search for this author on this site</a></li></ul></div><div class="author-tooltip-6"><div class="author-tooltip-name">NESRINE SASSI </div><div class="author-tooltip-affiliation"><span class="author-tooltip-text"><div class='author-affiliation'><span class='nlm-sup'>1</span>Department of Urology, Osaka University Graduate School of Medicine, Osaka, Japan</div></span></div><ul class="author-tooltip-find-more"><li class="author-tooltip-gs-link first"><a href="/lookup/google-scholar?link_type=googlescholar&gs_type=author&author%5B0%5D=NESRINE%2BSASSI%2B" target="_blank" class="" data-icon-position="" data-hide-link-title="0">Find this author on Google Scholar</a></li><li class="author-tooltip-pubmed-link"><a href="/lookup/external-ref?access_num=SASSI%20N&link_type=AUTHORSEARCH" target="_blank" class="" data-icon-position="" data-hide-link-title="0">Find this author on PubMed</a></li><li class="author-site-search-link last"><a href="/search/author1%3ANESRINE%2BSASSI%2B" rel="nofollow" class="" data-icon-position="" data-hide-link-title="0">Search for this author on this site</a></li></ul></div><div class="author-tooltip-7"><div class="author-tooltip-name">YOHEI OKUDA </div><div class="author-tooltip-affiliation"><span class="author-tooltip-text"><div class='author-affiliation'><span class='nlm-sup'>1</span>Department of Urology, Osaka University Graduate School of Medicine, Osaka, Japan</div></span></div><ul class="author-tooltip-find-more"><li class="author-tooltip-gs-link first"><a href="/lookup/google-scholar?link_type=googlescholar&gs_type=author&author%5B0%5D=YOHEI%2BOKUDA%2B" target="_blank" class="" data-icon-position="" data-hide-link-title="0">Find this author on Google Scholar</a></li><li class="author-tooltip-pubmed-link"><a href="/lookup/external-ref?access_num=OKUDA%20Y&link_type=AUTHORSEARCH" target="_blank" class="" data-icon-position="" data-hide-link-title="0">Find this author on PubMed</a></li><li class="author-site-search-link last"><a href="/search/author1%3AYOHEI%2BOKUDA%2B" rel="nofollow" class="" data-icon-position="" data-hide-link-title="0">Search for this author on this site</a></li></ul></div><div class="author-tooltip-8"><div class="author-tooltip-name">TOSHIKI OKA </div><div class="author-tooltip-affiliation"><span class="author-tooltip-text"><div class='author-affiliation'><span class='nlm-sup'>1</span>Department of Urology, Osaka University Graduate School of Medicine, Osaka, Japan</div></span></div><ul class="author-tooltip-find-more"><li class="author-tooltip-gs-link first"><a href="/lookup/google-scholar?link_type=googlescholar&gs_type=author&author%5B0%5D=TOSHIKI%2BOKA%2B" target="_blank" class="" data-icon-position="" data-hide-link-title="0">Find this author on Google Scholar</a></li><li class="author-tooltip-pubmed-link"><a href="/lookup/external-ref?access_num=OKA%20T&link_type=AUTHORSEARCH" target="_blank" class="" data-icon-position="" data-hide-link-title="0">Find this author on PubMed</a></li><li class="author-site-search-link last"><a href="/search/author1%3ATOSHIKI%2BOKA%2B" rel="nofollow" class="" data-icon-position="" data-hide-link-title="0">Search for this author on this site</a></li></ul></div><div class="author-tooltip-9"><div class="author-tooltip-name">TOSHIHIRO UEMURA </div><div class="author-tooltip-affiliation"><span class="author-tooltip-text"><div class='author-affiliation'><span class='nlm-sup'>1</span>Department of Urology, Osaka University Graduate School of Medicine, Osaka, Japan</div></span></div><ul class="author-tooltip-find-more"><li class="author-tooltip-gs-link first"><a href="/lookup/google-scholar?link_type=googlescholar&gs_type=author&author%5B0%5D=TOSHIHIRO%2BUEMURA%2B" target="_blank" class="" data-icon-position="" data-hide-link-title="0">Find this author on Google Scholar</a></li><li class="author-tooltip-pubmed-link"><a href="/lookup/external-ref?access_num=UEMURA%20T&link_type=AUTHORSEARCH" target="_blank" class="" data-icon-position="" data-hide-link-title="0">Find this author on PubMed</a></li><li class="author-site-search-link last"><a href="/search/author1%3ATOSHIHIRO%2BUEMURA%2B" rel="nofollow" class="" data-icon-position="" data-hide-link-title="0">Search for this author on this site</a></li></ul></div><div class="author-tooltip-10"><div class="author-tooltip-name">AKINARU YAMAMOTO </div><div class="author-tooltip-affiliation"><span class="author-tooltip-text"><div class='author-affiliation'><span class='nlm-sup'>1</span>Department of Urology, Osaka University Graduate School of Medicine, Osaka, Japan</div></span></div><ul class="author-tooltip-find-more"><li class="author-tooltip-gs-link first"><a href="/lookup/google-scholar?link_type=googlescholar&gs_type=author&author%5B0%5D=AKINARU%2BYAMAMOTO%2B" target="_blank" class="" data-icon-position="" data-hide-link-title="0">Find this author on Google Scholar</a></li><li class="author-tooltip-pubmed-link"><a href="/lookup/external-ref?access_num=YAMAMOTO%20A&link_type=AUTHORSEARCH" target="_blank" class="" data-icon-position="" data-hide-link-title="0">Find this author on PubMed</a></li><li class="author-site-search-link last"><a href="/search/author1%3AAKINARU%2BYAMAMOTO%2B" rel="nofollow" class="" data-icon-position="" data-hide-link-title="0">Search for this author on this site</a></li></ul></div><div class="author-tooltip-11"><div class="author-tooltip-name">YU ISHIZUYA </div><div class="author-tooltip-affiliation"><span class="author-tooltip-text"><div class='author-affiliation'><span class='nlm-sup'>1</span>Department of Urology, Osaka University Graduate School of Medicine, Osaka, Japan</div></span></div><ul class="author-tooltip-find-more"><li class="author-tooltip-gs-link first"><a href="/lookup/google-scholar?link_type=googlescholar&gs_type=author&author%5B0%5D=YU%2BISHIZUYA%2B" target="_blank" class="" data-icon-position="" data-hide-link-title="0">Find this author on Google Scholar</a></li><li class="author-tooltip-pubmed-link"><a href="/lookup/external-ref?access_num=ISHIZUYA%20Y&link_type=AUTHORSEARCH" target="_blank" class="" data-icon-position="" data-hide-link-title="0">Find this author on PubMed</a></li><li class="author-site-search-link last"><a href="/search/author1%3AYU%2BISHIZUYA%2B" rel="nofollow" class="" data-icon-position="" data-hide-link-title="0">Search for this author on this site</a></li></ul></div><div class="author-tooltip-12"><div class="author-tooltip-name">TAKUJI HAYASHI </div><div class="author-tooltip-affiliation"><span class="author-tooltip-text"><div class='author-affiliation'><span class='nlm-sup'>1</span>Department of Urology, Osaka University Graduate School of Medicine, Osaka, Japan</div></span></div><ul class="author-tooltip-find-more"><li class="author-tooltip-gs-link first"><a href="/lookup/google-scholar?link_type=googlescholar&gs_type=author&author%5B0%5D=TAKUJI%2BHAYASHI%2B" target="_blank" class="" data-icon-position="" data-hide-link-title="0">Find this author on Google Scholar</a></li><li class="author-tooltip-pubmed-link"><a href="/lookup/external-ref?access_num=HAYASHI%20T&link_type=AUTHORSEARCH" target="_blank" class="" data-icon-position="" data-hide-link-title="0">Find this author on PubMed</a></li><li class="author-site-search-link last"><a href="/search/author1%3ATAKUJI%2BHAYASHI%2B" rel="nofollow" class="" data-icon-position="" data-hide-link-title="0">Search for this author on this site</a></li></ul></div><div class="author-tooltip-13"><div class="author-tooltip-name">YOSHIYUKI YAMAMOTO </div><div class="author-tooltip-affiliation"><span class="author-tooltip-text"><div class='author-affiliation'><span class='nlm-sup'>1</span>Department of Urology, Osaka University Graduate School of Medicine, Osaka, Japan</div></span></div><ul class="author-tooltip-find-more"><li class="author-tooltip-gs-link first"><a href="/lookup/google-scholar?link_type=googlescholar&gs_type=author&author%5B0%5D=YOSHIYUKI%2BYAMAMOTO%2B" target="_blank" class="" data-icon-position="" data-hide-link-title="0">Find this author on Google Scholar</a></li><li class="author-tooltip-pubmed-link"><a href="/lookup/external-ref?access_num=YAMAMOTO%20Y&link_type=AUTHORSEARCH" target="_blank" class="" data-icon-position="" data-hide-link-title="0">Find this author on PubMed</a></li><li class="author-site-search-link last"><a href="/search/author1%3AYOSHIYUKI%2BYAMAMOTO%2B" rel="nofollow" class="" data-icon-position="" data-hide-link-title="0">Search for this author on this site</a></li></ul></div><div class="author-tooltip-14"><div class="author-tooltip-name">KOJI HATANO </div><div class="author-tooltip-affiliation"><span class="author-tooltip-text"><div class='author-affiliation'><span class='nlm-sup'>1</span>Department of Urology, Osaka University Graduate School of Medicine, Osaka, Japan</div></span></div><ul class="author-tooltip-find-more"><li class="author-tooltip-gs-link first"><a href="/lookup/google-scholar?link_type=googlescholar&gs_type=author&author%5B0%5D=KOJI%2BHATANO%2B" target="_blank" class="" data-icon-position="" data-hide-link-title="0">Find this author on Google Scholar</a></li><li class="author-tooltip-pubmed-link"><a href="/lookup/external-ref?access_num=HATANO%20K&link_type=AUTHORSEARCH" target="_blank" class="" data-icon-position="" data-hide-link-title="0">Find this author on PubMed</a></li><li class="author-site-search-link last"><a href="/search/author1%3AKOJI%2BHATANO%2B" rel="nofollow" class="" data-icon-position="" data-hide-link-title="0">Search for this author on this site</a></li></ul></div><div class="author-tooltip-15"><div class="author-tooltip-name">ATSUNARI KAWASHIMA </div><div class="author-tooltip-affiliation"><span class="author-tooltip-text"><div class='author-affiliation'><span class='nlm-sup'>1</span>Department of Urology, Osaka University Graduate School of Medicine, Osaka, Japan</div></span></div><ul class="author-tooltip-find-more"><li class="author-tooltip-gs-link first"><a href="/lookup/google-scholar?link_type=googlescholar&gs_type=author&author%5B0%5D=ATSUNARI%2BKAWASHIMA%2B" target="_blank" class="" data-icon-position="" data-hide-link-title="0">Find this author on Google Scholar</a></li><li class="author-tooltip-pubmed-link"><a href="/lookup/external-ref?access_num=KAWASHIMA%20A&link_type=AUTHORSEARCH" target="_blank" class="" data-icon-position="" data-hide-link-title="0">Find this author on PubMed</a></li><li class="author-site-search-link last"><a href="/search/author1%3AATSUNARI%2BKAWASHIMA%2B" rel="nofollow" class="" data-icon-position="" data-hide-link-title="0">Search for this author on this site</a></li></ul></div><div class="author-tooltip-16"><div class="author-tooltip-name">TETSUYA TAKAO </div><div class="author-tooltip-affiliation"><span class="author-tooltip-text"><div class='author-affiliation'><span class='nlm-sup'>2</span>Department of Urology, Osaka General Medical Center, Osaka, Japan</div></span></div><ul class="author-tooltip-find-more"><li class="author-tooltip-gs-link first"><a href="/lookup/google-scholar?link_type=googlescholar&gs_type=author&author%5B0%5D=TETSUYA%2BTAKAO%2B" target="_blank" class="" data-icon-position="" data-hide-link-title="0">Find this author on Google Scholar</a></li><li class="author-tooltip-pubmed-link"><a href="/lookup/external-ref?access_num=TAKAO%20T&link_type=AUTHORSEARCH" target="_blank" class="" data-icon-position="" data-hide-link-title="0">Find this author on PubMed</a></li><li class="author-site-search-link last"><a href="/search/author1%3ATETSUYA%2BTAKAO%2B" rel="nofollow" class="" data-icon-position="" data-hide-link-title="0">Search for this author on this site</a></li></ul></div><div class="author-tooltip-17"><div class="author-tooltip-name">KENSAKU NISHIMURA </div><div class="author-tooltip-affiliation"><span class="author-tooltip-text"><div class='author-affiliation'><span class='nlm-sup'>3</span>Department of Urology, National Hospital Organization Osaka National Hospital, Osaka, Japan</div></span></div><ul class="author-tooltip-find-more"><li class="author-tooltip-gs-link first"><a href="/lookup/google-scholar?link_type=googlescholar&gs_type=author&author%5B0%5D=KENSAKU%2BNISHIMURA%2B" target="_blank" class="" data-icon-position="" data-hide-link-title="0">Find this author on Google Scholar</a></li><li class="author-tooltip-pubmed-link"><a href="/lookup/external-ref?access_num=NISHIMURA%20K&link_type=AUTHORSEARCH" target="_blank" class="" data-icon-position="" data-hide-link-title="0">Find this author on PubMed</a></li><li class="author-site-search-link last"><a href="/search/author1%3AKENSAKU%2BNISHIMURA%2B" rel="nofollow" class="" data-icon-position="" data-hide-link-title="0">Search for this author on this site</a></li></ul></div><div class="author-tooltip-18"><div class="author-tooltip-name">SHINGO TAKADA </div><div class="author-tooltip-affiliation"><span class="author-tooltip-text"><div class='author-affiliation'><span class='nlm-sup'>4</span>Department of Urology, Osaka Police Hospital, Osaka, Japan</div></span></div><ul class="author-tooltip-find-more"><li class="author-tooltip-gs-link first"><a href="/lookup/google-scholar?link_type=googlescholar&gs_type=author&author%5B0%5D=SHINGO%2BTAKADA%2B" target="_blank" class="" data-icon-position="" data-hide-link-title="0">Find this author on Google Scholar</a></li><li class="author-tooltip-pubmed-link"><a href="/lookup/external-ref?access_num=TAKADA%20S&link_type=AUTHORSEARCH" target="_blank" class="" data-icon-position="" data-hide-link-title="0">Find this author on PubMed</a></li><li class="author-site-search-link last"><a href="/search/author1%3ASHINGO%2BTAKADA%2B" rel="nofollow" class="" data-icon-position="" data-hide-link-title="0">Search for this author on this site</a></li></ul></div><div class="author-tooltip-19"><div class="author-tooltip-name">MASAO TSUJIHATA </div><div class="author-tooltip-affiliation"><span class="author-tooltip-text"><div class='author-affiliation'><span class='nlm-sup'>5</span>Department of Urology, Osaka Rosai Hospital, Osaka, Japan</div></span></div><ul class="author-tooltip-find-more"><li class="author-tooltip-gs-link first"><a href="/lookup/google-scholar?link_type=googlescholar&gs_type=author&author%5B0%5D=MASAO%2BTSUJIHATA%2B" target="_blank" class="" data-icon-position="" data-hide-link-title="0">Find this author on Google Scholar</a></li><li class="author-tooltip-pubmed-link"><a href="/lookup/external-ref?access_num=TSUJIHATA%20M&link_type=AUTHORSEARCH" target="_blank" class="" data-icon-position="" data-hide-link-title="0">Find this author on PubMed</a></li><li class="author-site-search-link last"><a href="/search/author1%3AMASAO%2BTSUJIHATA%2B" rel="nofollow" class="" data-icon-position="" data-hide-link-title="0">Search for this author on this site</a></li></ul></div><div class="author-tooltip-20"><div class="author-tooltip-name">NORIO NONOMURA </div><div class="author-tooltip-affiliation"><span class="author-tooltip-text"><div class='author-affiliation'><span class='nlm-sup'>1</span>Department of Urology, Osaka University Graduate School of Medicine, Osaka, Japan</div></span></div><ul class="author-tooltip-find-more"><li class="author-tooltip-gs-link first"><a href="/lookup/google-scholar?link_type=googlescholar&gs_type=author&author%5B0%5D=NORIO%2BNONOMURA%2B" target="_blank" class="" data-icon-position="" data-hide-link-title="0">Find this author on Google Scholar</a></li><li class="author-tooltip-pubmed-link"><a href="/lookup/external-ref?access_num=NONOMURA%20N&link_type=AUTHORSEARCH" target="_blank" class="" data-icon-position="" data-hide-link-title="0">Find this author on PubMed</a></li><li class="author-site-search-link last"><a href="/search/author1%3ANORIO%2BNONOMURA%2B" rel="nofollow" class="" data-icon-position="" data-hide-link-title="0">Search for this author on this site</a></li></ul></div></div></div> </div> </div> </div> </div> </div> </div> <!-- /.panel-row-wrapper --> <div class="panel-row-wrapper clearfix"> <div class="main-content-wrapper grid-17 suffix-1 alpha"> <div class="panel-panel panel-region-content"> <div class="inside"><div class="panel-pane pane-highwire-panel-tabs pane-panels-ajax-tab-tabs" > <div class="pane-content"> <div class="item-list"><ul class="tabs inline panels-ajax-tab"><li class="first"><a href="/content/45/2/639" class="panels-ajax-tab-tab" data-panel-name="jnl_iiar_tab_art" data-target-id="highwire_article_tabs" data-entity-context="node:83129" data-trigger="" data-url-enabled="1">Article</a><a href="/panels_ajax_tab/jnl_iiar_tab_art/node:83129/1" rel="nofollow" style="display:none" class="js-crawler-link"></a></li><li><a href="/content/45/2/639/tab-figures-data" class="panels-ajax-tab-tab" data-panel-name="jnl_iiar_tab_data" data-target-id="highwire_article_tabs" data-entity-context="node:83129" data-trigger="tab-figures-data" data-url-enabled="1">Figures & Data</a><a href="/panels_ajax_tab/jnl_iiar_tab_data/node:83129/1" rel="nofollow" style="display:none" class="js-crawler-link"></a></li><li><a href="/content/45/2/639/tab-article-info" class="panels-ajax-tab-tab" data-panel-name="jnl_iiar_tab_info" data-target-id="highwire_article_tabs" data-entity-context="node:83129" data-trigger="tab-article-info" data-url-enabled="1">Info & Metrics</a><a href="/panels_ajax_tab/jnl_iiar_tab_info/node:83129/1" rel="nofollow" style="display:none" class="js-crawler-link"></a></li><li class="last"><a href="/content/anticanres/45/2/639.full.pdf" class="panels-ajax-tab-tab" data-panel-name="jnl_iiar_tab_pdf" data-target-id="highwire_article_tabs" data-entity-context="node:83129" data-trigger="tab-pdf" data-url-enabled="1"><i class="icon-file-alt"></i> PDF</a><a href="/panels_ajax_tab/jnl_iiar_tab_pdf/node:83129/1" rel="nofollow" style="display:none" class="js-crawler-link"></a></li></ul></div> </div> </div> <div class="panel-separator"></div><div class="panel-pane pane-highwire-panel-tabs-container" > <div class="pane-content"> <div data-panels-ajax-tab-preloaded="jnl_iiar_tab_art" id="panels-ajax-tab-container-highwire_article_tabs" class="panels-ajax-tab-container"><div class="panels-ajax-tab-loading" style ="display:none"><img class="loading" src="https://ar.iiarjournals.org/sites/all/modules/contrib/panels_ajax_tab/images/loading.gif" alt="Loading" title="Loading" /></div><div class="panels-ajax-tab-wrap-jnl_iiar_tab_art"><div class="panel-display panel-1col clearfix" > <div class="panel-panel panel-col"> <div><div class="panel-pane pane-highwire-markup" > <div class="pane-content"> <div class="highwire-markup"><div xmlns="http://www.w3.org/1999/xhtml" data-highwire-cite-ref-tooltip-instance="highwire_reflinks_tooltip" class="content-block-markup" xmlns:xhtml="http://www.w3.org/1999/xhtml"><div class="article fulltext-view "><span class="highwire-journal-article-marker-start"></span><div class="section abstract" id="abstract-1"><h2>Abstract</h2><p id="p-4">Background/Aim: Combination therapy with immune checkpoint inhibitors has become the standard first-line treatment for metastatic renal cell carcinoma (mRCC), leading to changes in second-line treatment options, such as nivolumab or tyrosine kinase inhibitors (TKIs). However, very few studies have compared the efficacy of these drugs in patients with mRCC, particularly those with bone metastases (BM), which are associated with a poor prognosis. This study compared the efficacy of nivolumab and TKIs as second-line treatments for mRCC patients with BM and examined the microenvironments of primary tumors and BM lesions. Patients and Methods: This multi-institutional retrospective study included 87 mRCC patients with BM who received either nivolumab or TKIs as second-line treatments. We analyzed tumor-infiltrating immune cells expressing CD8 and CD20, along with PD-L1, HIF2α, c-MET, VEGFR2, and AXL, in primary tumors and BM sites using immunohistochemistry. Results: This analysis indicated that poor-risk classification, as per the International Metastatic RCC Database Consortium criteria (p<0.01), and elevated serum alkaline phosphatase levels (p=0.031) were significantly associated with poor prognosis. No significant difference in overall survival was observed between patients receiving nivolumab and those receiving TKIs. However, the objective response rate of patients with BM lesions was significantly higher when receiving TKIs than when receiving nivolumab (p=0.014). Immunohistochemistry revealed significantly higher VEGFR2 expression in BM lesions than primary tumors. Conclusion: TKIs could be a promising second-line treatment option for mRCC patients with bone-limited metastases.</p></div><span class="kwd-group-title">Key Words:</span><ul class="kwd-group"><li class="kwd"><a href="/keyword/renal-cell-carcinoma" class="hw-term hw-article-keyword hw-article-keyword-renal-cell-carcinoma" rel="nofollow">Renal cell carcinoma</a></li><li class="kwd"><a href="/keyword/bone-metastasis" class="hw-term hw-article-keyword hw-article-keyword-bone-metastasis" rel="nofollow">bone metastasis</a></li><li class="kwd"><a href="/keyword/second-line-treatment" class="hw-term hw-article-keyword hw-article-keyword-second-line-treatment" rel="nofollow">second-line treatment</a></li><li class="kwd"><a href="/keyword/nivolumab" class="hw-term hw-article-keyword hw-article-keyword-nivolumab" rel="nofollow">nivolumab</a></li><li class="kwd"><a href="/keyword/tyrosine-kinase-inhibitor" class="hw-term hw-article-keyword hw-article-keyword-tyrosine-kinase-inhibitor" rel="nofollow">tyrosine kinase inhibitor</a></li><li class="kwd"><a href="/keyword/overall-survival" class="hw-term hw-article-keyword hw-article-keyword-overall-survival" rel="nofollow">overall survival</a></li></ul><p id="p-5">Renal cell carcinoma (RCC) ranks 14<sup>th</sup> among the most frequently diagnosed cancers worldwide (<a id="xref-ref-1-1" class="xref-bibr" href="#ref-1">1</a>). In 2020, an estimated 431,288 new cases of RCC and 179,368 associated deaths were reported. With advances in imaging and inspection technology, the incidence of RCC has been increasing at an annual rate of 1-2% (<a id="xref-ref-2-1" class="xref-bibr" href="#ref-2">2</a>). Immune checkpoint inhibitor (ICI) combination therapy, such as ICI plus ICI or ICI plus tyrosine kinase inhibitor (TKI), has emerged as the first-line systemic treatment for metastatic RCC (mRCC). Owing to the refractoriness of mRCC to ICI combination therapy, the majority of patients develop progressive disease requiring subsequent TKIs or nivolumab for management (<a id="xref-ref-3-1" class="xref-bibr" href="#ref-3">3</a>). To date, although the comparable efficacies of axitinib and nivolumab as secondary treatments for mRCC have been reported (<a id="xref-ref-4-1" class="xref-bibr" href="#ref-4">4</a>), there are limited real-world clinical reports on second-line treatments for RCC.</p><p id="p-6">Among the various types of metastases, RCC is especially susceptible to bone metastasis (BM), which occurs in approximately 30% of the patients with mRCC (<a id="xref-ref-5-1" class="xref-bibr" href="#ref-5">5</a>). BM may lead to severe complications, including skeletal-related events, and is a poor prognostic factor for patients with mRCC (<a id="xref-ref-6-1" class="xref-bibr" href="#ref-6">6</a>). Negishi <em>et al</em>. reported that the effectiveness of ICIs against BM in mRCC is limited to only 5% (<a id="xref-ref-7-1" class="xref-bibr" href="#ref-7">7</a>). However, the METEOR trial reported that cabozantinib, a well-known TKI, led to a better prognosis in mRCC with BM than everolimus after at least one previous TKI treatment (<a id="xref-ref-8-1" class="xref-bibr" href="#ref-8">8</a>). However, the efficacy of cabozantinib in treating bone metastatic lesions remains unclear.</p><p id="p-7">Therefore, we aimed to compare the treatment efficacies of second-line TKIs and nivolumab in patients with RCC and BM. Additionally, we evaluated the expression of receptors targeted by cabozantinib, the immune microenvironment, and hypoxic conditions using immunohistochemistry to compare primary tumors and BM lesions.</p><div class="section patients-methods" id="sec-1"><h2 class="">Patients and Methods</h2><p id="p-8"><em>Patient selection</em>. We retrospectively reviewed the clinical data of 721 patients with RCC and analyzed the clinicopathological data of 87 patients with mRCC with BM who initiated second-line treatment with nivolumab (n=29) or TKI (n=58) at Osaka University Hospital, Osaka Police Hospital, Osaka General Medical Center, Osaka Rosai Hospital, and Osaka National Hospital between January 2008 and December 2023. BM was diagnosed using computed tomography with MRI or bone scintigraphy, which was performed as needed (<a id="xref-ref-9-1" class="xref-bibr" href="#ref-9">9</a>). The TKIs included were sunitinib, axitinib, cabozantinib, sorafenib, and pazopanib. The dosage and administration intervals followed standard treatment protocols.</p><p id="p-9">The following patient data were collected from the hospital records of the patients: age, sex, histopathology of RCC, International Metastatic Renal Cell Carcinoma Database (IMDC) classification for first-line therapy, previous nephrectomy, local therapy for BM site, location of metastatic sites, number of BMs, first-line therapy regimen, type of second-line regimen, bone modifying agent, serum concentration of alkaline phosphatase (ALP), serum concentration of lactate dehydrogenase, neutrophil-lymphocyte ratio, best overall response rate (ORR) for the second line therapy, second-line therapy cancer-specific survival (CSS), and overall survival (OS).</p><p id="p-10">The therapeutic efficacy of second-line treatment was assessed every 2-3 months using computed tomography according to the Response Evaluation Criteria in Solid Tumors version 1.1 and MD Anderson (MDA) criteria (<a id="xref-ref-10-1" class="xref-bibr" href="#ref-10">10</a>). The best response of each patient during treatment was determined and classified as complete response, partial response, stable disease, or progressive disease. This study was approved by the Institutional Review Board of the Osaka University Hospital (# 018-0003). All procedures were conducted in accordance with the Declaration of Helsinki, and informed consent was obtained from all participants.</p><p id="p-11"><em>Immunohistochemistry and quantification</em>. The primary RCC tissue resected after total nephrectomy was stored as formalin-fixed paraffin-embedded tissue blocks. Resected RCC tissue from the BM site in the same patients was subjected to tris-ethylenediami-netetraacetic acid treatment until tissue softening was observed. This was followed by paraffin fixation. Immunohistochemical staining was performed on 4-μm-thick paraffin-embedded tissue sections from primary RCC and BM tissues. The tissue sections were deparaffinized using xylene and a graded series of ethanol solutions and stained with eosin. Other sections were treated with EDTA buffer (pH 9.0) and activated by warming at 125°C for 30 s using a Pascal pressure chamber (S2800, DAKO, Carpinteria, CA, USA) for antigen activation treatment. Endogenous peroxidase activity was blocked by incubating the sections with 0.3% hydrogen peroxide for 5 min, followed by overnight incubation with primary antibodies against CD8 (1:100; ab17147, Abcam, Cambridge, UK) as a marker for cytotoxic T-lymphocytes, CD20 (1:800; ab9475, Abcam) as a marker for B-cells, PD-L1 (clone 28-8, 1:200; ab205921, Abcam), HIF2α (1:200; ab243861, Abcam), c-MET (1:100; ab51067, Abcam), VEGFR2 (1:100; ab115805, Abcam), and AXL (1:2,000; ab219651, Abcam) at 4°C. The EnVision + system horseradish peroxidase-labeled polyclonal anti-rabbit and anti-mouse antibody (DAKO) was used, and staining was performed using 3,3′Diaminobenzidine substrate (MK210, TaKaRa, Shiga, Japan) according to the manufacturer’s instructions. Finally, the sections were counterstained with hematoxylin, dehydrated using a graded series of ethanol concentrations, and cleared with xylene.</p><p id="p-12">The CD8<sup>+</sup> and CD20<sup>+</sup> cell counts within the tumor were quantified separately. Three distinct random regions featuring the highest abundance of positive cells were identified using a ×40 objective lens, and the average count was used for statistical analysis (<a id="xref-ref-11-1" class="xref-bibr" href="#ref-11">11</a>). The membrane PD-L1 expression in the tumor cells was assessed at three random locations using a ×40 objective lens, and the average count was used for statistical analysis (<a id="xref-ref-12-1" class="xref-bibr" href="#ref-12">12</a>). HIF2α was assessed for positivity exclusively within the nuclei of tumor cells (<a id="xref-ref-13-1" class="xref-bibr" href="#ref-13">13</a>). The ratios of c-MET, VEGFR2, and AXL expression in the membrane and cytoplasm of tumor cells were determined (<a id="xref-ref-14-1" class="xref-bibr" href="#ref-14">14</a>-<a id="xref-ref-16-1" class="xref-bibr" href="#ref-16">16</a>). HIF2α, c-MET, VEGFR2, and AXL were evaluated and analyzed in three random fields of view using a ×40 objective lens. The number of positive cells and their levels of expression were automatically determined using a microscope (BZ-X710; KEYENCE, Osaka, Japan).</p><p id="p-13"><em>Statistical analysis</em>. Clinical characteristics were compared using the Mann–Whitney <em>U</em>-test. Fisher’s exact test was used to analyze the therapeutic effects of the ICIs and TKIs. Univariate and multivariate logistic regression analyses were performed to assess the relative contributions to CSS and OS. CSS and OS were estimated using the Kaplan–Meier method and Cox proportional hazard regression. All <em>p</em>-values were two-sided, and differences were considered statistically significant at <em>p</em><0.05. Data were analyzed using JMP Pro (v.17.0.0; SAS Institute, Cary, NC, USA).</p></div><div class="section results" id="sec-2"><h2 class="">Results</h2><p id="p-14"><em>Patient characteristics</em>. This study included a total of 721 patients with RCC, and the clinicopathological characteristics and outcomes of the 87 patients with mRCC and BM included in the study are summarized in <a id="xref-table-wrap-1-1" class="xref-table" href="#T1">Table I</a>. The median age of the patients in the nivolumab and TKI groups was 66 years (range=29-87 years) and 69 years (range=33-84 years), respectively. The most prevalent histological type was clear cell carcinoma, observed in 25 (86%) and 47 (81%) patients treated with nivolumab and TKI, respectively. The nivolumab group predominantly comprised patients with poor IMDC risk (52.0%), whereas 76.0% of patients treated with a TKI were classified as having favorable and intermediate risk. The most commonly prescribed TKI was axitinib (n=35, 60%), followed by cabozantinib (n=14, 24%).</p><div id="T1" class="table pos-float"><div class="table-inline table-callout-links"><div class="callout"><span>View this table:</span><ul class="callout-links"><li class="view-inline first"><a href="" class="table-expand-inline" data-table-url="/highwire/markup/83153/expansion?postprocessors=highwire_tables%2Chighwire_reclass%2Chighwire_figures%2Chighwire_math%2Chighwire_inline_linked_media%2Chighwire_embed&table-expand-inline=1" data-icon-position="" data-hide-link-title="0">View inline</a></li><li class="view-popup"><a href="/highwire/markup/83153/expansion?width=1000&height=500&iframe=true&postprocessors=highwire_tables%2Chighwire_reclass%2Chighwire_figures%2Chighwire_math%2Chighwire_inline_linked_media%2Chighwire_embed" class="colorbox colorbox-load table-expand-popup" rel="gallery-fragment-tables" data-icon-position="" data-hide-link-title="0">View popup</a></li><li class="download-ppt last"><a href="/highwire/powerpoint/83153" class="highwire-figure-link highwire-figure-link-ppt" data-icon-position="" data-hide-link-title="0">Download powerpoint</a></li></ul></div></div><div class="table-caption"><span class="table-label">Table I.</span> <p id="p-15" class="first-child">Patient characteristics.</p><div class="sb-div caption-clear"></div></div></div><p id="p-16"><em>Clinical outcomes of patients treated with second-line nivolumab or tyrosine kinase inhibitors</em>. Overall, the median follow-up durations of patients treated with nivolumab and TKIs were 7.0 months (range=1-73 months) and 11.5 months (range=1-93 months) months, respectively. There were no significant differences between the CSS and OS of the patients treated with nivolumab and TKI (<em>p</em>=0.76 and <em>p</em>=0.55, respectively) (<a id="xref-fig-1-1" class="xref-fig" href="#F1">Figure 1</a>, <a id="xref-table-wrap-2-1" class="xref-table" href="#T2">Table II</a>, <a id="xref-table-wrap-3-1" class="xref-table" href="#T3">Table III</a>). Multivariate analyses revealed that poor risk based on the IMDC classification and high serum ALP concentration (≥288 U/l) were significantly associated with reduced OS [hazard ratio (HR)=3.24, 95%CI=1.84-5.71, <em>p</em><0.01; HR=1.78, 95%CI=1.05-3.01, <em>p</em><0.01, <a id="xref-table-wrap-3-2" class="xref-table" href="#T3">Table III</a>]. Accordingly, OS was significantly shorter for patients with poor risk based on the IMDC classification and high serum ALP concentration (≥288 U/l) (HR=3.58, 95%CI=2.08-6.17, <em>p</em><0.01; HR=2.01, 95%CI=1.21-3.35, <em>p</em><0.01, <a id="xref-fig-2-1" class="xref-fig" href="#F2">Figure 2</a>).</p><div id="F1" class="fig pos-float odd"><div class="highwire-figure"><div class="fig-inline-img-wrapper"><div class="fig-inline-img"><a href="https://ar.iiarjournals.org/content/anticanres/45/2/639/F1.large.jpg?width=800&height=600&carousel=1" title="Kaplan–Meier curves of cancer-specific survival (A) and overall survival (B) for patients with metastatic renal cell carcinoma after second-line treatment with immune checkpoint inhibitors (ICIs) and tyrosine kinase inhibitors (TKIs)." class="highwire-fragment fragment-images colorbox-load" rel="gallery-fragment-images-1188653354" data-figure-caption="<div class="highwire-markup">Kaplan–Meier curves of cancer-specific survival (A) and overall survival (B) for patients with metastatic renal cell carcinoma after second-line treatment with immune checkpoint inhibitors (ICIs) and tyrosine kinase inhibitors (TKIs).</div>" data-icon-position="" data-hide-link-title="0"><span class="hw-responsive-img"><img class="highwire-fragment fragment-image lazyload" alt="Figure 1." src="data:image/gif;base64,R0lGODlhAQABAIAAAAAAAP///yH5BAEAAAAALAAAAAABAAEAAAIBRAA7" data-src="https://ar.iiarjournals.org/content/anticanres/45/2/639/F1.medium.gif" width="440" height="182"/><noscript><img class="highwire-fragment fragment-image" alt="Figure 1." src="https://ar.iiarjournals.org/content/anticanres/45/2/639/F1.medium.gif" width="440" height="182"/></noscript></span></a></div></div><ul class="highwire-figure-links inline"><li class="download-fig first"><a href="https://ar.iiarjournals.org/content/anticanres/45/2/639/F1.large.jpg?download=true" class="highwire-figure-link highwire-figure-link-download" title="Download Figure 1." data-icon-position="" data-hide-link-title="0">Download figure</a></li><li class="new-tab"><a href="https://ar.iiarjournals.org/content/anticanres/45/2/639/F1.large.jpg" class="highwire-figure-link highwire-figure-link-newtab" target="_blank" data-icon-position="" data-hide-link-title="0">Open in new tab</a></li><li class="download-ppt last"><a href="/highwire/powerpoint/83223" class="highwire-figure-link highwire-figure-link-ppt" data-icon-position="" data-hide-link-title="0">Download powerpoint</a></li></ul></div><div class="fig-caption" xmlns:xhtml="http://www.w3.org/1999/xhtml"><span class="fig-label">Figure 1.</span> <p id="p-17" class="first-child">Kaplan–Meier curves of cancer-specific survival (A) and overall survival (B) for patients with metastatic renal cell carcinoma after second-line treatment with immune checkpoint inhibitors (ICIs) and tyrosine kinase inhibitors (TKIs).</p><div class="sb-div caption-clear"></div></div></div><div id="T2" class="table pos-float"><div class="table-inline table-callout-links"><div class="callout"><span>View this table:</span><ul class="callout-links"><li class="view-inline first"><a href="" class="table-expand-inline" data-table-url="/highwire/markup/83236/expansion?postprocessors=highwire_tables%2Chighwire_reclass%2Chighwire_figures%2Chighwire_math%2Chighwire_inline_linked_media%2Chighwire_embed&table-expand-inline=1" data-icon-position="" data-hide-link-title="0">View inline</a></li><li class="view-popup"><a href="/highwire/markup/83236/expansion?width=1000&height=500&iframe=true&postprocessors=highwire_tables%2Chighwire_reclass%2Chighwire_figures%2Chighwire_math%2Chighwire_inline_linked_media%2Chighwire_embed" class="colorbox colorbox-load table-expand-popup" rel="gallery-fragment-tables" data-icon-position="" data-hide-link-title="0">View popup</a></li><li class="download-ppt last"><a href="/highwire/powerpoint/83236" class="highwire-figure-link highwire-figure-link-ppt" data-icon-position="" data-hide-link-title="0">Download powerpoint</a></li></ul></div></div><div class="table-caption"><span class="table-label">Table II.</span> <p id="p-18" class="first-child">Univariate and multivariate analyses of CSS after second-line therapy.</p><div class="sb-div caption-clear"></div></div></div><div id="T3" class="table pos-float"><div class="table-inline table-callout-links"><div class="callout"><span>View this table:</span><ul class="callout-links"><li class="view-inline first"><a href="" class="table-expand-inline" data-table-url="/highwire/markup/83235/expansion?postprocessors=highwire_tables%2Chighwire_reclass%2Chighwire_figures%2Chighwire_math%2Chighwire_inline_linked_media%2Chighwire_embed&table-expand-inline=1" data-icon-position="" data-hide-link-title="0">View inline</a></li><li class="view-popup"><a href="/highwire/markup/83235/expansion?width=1000&height=500&iframe=true&postprocessors=highwire_tables%2Chighwire_reclass%2Chighwire_figures%2Chighwire_math%2Chighwire_inline_linked_media%2Chighwire_embed" class="colorbox colorbox-load table-expand-popup" rel="gallery-fragment-tables" data-icon-position="" data-hide-link-title="0">View popup</a></li><li class="download-ppt last"><a href="/highwire/powerpoint/83235" class="highwire-figure-link highwire-figure-link-ppt" data-icon-position="" data-hide-link-title="0">Download powerpoint</a></li></ul></div></div><div class="table-caption"><span class="table-label">Table III.</span> <p id="p-19" class="first-child">Univariate and multivariate analyses of OS after the introduction of second-line therapy.</p><div class="sb-div caption-clear"></div></div></div><div id="F2" class="fig pos-float odd"><div class="highwire-figure"><div class="fig-inline-img-wrapper"><div class="fig-inline-img"><a href="https://ar.iiarjournals.org/content/anticanres/45/2/639/F2.large.jpg?width=800&height=600&carousel=1" title="Kaplan–Meier curves of cancer-specific survival and overall survival for patients with metastatic renal cell carcinoma stratified according to International Metastatic Database Consortium (IMDC) risk classification (A, C) and alkaline phosphatase (ALP) concentration (B, D)." class="highwire-fragment fragment-images colorbox-load" rel="gallery-fragment-images-1188653354" data-figure-caption="<div class="highwire-markup">Kaplan–Meier curves of cancer-specific survival and overall survival for patients with metastatic renal cell carcinoma stratified according to International Metastatic Database Consortium (IMDC) risk classification (A, C) and alkaline phosphatase (ALP) concentration (B, D).</div>" data-icon-position="" data-hide-link-title="0"><span class="hw-responsive-img"><img class="highwire-fragment fragment-image lazyload" alt="Figure 2." src="data:image/gif;base64,R0lGODlhAQABAIAAAAAAAP///yH5BAEAAAAALAAAAAABAAEAAAIBRAA7" data-src="https://ar.iiarjournals.org/content/anticanres/45/2/639/F2.medium.gif" width="440" height="339"/><noscript><img class="highwire-fragment fragment-image" alt="Figure 2." src="https://ar.iiarjournals.org/content/anticanres/45/2/639/F2.medium.gif" width="440" height="339"/></noscript></span></a></div></div><ul class="highwire-figure-links inline"><li class="download-fig first"><a href="https://ar.iiarjournals.org/content/anticanres/45/2/639/F2.large.jpg?download=true" class="highwire-figure-link highwire-figure-link-download" title="Download Figure 2." data-icon-position="" data-hide-link-title="0">Download figure</a></li><li class="new-tab"><a href="https://ar.iiarjournals.org/content/anticanres/45/2/639/F2.large.jpg" class="highwire-figure-link highwire-figure-link-newtab" target="_blank" data-icon-position="" data-hide-link-title="0">Open in new tab</a></li><li class="download-ppt last"><a href="/highwire/powerpoint/83288" class="highwire-figure-link highwire-figure-link-ppt" data-icon-position="" data-hide-link-title="0">Download powerpoint</a></li></ul></div><div class="fig-caption"><span class="fig-label">Figure 2.</span> <p id="p-20" class="first-child">Kaplan–Meier curves of cancer-specific survival and overall survival for patients with metastatic renal cell carcinoma stratified according to International Metastatic Database Consortium (IMDC) risk classification (A, C) and alkaline phosphatase (ALP) concentration (B, D).</p><div class="sb-div caption-clear"></div></div></div><p id="p-21">To exclude the influence of radiation therapy on the BM site, we examined 72 patients with untreated BM sites (<a id="xref-table-wrap-4-1" class="xref-table" href="#T4">Table IV</a>). A comparison of the outcomes of second-line treatment for BM according to the MDA criteria indicated that the ORR was significantly higher for the TKI group (29.2%) than for the nivolumab group (4.2%) (<em>p</em>=0.014) (<a id="xref-fig-3-1" class="xref-fig" href="#F3">Figure 3</a>, <a id="xref-table-wrap-5-1" class="xref-table" href="#T5">Table V</a>). This indicated that TKIs may be more effective than nivolumab for treatment-naïve BM.</p><div id="T4" class="table pos-float"><div class="table-inline table-callout-links"><div class="callout"><span>View this table:</span><ul class="callout-links"><li class="view-inline first"><a href="" class="table-expand-inline" data-table-url="/highwire/markup/83263/expansion?postprocessors=highwire_tables%2Chighwire_reclass%2Chighwire_figures%2Chighwire_math%2Chighwire_inline_linked_media%2Chighwire_embed&table-expand-inline=1" data-icon-position="" data-hide-link-title="0">View inline</a></li><li class="view-popup"><a href="/highwire/markup/83263/expansion?width=1000&height=500&iframe=true&postprocessors=highwire_tables%2Chighwire_reclass%2Chighwire_figures%2Chighwire_math%2Chighwire_inline_linked_media%2Chighwire_embed" class="colorbox colorbox-load table-expand-popup" rel="gallery-fragment-tables" data-icon-position="" data-hide-link-title="0">View popup</a></li><li class="download-ppt last"><a href="/highwire/powerpoint/83263" class="highwire-figure-link highwire-figure-link-ppt" data-icon-position="" data-hide-link-title="0">Download powerpoint</a></li></ul></div></div><div class="table-caption"><span class="table-label">Table IV.</span> <p id="p-22" class="first-child">Background of patients with locally untreated bone metastasis.</p><div class="sb-div caption-clear"></div></div></div><div id="F3" class="fig pos-float odd"><div class="highwire-figure"><div class="fig-inline-img-wrapper"><div class="fig-inline-img"><a href="https://ar.iiarjournals.org/content/anticanres/45/2/639/F3.large.jpg?width=800&height=600&carousel=1" title="Bone metastasis is shown for a 66-year-old male with metastatic clear cell renal cell carcinoma whose treatment was initiated with ipilimumab plus nivolumab; however, was switched to cabozantinib after 13 months. (A) Computed tomography (CT) images just before induction of cabozantinib. (B) CT images after 11 months of cabozantinib treatment show that according to RECIST criteria, the metastatic lesion in the right iliac bone is assessed as SD (stable disease). However, according to MDA criteria, the appearance of sclerotic bone lesions indicates PR (partial response). The white arrow indicates the development of a partial sclerotic fill-in of lytic lesions." class="highwire-fragment fragment-images colorbox-load" rel="gallery-fragment-images-1188653354" data-figure-caption="<div class="highwire-markup">Bone metastasis is shown for a 66-year-old male with metastatic clear cell renal cell carcinoma whose treatment was initiated with ipilimumab plus nivolumab; however, was switched to cabozantinib after 13 months. (A) Computed tomography (CT) images just before induction of cabozantinib. (B) CT images after 11 months of cabozantinib treatment show that according to RECIST criteria, the metastatic lesion in the right iliac bone is assessed as SD (stable disease). However, according to MDA criteria, the appearance of sclerotic bone lesions indicates PR (partial response). The white arrow indicates the development of a partial sclerotic fill-in of lytic lesions.</div>" data-icon-position="" data-hide-link-title="0"><span class="hw-responsive-img"><img class="highwire-fragment fragment-image lazyload" alt="Figure 3." src="data:image/gif;base64,R0lGODlhAQABAIAAAAAAAP///yH5BAEAAAAALAAAAAABAAEAAAIBRAA7" data-src="https://ar.iiarjournals.org/content/anticanres/45/2/639/F3.medium.gif" width="440" height="271"/><noscript><img class="highwire-fragment fragment-image" alt="Figure 3." src="https://ar.iiarjournals.org/content/anticanres/45/2/639/F3.medium.gif" width="440" height="271"/></noscript></span></a></div></div><ul class="highwire-figure-links inline"><li class="download-fig first"><a href="https://ar.iiarjournals.org/content/anticanres/45/2/639/F3.large.jpg?download=true" class="highwire-figure-link highwire-figure-link-download" title="Download Figure 3." data-icon-position="" data-hide-link-title="0">Download figure</a></li><li class="new-tab"><a href="https://ar.iiarjournals.org/content/anticanres/45/2/639/F3.large.jpg" class="highwire-figure-link highwire-figure-link-newtab" target="_blank" data-icon-position="" data-hide-link-title="0">Open in new tab</a></li><li class="download-ppt last"><a href="/highwire/powerpoint/83075" class="highwire-figure-link highwire-figure-link-ppt" data-icon-position="" data-hide-link-title="0">Download powerpoint</a></li></ul></div><div class="fig-caption"><span class="fig-label">Figure 3.</span> <p id="p-23" class="first-child">Bone metastasis is shown for a 66-year-old male with metastatic clear cell renal cell carcinoma whose treatment was initiated with ipilimumab plus nivolumab; however, was switched to cabozantinib after 13 months. (A) Computed tomography (CT) images just before induction of cabozantinib. (B) CT images after 11 months of cabozantinib treatment show that according to RECIST criteria, the metastatic lesion in the right iliac bone is assessed as SD (stable disease). However, according to MDA criteria, the appearance of sclerotic bone lesions indicates PR (partial response). The white arrow indicates the development of a partial sclerotic fill-in of lytic lesions.</p><div class="sb-div caption-clear"></div></div></div><div id="T5" class="table pos-float"><div class="table-inline table-callout-links"><div class="callout"><span>View this table:</span><ul class="callout-links"><li class="view-inline first"><a href="" class="table-expand-inline" data-table-url="/highwire/markup/83102/expansion?postprocessors=highwire_tables%2Chighwire_reclass%2Chighwire_figures%2Chighwire_math%2Chighwire_inline_linked_media%2Chighwire_embed&table-expand-inline=1" data-icon-position="" data-hide-link-title="0">View inline</a></li><li class="view-popup"><a href="/highwire/markup/83102/expansion?width=1000&height=500&iframe=true&postprocessors=highwire_tables%2Chighwire_reclass%2Chighwire_figures%2Chighwire_math%2Chighwire_inline_linked_media%2Chighwire_embed" class="colorbox colorbox-load table-expand-popup" rel="gallery-fragment-tables" data-icon-position="" data-hide-link-title="0">View popup</a></li><li class="download-ppt last"><a href="/highwire/powerpoint/83102" class="highwire-figure-link highwire-figure-link-ppt" data-icon-position="" data-hide-link-title="0">Download powerpoint</a></li></ul></div></div><div class="table-caption"><span class="table-label">Table V.</span> <p id="p-24" class="first-child">Overall response rate of second-line treatment to locally untreated BM according to the MDA criteria and RECIST 1.1.</p><div class="sb-div caption-clear"></div></div></div><p id="p-25"><em>Significant difference between the tumor microenvironments of primary tumors and bone metastasis</em>. We investigated the presence of tumor-infiltrated immune cells and several molecules targeted by TKIs in the tumor microenvironment of primary tumors and BM sites. Representative immuno-histochemistry results are shown in <a id="xref-fig-4-1" class="xref-fig" href="#F4">Figure 4</a> and <a id="xref-fig-5-1" class="xref-fig" href="#F5">Figure 5</a>. Consequently, we observed a significant increase in VEGFR2-positive cells in the BM lesions (<em>p</em>=0.048). In addition, we confirmed that the CD8<sup>+</sup> T-cell and CD20<sup>+</sup> B-cell counts were higher in primary tumors (<em>p</em>=0.075 and <em>p</em>=0.10, respectively; <a id="xref-fig-6-1" class="xref-fig" href="#F6">Figure 6</a>). Collectively, these results indicate that primary tumors and BM have different tumor microenvironments, affecting the efficacy of TKIs and nivolumab therapies.</p><div id="F4" class="fig pos-float odd"><div class="highwire-figure"><div class="fig-inline-img-wrapper"><div class="fig-inline-img"><a href="https://ar.iiarjournals.org/content/anticanres/45/2/639/F4.large.jpg?width=800&height=600&carousel=1" title="Immunohistochemical staining results for a primary site of clear cell renal cell carcinoma. Scale bar represents 200 μm." class="highwire-fragment fragment-images colorbox-load" rel="gallery-fragment-images-1188653354" data-figure-caption="<div class="highwire-markup">Immunohistochemical staining results for a primary site of clear cell renal cell carcinoma. Scale bar represents 200 μm.</div>" data-icon-position="" data-hide-link-title="0"><span class="hw-responsive-img"><img class="highwire-fragment fragment-image lazyload" alt="Figure 4." src="data:image/gif;base64,R0lGODlhAQABAIAAAAAAAP///yH5BAEAAAAALAAAAAABAAEAAAIBRAA7" data-src="https://ar.iiarjournals.org/content/anticanres/45/2/639/F4.medium.gif" width="440" height="336"/><noscript><img class="highwire-fragment fragment-image" alt="Figure 4." src="https://ar.iiarjournals.org/content/anticanres/45/2/639/F4.medium.gif" width="440" height="336"/></noscript></span></a></div></div><ul class="highwire-figure-links inline"><li class="download-fig first"><a href="https://ar.iiarjournals.org/content/anticanres/45/2/639/F4.large.jpg?download=true" class="highwire-figure-link highwire-figure-link-download" title="Download Figure 4." data-icon-position="" data-hide-link-title="0">Download figure</a></li><li class="new-tab"><a href="https://ar.iiarjournals.org/content/anticanres/45/2/639/F4.large.jpg" class="highwire-figure-link highwire-figure-link-newtab" target="_blank" data-icon-position="" data-hide-link-title="0">Open in new tab</a></li><li class="download-ppt last"><a href="/highwire/powerpoint/83159" class="highwire-figure-link highwire-figure-link-ppt" data-icon-position="" data-hide-link-title="0">Download powerpoint</a></li></ul></div><div class="fig-caption"><span class="fig-label">Figure 4.</span> <p id="p-26" class="first-child">Immunohistochemical staining results for a primary site of clear cell renal cell carcinoma. Scale bar represents 200 μm.</p><div class="sb-div caption-clear"></div></div></div><div id="F5" class="fig pos-float odd"><div class="highwire-figure"><div class="fig-inline-img-wrapper"><div class="fig-inline-img"><a href="https://ar.iiarjournals.org/content/anticanres/45/2/639/F5.large.jpg?width=800&height=600&carousel=1" title="Immunohistochemical staining results for a bone metastatic lesion of clear cell renal cell carcinoma. Scale bar represents 200 μm." class="highwire-fragment fragment-images colorbox-load" rel="gallery-fragment-images-1188653354" data-figure-caption="<div class="highwire-markup">Immunohistochemical staining results for a bone metastatic lesion of clear cell renal cell carcinoma. Scale bar represents 200 μm.</div>" data-icon-position="" data-hide-link-title="0"><span class="hw-responsive-img"><img class="highwire-fragment fragment-image lazyload" alt="Figure 5." src="data:image/gif;base64,R0lGODlhAQABAIAAAAAAAP///yH5BAEAAAAALAAAAAABAAEAAAIBRAA7" data-src="https://ar.iiarjournals.org/content/anticanres/45/2/639/F5.medium.gif" width="440" height="335"/><noscript><img class="highwire-fragment fragment-image" alt="Figure 5." src="https://ar.iiarjournals.org/content/anticanres/45/2/639/F5.medium.gif" width="440" height="335"/></noscript></span></a></div></div><ul class="highwire-figure-links inline"><li class="download-fig first"><a href="https://ar.iiarjournals.org/content/anticanres/45/2/639/F5.large.jpg?download=true" class="highwire-figure-link highwire-figure-link-download" title="Download Figure 5." data-icon-position="" data-hide-link-title="0">Download figure</a></li><li class="new-tab"><a href="https://ar.iiarjournals.org/content/anticanres/45/2/639/F5.large.jpg" class="highwire-figure-link highwire-figure-link-newtab" target="_blank" data-icon-position="" data-hide-link-title="0">Open in new tab</a></li><li class="download-ppt last"><a href="/highwire/powerpoint/83186" class="highwire-figure-link highwire-figure-link-ppt" data-icon-position="" data-hide-link-title="0">Download powerpoint</a></li></ul></div><div class="fig-caption"><span class="fig-label">Figure 5.</span> <p id="p-27" class="first-child">Immunohistochemical staining results for a bone metastatic lesion of clear cell renal cell carcinoma. Scale bar represents 200 μm.</p><div class="sb-div caption-clear"></div></div></div><div id="F6" class="fig pos-float odd"><div class="highwire-figure"><div class="fig-inline-img-wrapper"><div class="fig-inline-img"><a href="https://ar.iiarjournals.org/content/anticanres/45/2/639/F6.large.jpg?width=800&height=600&carousel=1" title="Comparison of expression levels of CD8, CD20, PD-L1, HIF2α, c-MET, VEGFR2, and AXL in the primary tumor and bone metastatic lesions of clear cell renal cell carcinoma." class="highwire-fragment fragment-images colorbox-load" rel="gallery-fragment-images-1188653354" data-figure-caption="<div class="highwire-markup">Comparison of expression levels of CD8, CD20, PD-L1, HIF2α, c-MET, VEGFR2, and AXL in the primary tumor and bone metastatic lesions of clear cell renal cell carcinoma.</div>" data-icon-position="" data-hide-link-title="0"><span class="hw-responsive-img"><img class="highwire-fragment fragment-image lazyload" alt="Figure 6." src="data:image/gif;base64,R0lGODlhAQABAIAAAAAAAP///yH5BAEAAAAALAAAAAABAAEAAAIBRAA7" data-src="https://ar.iiarjournals.org/content/anticanres/45/2/639/F6.medium.gif" width="353" height="440"/><noscript><img class="highwire-fragment fragment-image" alt="Figure 6." src="https://ar.iiarjournals.org/content/anticanres/45/2/639/F6.medium.gif" width="353" height="440"/></noscript></span></a></div></div><ul class="highwire-figure-links inline"><li class="download-fig first"><a href="https://ar.iiarjournals.org/content/anticanres/45/2/639/F6.large.jpg?download=true" class="highwire-figure-link highwire-figure-link-download" title="Download Figure 6." data-icon-position="" data-hide-link-title="0">Download figure</a></li><li class="new-tab"><a href="https://ar.iiarjournals.org/content/anticanres/45/2/639/F6.large.jpg" class="highwire-figure-link highwire-figure-link-newtab" target="_blank" data-icon-position="" data-hide-link-title="0">Open in new tab</a></li><li class="download-ppt last"><a href="/highwire/powerpoint/83287" class="highwire-figure-link highwire-figure-link-ppt" data-icon-position="" data-hide-link-title="0">Download powerpoint</a></li></ul></div><div class="fig-caption"><span class="fig-label">Figure 6.</span> <p id="p-28" class="first-child">Comparison of expression levels of CD8, CD20, PD-L1, HIF2α, c-MET, VEGFR2, and AXL in the primary tumor and bone metastatic lesions of clear cell renal cell carcinoma.</p><div class="sb-div caption-clear"></div></div></div></div><div class="section discussion" id="sec-3"><h2 class="">Discussion</h2><p id="p-29">The guidelines of the European Association of Urology recommend ICI combination therapy as the first-line treatment for mRCC (<a id="xref-ref-17-1" class="xref-bibr" href="#ref-17">17</a>). There is currently no established drug selection for the second-line treatment of mRCC; however, several studies have suggested that second-line treatment should generally comprise nivolumab monotherapy or TKI therapy (<a id="xref-ref-17-2" class="xref-bibr" href="#ref-17">17</a>). On the contrary, the effectiveness of TKI and ICI greatly depends on the tumor microenvironment, which varies significantly due to several patient factors including tumor heterogeneity (<a id="xref-ref-18-1" class="xref-bibr" href="#ref-18">18</a>). For RCC, the characteristics of metastatic tumor cells and the surrounding microenvironment may not always match those of primary tumors (<a id="xref-ref-19-1" class="xref-bibr" href="#ref-19">19</a>). Therefore, a comparative analysis of the molecular biomarker expression profiles of primary and metastatic specimens, such as the bone, should be performed (<a id="xref-ref-20-1" class="xref-bibr" href="#ref-20">20</a>).</p><p id="p-30">The bone matrix is inherently rich in growth factors, making it a favorable and fertile environment for metastatic tumors, irrespective of the primary tumor type. BM is considered a poor prognostic factor for patients with mRCC (<a id="xref-ref-21-1" class="xref-bibr" href="#ref-21">21</a>). In the microenvironment of BM lesions, regulatory T-cells and myeloid-derived suppressor cells are abundant, suppressing tumor immunity (<a id="xref-ref-22-1" class="xref-bibr" href="#ref-22">22</a>, <a id="xref-ref-23-1" class="xref-bibr" href="#ref-23">23</a>), which may lead to poor prognosis for patients with mRCC and BM. Moreover, in RCC, inactivation of the von Hippel-Lindau tumor suppressor gene is common and leads to an increase in hypoxia-inducible factor-alpha, resulting in the over-expression of vascular endothelial growth factor (VEGF) (<a id="xref-ref-24-1" class="xref-bibr" href="#ref-24">24</a>). This growth factor promotes tumor angiogenesis and plays a crucial role in the invasion and metastasis of RCC. On the contrary, tyrosine kinase is an important enzyme in intracellular signal transduction, and binding of VEGF to the VEGF receptor (VEGFR) increases receptor tyrosine kinase activity, initiating intracellular signal transduction. Therefore, we aimed to compare the efficacies of nivolumab and TKIs as second-line treatments for patients with mRCC with BM, elucidating the differences between the tumor microenvironments of primary and BM lesions.</p><p id="p-31">In this study, we present two novel findings. First, we found that TKIs were more effective as second-line treatments for BM lesions in RCC than nivolumab monotherapy, as evidenced by the higher ORR at the BM sites (<a id="xref-table-wrap-5-2" class="xref-table" href="#T5">Table V</a>). Previous studies have demonstrated significant differences in the treatment efficacy of ICI across metastatic lesions (<a id="xref-ref-25-1" class="xref-bibr" href="#ref-25">25</a>). In a large-scale tumor-agnostic study, BM lesions were associated with resistance to ICI (<a id="xref-ref-26-1" class="xref-bibr" href="#ref-26">26</a>). In patients with mRCC treated with second-line nivolumab, treatment efficacy varies significantly with the metastatic site, with bone metastases exhibiting a particularly low ORR of 5%, compared with 36% for lung and 50% for liver metastases (<a id="xref-ref-7-2" class="xref-bibr" href="#ref-7">7</a>). In patients with mRCC treated with nivolumab as second-line therapy or beyond, BM, rather than lung or lymph node metastases, was associated with poor progression-free survival (PFS) and OS (<a id="xref-ref-27-1" class="xref-bibr" href="#ref-27">27</a>). In the present study, an elevated serum ALP concentration, which reflects the overall deterioration of systemic conditions such as BM volume, was an independent poor prognostic factor for second-line treatment of mRCC with BM (<a id="xref-table-wrap-3-3" class="xref-table" href="#T3">Table III</a>). Therefore, TKIs are considered a promising option for patients with mRCC with BM and without other visceral metastases.</p><p id="p-32">Second, VEGFR2 expression was higher in BM lesions than in primary tumors, and BM lesions exhibited a trend of decreased CD8<sup>+</sup> tumor-infiltrating T-lymphocytes and tumor-infiltrating CD20<sup>+</sup> B-cells (<a id="xref-fig-6-2" class="xref-fig" href="#F6">Figure 6</a>), which may contribute to the lower ORR of nivolumab than of TKI for BM lesions. Tumor-infiltrating B-lymphocytes in mRCC might recruit and activate CD8<sup>+</sup> tumor-infiltrating T-lymphocytes, thereby enhancing antitumor effects, and this process is involved in the formation of tertiary lymphoid structures (<a id="xref-ref-28-1" class="xref-bibr" href="#ref-28">28</a>, <a id="xref-ref-29-1" class="xref-bibr" href="#ref-29">29</a>). TKIs are also considered more likely to be effective for cases of RCC with high expression of VEGFR2 (<a id="xref-ref-30-1" class="xref-bibr" href="#ref-30">30</a>). In this study, we described a significant increase in VEGFR2- positive cells in BM sites, demonstrating the potential benefits of TKI in patients with mRCC with BM. Specifically, considering that cabozantinib exhibited the strongest inhibition toward VEGFR2 among several types of TKIs, cabozantinib may likely contribute to the enhanced antitumor activity in BM (<a id="xref-ref-31-1" class="xref-bibr" href="#ref-31">31</a>).</p><p id="p-33"><em>Study limitations</em>. First, this was a retrospective study with few cases. While it was a multicenter study including five hospitals, the number of patients with mRCC with BM receiving second-line treatment was limited, and even fewer underwent surgery for BM lesions. The prior therapy does not affect the response to nivolumab (<a id="xref-ref-32-1" class="xref-bibr" href="#ref-32">32</a>), but a study design with a certain first line therapy is needed. Therefore, future studies with larger sample sizes and more well-organized designs are warranted. Second, we used the MDA criteria and Response Evaluation Criteria in Solid Tumors to evaluate the treatment efficacy for BM lesions, but there is currently no consensus on the best response evaluation system (<a id="xref-ref-33-1" class="xref-bibr" href="#ref-33">33</a>). Notwithstanding, several studies have used the MDA criteria to evaluate BM lesions (<a id="xref-ref-34-1" class="xref-bibr" href="#ref-34">34</a>). ICI combination therapy for mRCC is safe for elderly patients (<a id="xref-ref-35-1" class="xref-bibr" href="#ref-35">35</a>) and more effective than TKI alone (<a id="xref-ref-36-1" class="xref-bibr" href="#ref-36">36</a>), but the efficacy for BM is an issue for further investigation.</p><p id="p-34">In this study, we revealed that TKIs may have higher efficacy than nivolumab against BM lesions, and poor IMDC risk classification and elevated serum ALP concentrations are associated with a poorer prognosis in patients with mRCC and BM receiving second-line therapy. Overall, TKIs may be more effective than nivolumab in treating patients with mRCC with metastases limited to the bone.</p></div><div class="section fn-group" id="fn-group-1"><h2>Footnotes</h2><ul><li class="fn" id="fn-1"><p id="p-1"><strong>Authors’ Contributions</strong></p><p id="p-2">G.Y. contributed to data collection and analysis, table and figure preparation, reference collection, and manuscript writing. G.Y. and T.K. contributed to data collection and analysis, and supervised all activities. A.Y., M.T., Y.H., L.Y., S.N., Y.O., T.O., T.U., A.Y., Y.I., T.H., Y.Y., K.H., A.K., T.T., K.N., S.T., M.T., and N.N. supervised all the activities. The first draft of the manuscript was prepared by G. Y. and T. K. All Authors have read and approved the published version of the manuscript.</p></li><li class="fn" id="fn-2"><p id="p-35"><strong>Conflicts of Interest</strong></p><p id="p-36">The Authors declare no competing interests in relation to this study.</p></li><li class="fn" id="fn-3"><p id="p-37"><strong>Funding</strong></p><p id="p-38">This study was supported by JSPS KAKENHI (grant number: 21K09396).</p></li></ul></div><ul class="history-list"><li xmlns:hwp="http://schema.highwire.org/Journal" class="received" hwp:start="2024-12-20"><span class="received-label">Received </span>December 20, 2024.</li><li xmlns:hwp="http://schema.highwire.org/Journal" class="rev-recd" hwp:start="2025-01-07"><span class="rev-recd-label">Revision received </span>January 7, 2025.</li><li xmlns:hwp="http://schema.highwire.org/Journal" class="accepted" hwp:start="2025-01-08"><span class="accepted-label">Accepted </span>January 8, 2025.</li></ul><ul class="copyright-statement"><li class="fn" id="copyright-statement-1">Copyright © 2025 International Institute of Anticancer Research (Dr. George J. Delinasios), All rights reserved.</li></ul><div class="license" id="license-1"><p id="p-3">This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY-NC-ND) 4.0 international license (<a href="https://creativecommons.org/licenses/by-nc-nd/4.0" rel="license">https://creativecommons.org/licenses/by-nc-nd/4.0</a>).</p></div><div class="section ref-list" id="ref-list-1"><h2 class="">References</h2><ol class="cit-list"><li><a class="rev-xref-ref" href="#xref-ref-1-1" title="View reference 1 in text" id="ref-1">↵</a><div class="cit ref-cit ref-journal" id="cit-45.2.639.1" data-doi="10.1016/j.eururo.2022.08.019"><div class="cit-metadata"><ol class="cit-auth-list"><li><span class="cit-auth"><span class="cit-name-surname">Bukavina</span> <span class="cit-name-given-names">L</span></span>, </li><li><span class="cit-auth"><span class="cit-name-surname">Bensalah</span> <span class="cit-name-given-names">K</span></span>, </li><li><span class="cit-auth"><span class="cit-name-surname">Bray</span> <span class="cit-name-given-names">F</span></span>, </li><li><span class="cit-auth"><span class="cit-name-surname">Carlo</span> <span class="cit-name-given-names">M</span></span>, </li><li><span class="cit-auth"><span class="cit-name-surname">Challacombe</span> <span class="cit-name-given-names">B</span></span>, </li><li><span class="cit-auth"><span class="cit-name-surname">Karam</span> <span class="cit-name-given-names">JA</span></span>, </li><li><span class="cit-auth"><span class="cit-name-surname">Kassouf</span> <span class="cit-name-given-names">W</span></span>, </li><li><span class="cit-auth"><span class="cit-name-surname">Mitchell</span> <span class="cit-name-given-names">T</span></span>, </li><li><span class="cit-auth"><span class="cit-name-surname">Montironi</span> <span class="cit-name-given-names">R</span></span>, </li><li><span class="cit-auth"><span class="cit-name-surname">O’Brien</span> <span class="cit-name-given-names">T</span></span>, </li><li><span class="cit-auth"><span class="cit-name-surname">Panebianco</span> <span class="cit-name-given-names">V</span></span>, </li><li><span class="cit-auth"><span class="cit-name-surname">Scelo</span> <span class="cit-name-given-names">G</span></span>, </li><li><span class="cit-auth"><span class="cit-name-surname">Shuch</span> <span class="cit-name-given-names">B</span></span>, </li><li><span class="cit-auth"><span class="cit-name-surname">van Poppel</span> <span class="cit-name-given-names">H</span></span>, </li><li><span class="cit-auth"><span class="cit-name-surname">Blosser</span> <span class="cit-name-given-names">CD</span></span>, </li><li><span class="cit-auth"><span class="cit-name-surname">Psutka</span> <span class="cit-name-given-names">SP</span></span></li></ol><cite>: <span class="cit-article-title">Epidemiology of renal cell carcinoma: 2022 update</span>. <abbr class="cit-jnl-abbrev">Eur Urol</abbr> <span class="cit-vol">82</span>(<span class="cit-issue">5</span>): <span class="cit-fpage">529</span>-<span class="cit-lpage">542</span>, <span class="cit-pub-date">2022</span>.<span class="cit-pub-id-sep cit-pub-id-doi-sep"> </span><span class="cit-pub-id-scheme">DOI: </span><span class="cit-pub-id cit-pub-id-doi">10.1016/j.eururo.2022.08.019</span></cite></div><div class="cit-extra"><a href="{openurl}?query=rft.jtitle%253DEur%2BUrol%26rft.volume%253D82%26rft.spage%253D529%26rft_id%253Dinfo%253Adoi%252F10.1016%252Fj.eururo.2022.08.019%26rft_id%253Dinfo%253Apmid%252F36100483%26rft.genre%253Darticle%26rft_val_fmt%253Dinfo%253Aofi%252Ffmt%253Akev%253Amtx%253Ajournal%26ctx_ver%253DZ39.88-2004%26url_ver%253DZ39.88-2004%26url_ctx_fmt%253Dinfo%253Aofi%252Ffmt%253Akev%253Amtx%253Actx" class="cit-ref-sprinkles cit-ref-sprinkles-openurl cit-ref-sprinkles-open-url"><span>OpenUrl</span></a><a href="/lookup/external-ref?access_num=10.1016/j.eururo.2022.08.019&link_type=DOI" class="cit-ref-sprinkles cit-ref-sprinkles-doi cit-ref-sprinkles-crossref"><span>CrossRef</span></a><a href="/lookup/external-ref?access_num=36100483&link_type=MED&atom=%2Fanticanres%2F45%2F2%2F639.atom" class="cit-ref-sprinkles cit-ref-sprinkles-medline"><span>PubMed</span></a></div></div></li><li><a class="rev-xref-ref" href="#xref-ref-2-1" title="View reference 2 in text" id="ref-2">↵</a><div class="cit ref-cit ref-journal" id="cit-45.2.639.2" data-doi="10.3390/diagnostics13142430"><div class="cit-metadata"><ol class="cit-auth-list"><li><span class="cit-auth"><span class="cit-name-surname">Parosanu</span> <span class="cit-name-given-names">AI</span></span>, </li><li><span class="cit-auth"><span class="cit-name-surname">Baston</span> <span class="cit-name-given-names">C</span></span>, </li><li><span class="cit-auth"><span class="cit-name-surname">Stanciu</span> <span class="cit-name-given-names">IM</span></span>, </li><li><span class="cit-auth"><span class="cit-name-surname">Parlog</span> <span class="cit-name-given-names">CF</span></span>, </li><li><span class="cit-auth"><span class="cit-name-surname">Nitipir</span> <span class="cit-name-given-names">C</span></span></li></ol><cite>: <span class="cit-article-title">Second-line treatment of metastatic renal cell carcinoma in the era of predictive biomarkers</span>. <abbr class="cit-jnl-abbrev">Diagnostics (Basel)</abbr> <span class="cit-vol">13</span>(<span class="cit-issue">14</span>): <span class="cit-fpage">2430</span>, <span class="cit-pub-date">2023</span>.<span class="cit-pub-id-sep cit-pub-id-doi-sep"> </span><span class="cit-pub-id-scheme">DOI: </span><span class="cit-pub-id cit-pub-id-doi">10.3390/diagnostics13142430</span></cite></div><div class="cit-extra"><a href="{openurl}?query=rft.jtitle%253DDiagnostics%2B%2528Basel%2529%26rft.volume%253D13%26rft.spage%253D2430%26rft_id%253Dinfo%253Adoi%252F10.3390%252Fdiagnostics13142430%26rft_id%253Dinfo%253Apmid%252F37510173%26rft.genre%253Darticle%26rft_val_fmt%253Dinfo%253Aofi%252Ffmt%253Akev%253Amtx%253Ajournal%26ctx_ver%253DZ39.88-2004%26url_ver%253DZ39.88-2004%26url_ctx_fmt%253Dinfo%253Aofi%252Ffmt%253Akev%253Amtx%253Actx" class="cit-ref-sprinkles cit-ref-sprinkles-openurl cit-ref-sprinkles-open-url"><span>OpenUrl</span></a><a href="/lookup/external-ref?access_num=10.3390/diagnostics13142430&link_type=DOI" class="cit-ref-sprinkles cit-ref-sprinkles-doi cit-ref-sprinkles-crossref"><span>CrossRef</span></a><a href="/lookup/external-ref?access_num=37510173&link_type=MED&atom=%2Fanticanres%2F45%2F2%2F639.atom" class="cit-ref-sprinkles cit-ref-sprinkles-medline"><span>PubMed</span></a></div></div></li><li><a class="rev-xref-ref" href="#xref-ref-3-1" title="View reference 3 in text" id="ref-3">↵</a><div class="cit ref-cit ref-journal" id="cit-45.2.639.3" data-doi="10.1016/j.eururo.2022.03.006"><div class="cit-metadata"><ol class="cit-auth-list"><li><span class="cit-auth"><span class="cit-name-surname">Ljungberg</span> <span class="cit-name-given-names">B</span></span>, </li><li><span class="cit-auth"><span class="cit-name-surname">Albiges</span> <span class="cit-name-given-names">L</span></span>, </li><li><span class="cit-auth"><span class="cit-name-surname">Abu-Ghanem</span> <span class="cit-name-given-names">Y</span></span>, </li><li><span class="cit-auth"><span class="cit-name-surname">Bedke</span> <span class="cit-name-given-names">J</span></span>, </li><li><span class="cit-auth"><span class="cit-name-surname">Capitanio</span> <span class="cit-name-given-names">U</span></span>, </li><li><span class="cit-auth"><span class="cit-name-surname">Dabestani</span> <span class="cit-name-given-names">S</span></span>, </li><li><span class="cit-auth"><span class="cit-name-surname">Fernández-Pello</span> <span class="cit-name-given-names">S</span></span>, </li><li><span class="cit-auth"><span class="cit-name-surname">Giles</span> <span class="cit-name-given-names">RH</span></span>, </li><li><span class="cit-auth"><span class="cit-name-surname">Hofmann</span> <span class="cit-name-given-names">F</span></span>, </li><li><span class="cit-auth"><span class="cit-name-surname">Hora</span> <span class="cit-name-given-names">M</span></span>, </li><li><span class="cit-auth"><span class="cit-name-surname">Klatte</span> <span class="cit-name-given-names">T</span></span>, </li><li><span class="cit-auth"><span class="cit-name-surname">Kuusk</span> <span class="cit-name-given-names">T</span></span>, </li><li><span class="cit-auth"><span class="cit-name-surname">Lam</span> <span class="cit-name-given-names">TB</span></span>, </li><li><span class="cit-auth"><span class="cit-name-surname">Marconi</span> <span class="cit-name-given-names">L</span></span>, </li><li><span class="cit-auth"><span class="cit-name-surname">Powles</span> <span class="cit-name-given-names">T</span></span>, </li><li><span class="cit-auth"><span class="cit-name-surname">Tahbaz</span> <span class="cit-name-given-names">R</span></span>, </li><li><span class="cit-auth"><span class="cit-name-surname">Volpe</span> <span class="cit-name-given-names">A</span></span>, </li><li><span class="cit-auth"><span class="cit-name-surname">Bex</span> <span class="cit-name-given-names">A</span></span></li></ol><cite>: <span class="cit-article-title">European Association of Urology guidelines on renal cell carcinoma: the 2022 update</span>. <abbr class="cit-jnl-abbrev">Eur Urol</abbr> <span class="cit-vol">82</span>(<span class="cit-issue">4</span>): <span class="cit-fpage">399</span>-<span class="cit-lpage">410</span>, <span class="cit-pub-date">2022</span>.<span class="cit-pub-id-sep cit-pub-id-doi-sep"> </span><span class="cit-pub-id-scheme">DOI: </span><span class="cit-pub-id cit-pub-id-doi">10.1016/j.eururo.2022.03.006</span></cite></div><div class="cit-extra"><a href="{openurl}?query=rft.jtitle%253DEur%2BUrol%26rft.volume%253D82%26rft.spage%253D399%26rft_id%253Dinfo%253Adoi%252F10.1016%252Fj.eururo.2022.03.006%26rft_id%253Dinfo%253Apmid%252F35346519%26rft.genre%253Darticle%26rft_val_fmt%253Dinfo%253Aofi%252Ffmt%253Akev%253Amtx%253Ajournal%26ctx_ver%253DZ39.88-2004%26url_ver%253DZ39.88-2004%26url_ctx_fmt%253Dinfo%253Aofi%252Ffmt%253Akev%253Amtx%253Actx" class="cit-ref-sprinkles cit-ref-sprinkles-openurl cit-ref-sprinkles-open-url"><span>OpenUrl</span></a><a href="/lookup/external-ref?access_num=10.1016/j.eururo.2022.03.006&link_type=DOI" class="cit-ref-sprinkles cit-ref-sprinkles-doi cit-ref-sprinkles-crossref"><span>CrossRef</span></a><a href="/lookup/external-ref?access_num=35346519&link_type=MED&atom=%2Fanticanres%2F45%2F2%2F639.atom" class="cit-ref-sprinkles cit-ref-sprinkles-medline"><span>PubMed</span></a></div></div></li><li><a class="rev-xref-ref" href="#xref-ref-4-1" title="View reference 4 in text" id="ref-4">↵</a><div class="cit ref-cit ref-journal" id="cit-45.2.639.4" data-doi="10.1111/iju.15130"><div class="cit-metadata"><ol class="cit-auth-list"><li><span class="cit-auth"><span class="cit-name-surname">Kato</span> <span class="cit-name-given-names">T</span></span>, </li><li><span class="cit-auth"><span class="cit-name-surname">Yumiba</span> <span class="cit-name-given-names">S</span></span>, </li><li><span class="cit-auth"><span class="cit-name-surname">Nakata</span> <span class="cit-name-given-names">W</span></span>, </li><li><span class="cit-auth"><span class="cit-name-surname">Nakano</span> <span class="cit-name-given-names">K</span></span>, </li><li><span class="cit-auth"><span class="cit-name-surname">Nagahara</span> <span class="cit-name-given-names">A</span></span>, </li><li><span class="cit-auth"><span class="cit-name-surname">Matsuzaki</span> <span class="cit-name-given-names">K</span></span>, </li><li><span class="cit-auth"><span class="cit-name-surname">Hayashi</span> <span class="cit-name-given-names">Y</span></span>, </li><li><span class="cit-auth"><span class="cit-name-surname">Hatano</span> <span class="cit-name-given-names">K</span></span>, </li><li><span class="cit-auth"><span class="cit-name-surname">Kawashima</span> <span class="cit-name-given-names">A</span></span>, </li><li><span class="cit-auth"><span class="cit-name-surname">Takao</span> <span class="cit-name-given-names">T</span></span>, </li><li><span class="cit-auth"><span class="cit-name-surname">Nishimura</span> <span class="cit-name-given-names">K</span></span>, </li><li><span class="cit-auth"><span class="cit-name-surname">Nakai</span> <span class="cit-name-given-names">Y</span></span>, </li><li><span class="cit-auth"><span class="cit-name-surname">Nakayama</span> <span class="cit-name-given-names">M</span></span>, </li><li><span class="cit-auth"><span class="cit-name-surname">Nishimura</span> <span class="cit-name-given-names">K</span></span>, </li><li><span class="cit-auth"><span class="cit-name-surname">Takada</span> <span class="cit-name-given-names">S</span></span>, </li><li><span class="cit-auth"><span class="cit-name-surname">Tsujihata</span> <span class="cit-name-given-names">M</span></span>, </li><li><span class="cit-auth"><span class="cit-name-surname">Uemura</span> <span class="cit-name-given-names">M</span></span>, </li><li><span class="cit-auth"><span class="cit-name-surname">Nonomura</span> <span class="cit-name-given-names">N</span></span>, </li><li><span class="cit-auth"><span class="cit-name-surname">Imamura</span> <span class="cit-name-given-names">R</span></span></li></ol><cite>: <span class="cit-article-title">A comparative study on nivolumab and axitinib as secondary treatment in patients with metastatic renal cell carcinoma: A multi-institutional retrospective study in Japan</span>. <abbr class="cit-jnl-abbrev">Int J Urol</abbr> <span class="cit-vol">30</span>(<span class="cit-issue">9</span>): <span class="cit-fpage">723</span>-<span class="cit-lpage">729</span>, <span class="cit-pub-date">2023</span>.<span class="cit-pub-id-sep cit-pub-id-doi-sep"> </span><span class="cit-pub-id-scheme">DOI: </span><span class="cit-pub-id cit-pub-id-doi">10.1111/iju.15130</span></cite></div><div class="cit-extra"><a href="{openurl}?query=rft.jtitle%253DInt%2BJ%2BUrol%26rft.volume%253D30%26rft.spage%253D723%26rft_id%253Dinfo%253Adoi%252F10.1111%252Fiju.15130%26rft_id%253Dinfo%253Apmid%252F36578154%26rft.genre%253Darticle%26rft_val_fmt%253Dinfo%253Aofi%252Ffmt%253Akev%253Amtx%253Ajournal%26ctx_ver%253DZ39.88-2004%26url_ver%253DZ39.88-2004%26url_ctx_fmt%253Dinfo%253Aofi%252Ffmt%253Akev%253Amtx%253Actx" class="cit-ref-sprinkles cit-ref-sprinkles-openurl cit-ref-sprinkles-open-url"><span>OpenUrl</span></a><a href="/lookup/external-ref?access_num=10.1111/iju.15130&link_type=DOI" class="cit-ref-sprinkles cit-ref-sprinkles-doi cit-ref-sprinkles-crossref"><span>CrossRef</span></a><a href="/lookup/external-ref?access_num=36578154&link_type=MED&atom=%2Fanticanres%2F45%2F2%2F639.atom" class="cit-ref-sprinkles cit-ref-sprinkles-medline"><span>PubMed</span></a></div></div></li><li><a class="rev-xref-ref" href="#xref-ref-5-1" title="View reference 5 in text" id="ref-5">↵</a><div class="cit ref-cit ref-journal" id="cit-45.2.639.5" data-doi="10.1093/annonc/mdr362"><div class="cit-metadata"><ol class="cit-auth-list"><li><span class="cit-auth"><span class="cit-name-surname">Bianchi</span> <span class="cit-name-given-names">M</span></span>, </li><li><span class="cit-auth"><span class="cit-name-surname">Sun</span> <span class="cit-name-given-names">M</span></span>, </li><li><span class="cit-auth"><span class="cit-name-surname">Jeldres</span> <span class="cit-name-given-names">C</span></span>, </li><li><span class="cit-auth"><span class="cit-name-surname">Shariat</span> <span class="cit-name-given-names">SF</span></span>, </li><li><span class="cit-auth"><span class="cit-name-surname">Trinh</span> <span class="cit-name-given-names">QD</span></span>, </li><li><span class="cit-auth"><span class="cit-name-surname">Briganti</span> <span class="cit-name-given-names">A</span></span>, </li><li><span class="cit-auth"><span class="cit-name-surname">Tian</span> <span class="cit-name-given-names">Z</span></span>, </li><li><span class="cit-auth"><span class="cit-name-surname">Schmitges</span> <span class="cit-name-given-names">J</span></span>, </li><li><span class="cit-auth"><span class="cit-name-surname">Graefen</span> <span class="cit-name-given-names">M</span></span>, </li><li><span class="cit-auth"><span class="cit-name-surname">Perrotte</span> <span class="cit-name-given-names">P</span></span>, </li><li><span class="cit-auth"><span class="cit-name-surname">Menon</span> <span class="cit-name-given-names">M</span></span>, </li><li><span class="cit-auth"><span class="cit-name-surname">Montorsi</span> <span class="cit-name-given-names">F</span></span>, </li><li><span class="cit-auth"><span class="cit-name-surname">Karakiewicz</span> <span class="cit-name-given-names">PI</span></span></li></ol><cite>: <span class="cit-article-title">Distribution of metastatic sites in renal cell carcinoma: a population-based analysis</span>. <abbr class="cit-jnl-abbrev">Ann Oncol</abbr> <span class="cit-vol">23</span>(<span class="cit-issue">4</span>): <span class="cit-fpage">973</span>-<span class="cit-lpage">980</span>, <span class="cit-pub-date">2012</span>.<span class="cit-pub-id-sep cit-pub-id-doi-sep"> </span><span class="cit-pub-id-scheme">DOI: </span><span class="cit-pub-id cit-pub-id-doi">10.1093/annonc/mdr362</span></cite></div><div class="cit-extra"><a href="{openurl}?query=rft.jtitle%253DAnn%2BOncol%26rft_id%253Dinfo%253Adoi%252F10.1093%252Fannonc%252Fmdr362%26rft_id%253Dinfo%253Apmid%252F21890909%26rft.genre%253Darticle%26rft_val_fmt%253Dinfo%253Aofi%252Ffmt%253Akev%253Amtx%253Ajournal%26ctx_ver%253DZ39.88-2004%26url_ver%253DZ39.88-2004%26url_ctx_fmt%253Dinfo%253Aofi%252Ffmt%253Akev%253Amtx%253Actx" class="cit-ref-sprinkles cit-ref-sprinkles-openurl cit-ref-sprinkles-open-url"><span>OpenUrl</span></a><a href="/lookup/external-ref?access_num=10.1093/annonc/mdr362&link_type=DOI" class="cit-ref-sprinkles cit-ref-sprinkles-doi cit-ref-sprinkles-crossref"><span>CrossRef</span></a><a href="/lookup/external-ref?access_num=21890909&link_type=MED&atom=%2Fanticanres%2F45%2F2%2F639.atom" class="cit-ref-sprinkles cit-ref-sprinkles-medline"><span>PubMed</span></a></div></div></li><li><a class="rev-xref-ref" href="#xref-ref-6-1" title="View reference 6 in text" id="ref-6">↵</a><div class="cit ref-cit ref-journal" id="cit-45.2.639.6" data-doi="10.1016/j.eururo.2014.02.040"><div class="cit-metadata"><ol class="cit-auth-list"><li><span class="cit-auth"><span class="cit-name-surname">McKay</span> <span class="cit-name-given-names">RR</span></span>, </li><li><span class="cit-auth"><span class="cit-name-surname">Lin</span> <span class="cit-name-given-names">X</span></span>, </li><li><span class="cit-auth"><span class="cit-name-surname">Perkins</span> <span class="cit-name-given-names">JJ</span></span>, </li><li><span class="cit-auth"><span class="cit-name-surname">Heng</span> <span class="cit-name-given-names">DY</span></span>, </li><li><span class="cit-auth"><span class="cit-name-surname">Simantov</span> <span class="cit-name-given-names">R</span></span>, </li><li><span class="cit-auth"><span class="cit-name-surname">Choueiri</span> <span class="cit-name-given-names">TK</span></span></li></ol><cite>: <span class="cit-article-title">Prognostic significance of bone metastases and bisphosphonate therapy in patients with renal cell carcinoma</span>. <abbr class="cit-jnl-abbrev">Eur Urol</abbr> <span class="cit-vol">66</span>(<span class="cit-issue">3</span>): <span class="cit-fpage">502</span>-<span class="cit-lpage">509</span>, <span class="cit-pub-date">2014</span>.<span class="cit-pub-id-sep cit-pub-id-doi-sep"> </span><span class="cit-pub-id-scheme">DOI: </span><span class="cit-pub-id cit-pub-id-doi">10.1016/j.eururo.2014.02.040</span></cite></div><div class="cit-extra"><a href="{openurl}?query=rft.jtitle%253DEur%2BUrol%26rft.volume%253D66%26rft.spage%253D502%26rft_id%253Dinfo%253Adoi%252F10.1016%252Fj.eururo.2014.02.040%26rft_id%253Dinfo%253Apmid%252F24613250%26rft.genre%253Darticle%26rft_val_fmt%253Dinfo%253Aofi%252Ffmt%253Akev%253Amtx%253Ajournal%26ctx_ver%253DZ39.88-2004%26url_ver%253DZ39.88-2004%26url_ctx_fmt%253Dinfo%253Aofi%252Ffmt%253Akev%253Amtx%253Actx" class="cit-ref-sprinkles cit-ref-sprinkles-openurl cit-ref-sprinkles-open-url"><span>OpenUrl</span></a><a href="/lookup/external-ref?access_num=10.1016/j.eururo.2014.02.040&link_type=DOI" class="cit-ref-sprinkles cit-ref-sprinkles-doi cit-ref-sprinkles-crossref"><span>CrossRef</span></a><a href="/lookup/external-ref?access_num=24613250&link_type=MED&atom=%2Fanticanres%2F45%2F2%2F639.atom" class="cit-ref-sprinkles cit-ref-sprinkles-medline"><span>PubMed</span></a></div></div></li><li><a class="rev-xref-ref" href="#xref-ref-7-1" title="View reference 7 in text" id="ref-7">↵</a><div class="cit ref-cit ref-journal" id="cit-45.2.639.7" data-doi="10.21873/anticanres.14913"><div class="cit-metadata"><ol class="cit-auth-list"><li><span class="cit-auth"><span class="cit-name-surname">Negishi</span> <span class="cit-name-given-names">T</span></span>, </li><li><span class="cit-auth"><span class="cit-name-surname">Furubayashi</span> <span class="cit-name-given-names">N</span></span>, </li><li><span class="cit-auth"><span class="cit-name-surname">Nakagawa</span> <span class="cit-name-given-names">T</span></span>, </li><li><span class="cit-auth"><span class="cit-name-surname">Nishiyama</span> <span class="cit-name-given-names">N</span></span>, </li><li><span class="cit-auth"><span class="cit-name-surname">Kitamura</span> <span class="cit-name-given-names">H</span></span>, </li><li><span class="cit-auth"><span class="cit-name-surname">Hori</span> <span class="cit-name-given-names">Y</span></span>, </li><li><span class="cit-auth"><span class="cit-name-surname">Kuroiwa</span> <span class="cit-name-given-names">K</span></span>, </li><li><span class="cit-auth"><span class="cit-name-surname">Son</span> <span class="cit-name-given-names">Y</span></span>, </li><li><span class="cit-auth"><span class="cit-name-surname">Seki</span> <span class="cit-name-given-names">N</span></span>, </li><li><span class="cit-auth"><span class="cit-name-surname">Tomoda</span> <span class="cit-name-given-names">T</span></span>, </li><li><span class="cit-auth"><span class="cit-name-surname">Okajima</span> <span class="cit-name-given-names">E</span></span>, </li><li><span class="cit-auth"><span class="cit-name-surname">Nakamura</span> <span class="cit-name-given-names">M</span></span></li></ol><cite>: <span class="cit-article-title">Site-specific response to nivolumab in renal cell carcinoma</span>. <abbr class="cit-jnl-abbrev">Anticancer Res</abbr> <span class="cit-vol">41</span>(<span class="cit-issue">3</span>): <span class="cit-fpage">1539</span>-<span class="cit-lpage">1545</span>, <span class="cit-pub-date">2021</span>.<span class="cit-pub-id-sep cit-pub-id-doi-sep"> </span><span class="cit-pub-id-scheme">DOI: </span><span class="cit-pub-id cit-pub-id-doi">10.21873/anticanres.14913</span></cite></div><div class="cit-extra"><a href="{openurl}?query=rft.jtitle%253DAnticancer%2BResearch%26rft.stitle%253DAnticancer%2BRes%26rft.aulast%253DNEGISHI%26rft.auinit1%253DT.%26rft.volume%253D41%26rft.issue%253D3%26rft.spage%253D1539%26rft.epage%253D1545%26rft.atitle%253DSite-specific%2BResponse%2Bto%2BNivolumab%2Bin%2BRenal%2BCell%2BCarcinoma%26rft_id%253Dinfo%253Adoi%252F10.21873%252Fanticanres.14913%26rft_id%253Dinfo%253Apmid%252F33788747%26rft.genre%253Darticle%26rft_val_fmt%253Dinfo%253Aofi%252Ffmt%253Akev%253Amtx%253Ajournal%26ctx_ver%253DZ39.88-2004%26url_ver%253DZ39.88-2004%26url_ctx_fmt%253Dinfo%253Aofi%252Ffmt%253Akev%253Amtx%253Actx" class="cit-ref-sprinkles cit-ref-sprinkles-openurl cit-ref-sprinkles-open-url"><span>OpenUrl</span></a><a href="/lookup/ijlink/YTozOntzOjQ6InBhdGgiO3M6MTQ6Ii9sb29rdXAvaWpsaW5rIjtzOjU6InF1ZXJ5IjthOjQ6e3M6ODoibGlua1R5cGUiO3M6NDoiQUJTVCI7czoxMToiam91cm5hbENvZGUiO3M6MTA6ImFudGljYW5yZXMiO3M6NToicmVzaWQiO3M6OToiNDEvMy8xNTM5IjtzOjQ6ImF0b20iO3M6MjU6Ii9hbnRpY2FucmVzLzQ1LzIvNjM5LmF0b20iO31zOjg6ImZyYWdtZW50IjtzOjA6IiI7fQ==/YTozOntzOjQ6InBhdGgiO3M6MzAzOiIvbG9va3VwL2lqbGluay9ZVG96T250ek9qUTZJbkJoZEdnaU8zTTZNVFE2SWk5c2IyOXJkWEF2YVdwc2FXNXJJanR6T2pVNkluRjFaWEo1SWp0aE9qUTZlM002T0RvaWJHbHVhMVI1Y0dVaU8zTTZORG9pUVVKVFZDSTdjem94TVRvaWFtOTFjbTVoYkVOdlpHVWlPM002TVRBNkltRnVkR2xqWVc1eVpYTWlPM002TlRvaWNtVnphV1FpTzNNNk9Ub2lOREV2TXk4eE5UTTVJanR6T2pRNkltRjBiMjBpTzNNNk1qVTZJaTloYm5ScFkyRnVjbVZ6THpRMUx6SXZOak01TG1GMGIyMGlPMzF6T2pnNkltWnlZV2R0Wlc1MElqdHpPakE2SWlJN2ZRPT0iO3M6NToicXVlcnkiO2E6MDp7fXM6ODoiZnJhZ21lbnQiO3M6MDoiIjt9" class="cit-ref-sprinkles cit-ref-sprinkles-ijlink"><span><span class="cit-reflinks-abstract">Abstract</span><span class="cit-sep cit-reflinks-variant-name-sep">/</span><span class="cit-reflinks-full-text"><span class="free-full-text">FREE </span>Full Text</span></span></a></div></div></li><li><a class="rev-xref-ref" href="#xref-ref-8-1" title="View reference 8 in text" id="ref-8">↵</a><div class="cit ref-cit ref-journal" id="cit-45.2.639.8" data-doi="10.1200/JCO.2017.74.7352"><div class="cit-metadata"><ol class="cit-auth-list"><li><span class="cit-auth"><span class="cit-name-surname">Escudier</span> <span class="cit-name-given-names">B</span></span>, </li><li><span class="cit-auth"><span class="cit-name-surname">Powles</span> <span class="cit-name-given-names">T</span></span>, </li><li><span class="cit-auth"><span class="cit-name-surname">Motzer</span> <span class="cit-name-given-names">RJ</span></span>, </li><li><span class="cit-auth"><span class="cit-name-surname">Olencki</span> <span class="cit-name-given-names">T</span></span>, </li><li><span class="cit-auth"><span class="cit-name-surname">Arén Frontera</span> <span class="cit-name-given-names">O</span></span>, </li><li><span class="cit-auth"><span class="cit-name-surname">Oudard</span> <span class="cit-name-given-names">S</span></span>, </li><li><span class="cit-auth"><span class="cit-name-surname">Rolland</span> <span class="cit-name-given-names">F</span></span>, </li><li><span class="cit-auth"><span class="cit-name-surname">Tomczak</span> <span class="cit-name-given-names">P</span></span>, </li><li><span class="cit-auth"><span class="cit-name-surname">Castellano</span> <span class="cit-name-given-names">D</span></span>, </li><li><span class="cit-auth"><span class="cit-name-surname">Appleman</span> <span class="cit-name-given-names">LJ</span></span>, </li><li><span class="cit-auth"><span class="cit-name-surname">Drabkin</span> <span class="cit-name-given-names">H</span></span>, </li><li><span class="cit-auth"><span class="cit-name-surname">Vaena</span> <span class="cit-name-given-names">D</span></span>, </li><li><span class="cit-auth"><span class="cit-name-surname">Milwee</span> <span class="cit-name-given-names">S</span></span>, </li><li><span class="cit-auth"><span class="cit-name-surname">Youkstetter</span> <span class="cit-name-given-names">J</span></span>, </li><li><span class="cit-auth"><span class="cit-name-surname">Lougheed</span> <span class="cit-name-given-names">JC</span></span>, </li><li><span class="cit-auth"><span class="cit-name-surname">Bracarda</span> <span class="cit-name-given-names">S</span></span>, </li><li><span class="cit-auth"><span class="cit-name-surname">Choueiri</span> <span class="cit-name-given-names">TK</span></span></li></ol><cite>: <span class="cit-article-title">Cabozantinib, a new standard of care for patients with advanced renal cell carcinoma and bone metastases? Subgroup analysis of the METEOR trial</span>. <abbr class="cit-jnl-abbrev">J Clin Oncol</abbr> <span class="cit-vol">36</span>(<span class="cit-issue">8</span>): <span class="cit-fpage">765</span>-<span class="cit-lpage">772</span>, <span class="cit-pub-date">2018</span>.<span class="cit-pub-id-sep cit-pub-id-doi-sep"> </span><span class="cit-pub-id-scheme">DOI: </span><span class="cit-pub-id cit-pub-id-doi">10.1200/JCO.2017.74.7352</span></cite></div><div class="cit-extra"><a href="{openurl}?query=rft.jtitle%253DJ%2BClin%2BOncol%26rft.volume%253D36%26rft.spage%253D765%26rft_id%253Dinfo%253Adoi%252F10.1200%252FJCO.2017.74.7352%26rft_id%253Dinfo%253Apmid%252F29309249%26rft.genre%253Darticle%26rft_val_fmt%253Dinfo%253Aofi%252Ffmt%253Akev%253Amtx%253Ajournal%26ctx_ver%253DZ39.88-2004%26url_ver%253DZ39.88-2004%26url_ctx_fmt%253Dinfo%253Aofi%252Ffmt%253Akev%253Amtx%253Actx" class="cit-ref-sprinkles cit-ref-sprinkles-openurl cit-ref-sprinkles-open-url"><span>OpenUrl</span></a><a href="/lookup/external-ref?access_num=10.1200/JCO.2017.74.7352&link_type=DOI" class="cit-ref-sprinkles cit-ref-sprinkles-doi cit-ref-sprinkles-crossref"><span>CrossRef</span></a><a href="/lookup/external-ref?access_num=29309249&link_type=MED&atom=%2Fanticanres%2F45%2F2%2F639.atom" class="cit-ref-sprinkles cit-ref-sprinkles-medline"><span>PubMed</span></a></div></div></li><li><a class="rev-xref-ref" href="#xref-ref-9-1" title="View reference 9 in text" id="ref-9">↵</a><div class="cit ref-cit ref-journal" id="cit-45.2.639.9" data-doi="10.1007/s10147-021-02107-3"><div class="cit-metadata"><ol class="cit-auth-list"><li><span class="cit-auth"><span class="cit-name-surname">Ujike</span> <span class="cit-name-given-names">T</span></span>, </li><li><span class="cit-auth"><span class="cit-name-surname">Uemura</span> <span class="cit-name-given-names">M</span></span>, </li><li><span class="cit-auth"><span class="cit-name-surname">Kato</span> <span class="cit-name-given-names">T</span></span>, </li><li><span class="cit-auth"><span class="cit-name-surname">Hatano</span> <span class="cit-name-given-names">K</span></span>, </li><li><span class="cit-auth"><span class="cit-name-surname">Kawashima</span> <span class="cit-name-given-names">A</span></span>, </li><li><span class="cit-auth"><span class="cit-name-surname">Nagahara</span> <span class="cit-name-given-names">A</span></span>, </li><li><span class="cit-auth"><span class="cit-name-surname">Fujita</span> <span class="cit-name-given-names">K</span></span>, </li><li><span class="cit-auth"><span class="cit-name-surname">Imamura</span> <span class="cit-name-given-names">R</span></span>, </li><li><span class="cit-auth"><span class="cit-name-surname">Nonomura</span> <span class="cit-name-given-names">N</span></span></li></ol><cite>: <span class="cit-article-title">Novel diagnostic model for bone metastases in renal cell carcinoma patients based on bone scintigraphy analyzed by computer-aided diagnosis software and bone turnover markers</span>. <abbr class="cit-jnl-abbrev">Int J Clin Oncol</abbr> <span class="cit-vol">27</span>(<span class="cit-issue">4</span>): <span class="cit-fpage">774</span>-<span class="cit-lpage">780</span>, <span class="cit-pub-date">2022</span>.<span class="cit-pub-id-sep cit-pub-id-doi-sep"> </span><span class="cit-pub-id-scheme">DOI: </span><span class="cit-pub-id cit-pub-id-doi">10.1007/s10147-021-02107-3</span></cite></div><div class="cit-extra"><a href="{openurl}?query=rft.jtitle%253DInt%2BJ%2BClin%2BOncol%26rft.volume%253D27%26rft.spage%253D774%26rft_id%253Dinfo%253Adoi%252F10.1007%252Fs10147-021-02107-3%26rft_id%253Dinfo%253Apmid%252F35119579%26rft.genre%253Darticle%26rft_val_fmt%253Dinfo%253Aofi%252Ffmt%253Akev%253Amtx%253Ajournal%26ctx_ver%253DZ39.88-2004%26url_ver%253DZ39.88-2004%26url_ctx_fmt%253Dinfo%253Aofi%252Ffmt%253Akev%253Amtx%253Actx" class="cit-ref-sprinkles cit-ref-sprinkles-openurl cit-ref-sprinkles-open-url"><span>OpenUrl</span></a><a href="/lookup/external-ref?access_num=10.1007/s10147-021-02107-3&link_type=DOI" class="cit-ref-sprinkles cit-ref-sprinkles-doi cit-ref-sprinkles-crossref"><span>CrossRef</span></a><a href="/lookup/external-ref?access_num=35119579&link_type=MED&atom=%2Fanticanres%2F45%2F2%2F639.atom" class="cit-ref-sprinkles cit-ref-sprinkles-medline"><span>PubMed</span></a></div></div></li><li><a class="rev-xref-ref" href="#xref-ref-10-1" title="View reference 10 in text" id="ref-10">↵</a><div class="cit ref-cit ref-journal" id="cit-45.2.639.10" data-doi="10.7150/jca.1.80"><div class="cit-metadata"><ol class="cit-auth-list"><li><span class="cit-auth"><span class="cit-name-surname">Costelloe</span> <span class="cit-name-given-names">CM</span></span>, </li><li><span class="cit-auth"><span class="cit-name-surname">Chuang</span> <span class="cit-name-given-names">HH</span></span>, </li><li><span class="cit-auth"><span class="cit-name-surname">Madewell</span> <span class="cit-name-given-names">JE</span></span>, </li><li><span class="cit-auth"><span class="cit-name-surname">Ueno</span> <span class="cit-name-given-names">NT</span></span></li></ol><cite>: <span class="cit-article-title">Cancer response criteria and bone metastases: RECIST 1.1, MDA and PERCIST</span>. <abbr class="cit-jnl-abbrev">J Cancer</abbr> <span class="cit-vol">1</span>: <span class="cit-fpage">80</span>-<span class="cit-lpage">92</span>, <span class="cit-pub-date">2010</span>.<span class="cit-pub-id-sep cit-pub-id-doi-sep"> </span><span class="cit-pub-id-scheme">DOI: </span><span class="cit-pub-id cit-pub-id-doi">10.7150/jca.1.80</span></cite></div><div class="cit-extra"><a href="{openurl}?query=rft.stitle%253DJ%2BCancer%26rft.aulast%253DCostelloe%26rft.auinit1%253DC.%2BM.%26rft.volume%253D1%26rft.spage%253D80%26rft.epage%253D92%26rft.atitle%253DCancer%2BResponse%2BCriteria%2Band%2BBone%2BMetastases%253A%2BRECIST%2B1.1%252C%2BMDA%2Band%2BPERCIST.%26rft_id%253Dinfo%253Adoi%252F10.7150%252Fjca.1.80%26rft_id%253Dinfo%253Apmid%252F20842228%26rft.genre%253Darticle%26rft_val_fmt%253Dinfo%253Aofi%252Ffmt%253Akev%253Amtx%253Ajournal%26ctx_ver%253DZ39.88-2004%26url_ver%253DZ39.88-2004%26url_ctx_fmt%253Dinfo%253Aofi%252Ffmt%253Akev%253Amtx%253Actx" class="cit-ref-sprinkles cit-ref-sprinkles-openurl cit-ref-sprinkles-open-url"><span>OpenUrl</span></a><a href="/lookup/external-ref?access_num=10.7150/jca.1.80&link_type=DOI" class="cit-ref-sprinkles cit-ref-sprinkles-doi cit-ref-sprinkles-crossref"><span>CrossRef</span></a><a href="/lookup/external-ref?access_num=20842228&link_type=MED&atom=%2Fanticanres%2F45%2F2%2F639.atom" class="cit-ref-sprinkles cit-ref-sprinkles-medline"><span>PubMed</span></a></div></div></li><li><a class="rev-xref-ref" href="#xref-ref-11-1" title="View reference 11 in text" id="ref-11">↵</a><div class="cit ref-cit ref-journal" id="cit-45.2.639.11" data-doi="10.1371/journal.pone.0211135"><div class="cit-metadata"><ol class="cit-auth-list"><li><span class="cit-auth"><span class="cit-name-surname">Iga</span> <span class="cit-name-given-names">N</span></span>, </li><li><span class="cit-auth"><span class="cit-name-surname">Otsuka</span> <span class="cit-name-given-names">A</span></span>, </li><li><span class="cit-auth"><span class="cit-name-surname">Yamamoto</span> <span class="cit-name-given-names">Y</span></span>, </li><li><span class="cit-auth"><span class="cit-name-surname">Nakashima</span> <span class="cit-name-given-names">C</span></span>, </li><li><span class="cit-auth"><span class="cit-name-surname">Honda</span> <span class="cit-name-given-names">T</span></span>, </li><li><span class="cit-auth"><span class="cit-name-surname">Kitoh</span> <span class="cit-name-given-names">A</span></span>, </li><li><span class="cit-auth"><span class="cit-name-surname">Nakajima</span> <span class="cit-name-given-names">S</span></span>, </li><li><span class="cit-auth"><span class="cit-name-surname">Egawa</span> <span class="cit-name-given-names">G</span></span>, </li><li><span class="cit-auth"><span class="cit-name-surname">Nomura</span> <span class="cit-name-given-names">T</span></span>, </li><li><span class="cit-auth"><span class="cit-name-surname">Dainichi</span> <span class="cit-name-given-names">T</span></span>, </li><li><span class="cit-auth"><span class="cit-name-surname">Matsushita</span> <span class="cit-name-given-names">S</span></span>, </li><li><span class="cit-auth"><span class="cit-name-surname">Tanizaki</span> <span class="cit-name-given-names">H</span></span>, </li><li><span class="cit-auth"><span class="cit-name-surname">Yamamoto</span> <span class="cit-name-given-names">Y</span></span>, </li><li><span class="cit-auth"><span class="cit-name-surname">Funakoshi</span> <span class="cit-name-given-names">T</span></span>, </li><li><span class="cit-auth"><span class="cit-name-surname">Fujisawa</span> <span class="cit-name-given-names">Y</span></span>, </li><li><span class="cit-auth"><span class="cit-name-surname">Fujimura</span> <span class="cit-name-given-names">T</span></span>, </li><li><span class="cit-auth"><span class="cit-name-surname">Hata</span> <span class="cit-name-given-names">H</span></span>, </li><li><span class="cit-auth"><span class="cit-name-surname">Ishida</span> <span class="cit-name-given-names">Y</span></span>, </li><li><span class="cit-auth"><span class="cit-name-surname">Kabashima</span> <span class="cit-name-given-names">K</span></span></li></ol><cite>: <span class="cit-article-title">Accumulation of exhausted CD8+ T cells in extramammary Paget’s disease</span>. <abbr class="cit-jnl-abbrev">PLoS One</abbr> <span class="cit-vol">14</span>(<span class="cit-issue">1</span>): <span class="cit-fpage">e0211135</span>, <span class="cit-pub-date">2019</span>.<span class="cit-pub-id-sep cit-pub-id-doi-sep"> </span><span class="cit-pub-id-scheme">DOI: </span><span class="cit-pub-id cit-pub-id-doi">10.1371/journal.pone.0211135</span></cite></div><div class="cit-extra"><a href="{openurl}?query=rft.jtitle%253DPLoS%2BOne%26rft.volume%253D14%26rft.spage%253De0211135%26rft_id%253Dinfo%253Adoi%252F10.1371%252Fjournal.pone.0211135%26rft_id%253Dinfo%253Apmid%252F30682105%26rft.genre%253Darticle%26rft_val_fmt%253Dinfo%253Aofi%252Ffmt%253Akev%253Amtx%253Ajournal%26ctx_ver%253DZ39.88-2004%26url_ver%253DZ39.88-2004%26url_ctx_fmt%253Dinfo%253Aofi%252Ffmt%253Akev%253Amtx%253Actx" class="cit-ref-sprinkles cit-ref-sprinkles-openurl cit-ref-sprinkles-open-url"><span>OpenUrl</span></a><a href="/lookup/external-ref?access_num=10.1371/journal.pone.0211135&link_type=DOI" class="cit-ref-sprinkles cit-ref-sprinkles-doi cit-ref-sprinkles-crossref"><span>CrossRef</span></a><a href="/lookup/external-ref?access_num=30682105&link_type=MED&atom=%2Fanticanres%2F45%2F2%2F639.atom" class="cit-ref-sprinkles cit-ref-sprinkles-medline"><span>PubMed</span></a></div></div></li><li><a class="rev-xref-ref" href="#xref-ref-12-1" title="View reference 12 in text" id="ref-12">↵</a><div class="cit ref-cit ref-journal" id="cit-45.2.639.12" data-doi="10.3390/ijms21155390"><div class="cit-metadata"><ol class="cit-auth-list"><li><span class="cit-auth"><span class="cit-name-surname">Tomiyama</span> <span class="cit-name-given-names">E</span></span>, </li><li><span class="cit-auth"><span class="cit-name-surname">Fujita</span> <span class="cit-name-given-names">K</span></span>, </li><li><span class="cit-auth"><span class="cit-name-surname">Rodriguez Pena</span> <span class="cit-name-given-names">MDC</span></span>, </li><li><span class="cit-auth"><span class="cit-name-surname">Taheri</span> <span class="cit-name-given-names">D</span></span>, </li><li><span class="cit-auth"><span class="cit-name-surname">Banno</span> <span class="cit-name-given-names">E</span></span>, </li><li><span class="cit-auth"><span class="cit-name-surname">Kato</span> <span class="cit-name-given-names">T</span></span>, </li><li><span class="cit-auth"><span class="cit-name-surname">Hatano</span> <span class="cit-name-given-names">K</span></span>, </li><li><span class="cit-auth"><span class="cit-name-surname">Kawashima</span> <span class="cit-name-given-names">A</span></span>, </li><li><span class="cit-auth"><span class="cit-name-surname">Ujike</span> <span class="cit-name-given-names">T</span></span>, </li><li><span class="cit-auth"><span class="cit-name-surname">Uemura</span> <span class="cit-name-given-names">M</span></span>, </li><li><span class="cit-auth"><span class="cit-name-surname">Takao</span> <span class="cit-name-given-names">T</span></span>, </li><li><span class="cit-auth"><span class="cit-name-surname">Yamaguchi</span> <span class="cit-name-given-names">S</span></span>, </li><li><span class="cit-auth"><span class="cit-name-surname">Fushimi</span> <span class="cit-name-given-names">H</span></span>, </li><li><span class="cit-auth"><span class="cit-name-surname">Yoshimura</span> <span class="cit-name-given-names">K</span></span>, </li><li><span class="cit-auth"><span class="cit-name-surname">Uemura</span> <span class="cit-name-given-names">H</span></span>, </li><li><span class="cit-auth"><span class="cit-name-surname">Netto</span> <span class="cit-name-given-names">GJ</span></span>, </li><li><span class="cit-auth"><span class="cit-name-surname">Nonomura</span> <span class="cit-name-given-names">N</span></span></li></ol><cite>: <span class="cit-article-title">Expression of Nectin-4 and PD-L1 in upper tract urothelial carcinoma</span>. <abbr class="cit-jnl-abbrev">Int J Mol Sci</abbr> <span class="cit-vol">21</span>(<span class="cit-issue">15</span>): <span class="cit-fpage">5390</span>, <span class="cit-pub-date">2020</span>.<span class="cit-pub-id-sep cit-pub-id-doi-sep"> </span><span class="cit-pub-id-scheme">DOI: </span><span class="cit-pub-id cit-pub-id-doi">10.3390/ijms21155390</span></cite></div><div class="cit-extra"><a href="{openurl}?query=rft.jtitle%253DInt%2BJ%2BMol%2BSci%26rft.volume%253D21%26rft.spage%253D5390%26rft_id%253Dinfo%253Adoi%252F10.3390%252Fijms21155390%26rft_id%253Dinfo%253Apmid%252F32751328%26rft.genre%253Darticle%26rft_val_fmt%253Dinfo%253Aofi%252Ffmt%253Akev%253Amtx%253Ajournal%26ctx_ver%253DZ39.88-2004%26url_ver%253DZ39.88-2004%26url_ctx_fmt%253Dinfo%253Aofi%252Ffmt%253Akev%253Amtx%253Actx" class="cit-ref-sprinkles cit-ref-sprinkles-openurl cit-ref-sprinkles-open-url"><span>OpenUrl</span></a><a href="/lookup/external-ref?access_num=10.3390/ijms21155390&link_type=DOI" class="cit-ref-sprinkles cit-ref-sprinkles-doi cit-ref-sprinkles-crossref"><span>CrossRef</span></a><a href="/lookup/external-ref?access_num=32751328&link_type=MED&atom=%2Fanticanres%2F45%2F2%2F639.atom" class="cit-ref-sprinkles cit-ref-sprinkles-medline"><span>PubMed</span></a></div></div></li><li><a class="rev-xref-ref" href="#xref-ref-13-1" title="View reference 13 in text" id="ref-13">↵</a><div class="cit ref-cit ref-journal" id="cit-45.2.639.13" data-doi="10.1158/1078-0432.CCR-22-0963"><div class="cit-metadata"><ol class="cit-auth-list"><li><span class="cit-auth"><span class="cit-name-surname">Ma</span> <span class="cit-name-given-names">Y</span></span>, </li><li><span class="cit-auth"><span class="cit-name-surname">Joyce</span> <span class="cit-name-given-names">A</span></span>, </li><li><span class="cit-auth"><span class="cit-name-surname">Brandenburg</span> <span class="cit-name-given-names">O</span></span>, </li><li><span class="cit-auth"><span class="cit-name-surname">Saatchi</span> <span class="cit-name-given-names">F</span></span>, </li><li><span class="cit-auth"><span class="cit-name-surname">Stevens</span> <span class="cit-name-given-names">C</span></span>, </li><li><span class="cit-auth"><span class="cit-name-surname">Toffessi Tcheuyap</span> <span class="cit-name-given-names">V</span></span>, </li><li><span class="cit-auth"><span class="cit-name-surname">Christie</span> <span class="cit-name-given-names">A</span></span>, </li><li><span class="cit-auth"><span class="cit-name-surname">Do</span> <span class="cit-name-given-names">QN</span></span>, </li><li><span class="cit-auth"><span class="cit-name-surname">Fatunde</span> <span class="cit-name-given-names">O</span></span>, </li><li><span class="cit-auth"><span class="cit-name-surname">Macchiaroli</span> <span class="cit-name-given-names">A</span></span>, </li><li><span class="cit-auth"><span class="cit-name-surname">Wong</span> <span class="cit-name-given-names">SC</span></span>, </li><li><span class="cit-auth"><span class="cit-name-surname">Woolford</span> <span class="cit-name-given-names">L</span></span>, </li><li><span class="cit-auth"><span class="cit-name-surname">Yousuf</span> <span class="cit-name-given-names">Q</span></span>, </li><li><span class="cit-auth"><span class="cit-name-surname">Miyata</span> <span class="cit-name-given-names">J</span></span>, </li><li><span class="cit-auth"><span class="cit-name-surname">Carrillo</span> <span class="cit-name-given-names">D</span></span>, </li><li><span class="cit-auth"><span class="cit-name-surname">Onabolu</span> <span class="cit-name-given-names">O</span></span>, </li><li><span class="cit-auth"><span class="cit-name-surname">McKenzie</span> <span class="cit-name-given-names">T</span></span>, </li><li><span class="cit-auth"><span class="cit-name-surname">Mishra</span> <span class="cit-name-given-names">A</span></span>, </li><li><span class="cit-auth"><span class="cit-name-surname">Hardy</span> <span class="cit-name-given-names">T</span></span>, </li><li><span class="cit-auth"><span class="cit-name-surname">He</span> <span class="cit-name-given-names">W</span></span>, </li><li><span class="cit-auth"><span class="cit-name-surname">Li</span> <span class="cit-name-given-names">D</span></span>, </li><li><span class="cit-auth"><span class="cit-name-surname">Ivanishev</span> <span class="cit-name-given-names">A</span></span>, </li><li><span class="cit-auth"><span class="cit-name-surname">Zhang</span> <span class="cit-name-given-names">Q</span></span>, </li><li><span class="cit-auth"><span class="cit-name-surname">Pedrosa</span> <span class="cit-name-given-names">I</span></span>, </li><li><span class="cit-auth"><span class="cit-name-surname">Kapur</span> <span class="cit-name-given-names">P</span></span>, </li><li><span class="cit-auth"><span class="cit-name-surname">Schluep</span> <span class="cit-name-given-names">T</span></span>, </li><li><span class="cit-auth"><span class="cit-name-surname">Kanner</span> <span class="cit-name-given-names">SB</span></span>, </li><li><span class="cit-auth"><span class="cit-name-surname">Hamilton</span> <span class="cit-name-given-names">J</span></span>, </li><li><span class="cit-auth"><span class="cit-name-surname">Brugarolas</span> <span class="cit-name-given-names">J</span></span></li></ol><cite>: <span class="cit-article-title">HIF2 inactivation and tumor suppression with a tumor-directed RNA-silencing drug in mice and humans</span>. <abbr class="cit-jnl-abbrev">Clin Cancer Res</abbr> <span class="cit-vol">28</span>(<span class="cit-issue">24</span>): <span class="cit-fpage">5405</span>-<span class="cit-lpage">5418</span>, <span class="cit-pub-date">2022</span>.<span class="cit-pub-id-sep cit-pub-id-doi-sep"> </span><span class="cit-pub-id-scheme">DOI: </span><span class="cit-pub-id cit-pub-id-doi">10.1158/1078-0432.CCR-22-0963</span></cite></div><div class="cit-extra"><a href="{openurl}?query=rft.jtitle%253DClin%2BCancer%2BRes%26rft.volume%253D28%26rft.spage%253D5405%26rft_id%253Dinfo%253Adoi%252F10.1158%252F1078-0432.CCR-22-0963%26rft_id%253Dinfo%253Apmid%252F36190432%26rft.genre%253Darticle%26rft_val_fmt%253Dinfo%253Aofi%252Ffmt%253Akev%253Amtx%253Ajournal%26ctx_ver%253DZ39.88-2004%26url_ver%253DZ39.88-2004%26url_ctx_fmt%253Dinfo%253Aofi%252Ffmt%253Akev%253Amtx%253Actx" class="cit-ref-sprinkles cit-ref-sprinkles-openurl cit-ref-sprinkles-open-url"><span>OpenUrl</span></a><a href="/lookup/external-ref?access_num=10.1158/1078-0432.CCR-22-0963&link_type=DOI" class="cit-ref-sprinkles cit-ref-sprinkles-doi cit-ref-sprinkles-crossref"><span>CrossRef</span></a><a href="/lookup/external-ref?access_num=36190432&link_type=MED&atom=%2Fanticanres%2F45%2F2%2F639.atom" class="cit-ref-sprinkles cit-ref-sprinkles-medline"><span>PubMed</span></a></div></div></li><li><a class="rev-xref-ref" href="#xref-ref-14-1" title="View reference 14 in text" id="ref-14">↵</a><div class="cit ref-cit ref-journal" id="cit-45.2.639.14" data-doi="10.18632/oncotarget.21952"><div class="cit-metadata"><ol class="cit-auth-list"><li><span class="cit-auth"><span class="cit-name-surname">Lalani</span> <span class="cit-name-given-names">AA</span></span>, </li><li><span class="cit-auth"><span class="cit-name-surname">Gray</span> <span class="cit-name-given-names">KP</span></span>, </li><li><span class="cit-auth"><span class="cit-name-surname">Albiges</span> <span class="cit-name-given-names">L</span></span>, </li><li><span class="cit-auth"><span class="cit-name-surname">Callea</span> <span class="cit-name-given-names">M</span></span>, </li><li><span class="cit-auth"><span class="cit-name-surname">Pignon</span> <span class="cit-name-given-names">JC</span></span>, </li><li><span class="cit-auth"><span class="cit-name-surname">Pal</span> <span class="cit-name-given-names">S</span></span>, </li><li><span class="cit-auth"><span class="cit-name-surname">Gupta</span> <span class="cit-name-given-names">M</span></span>, </li><li><span class="cit-auth"><span class="cit-name-surname">Bhatt</span> <span class="cit-name-given-names">RS</span></span>, </li><li><span class="cit-auth"><span class="cit-name-surname">McDermott</span> <span class="cit-name-given-names">DF</span></span>, </li><li><span class="cit-auth"><span class="cit-name-surname">Atkins</span> <span class="cit-name-given-names">MB</span></span>, </li><li><span class="cit-auth"><span class="cit-name-surname">Woude</span> <span class="cit-name-given-names">GFV</span></span>, </li><li><span class="cit-auth"><span class="cit-name-surname">Harshman</span> <span class="cit-name-given-names">LC</span></span>, </li><li><span class="cit-auth"><span class="cit-name-surname">Choueiri</span> <span class="cit-name-given-names">TK</span></span>, </li><li><span class="cit-auth"><span class="cit-name-surname">Signoretti</span> <span class="cit-name-given-names">S</span></span></li></ol><cite>: <span class="cit-article-title">Differential expression of c-Met between primary and metastatic sites in clear-cell renal cell carcinoma and its association with PD-L1 expression</span>. <abbr class="cit-jnl-abbrev">Oncotarget</abbr> <span class="cit-vol">8</span>(<span class="cit-issue">61</span>): <span class="cit-fpage">103428</span>-<span class="cit-lpage">103436</span>, <span class="cit-pub-date">2017</span>.<span class="cit-pub-id-sep cit-pub-id-doi-sep"> </span><span class="cit-pub-id-scheme">DOI: </span><span class="cit-pub-id cit-pub-id-doi">10.18632/oncotarget.21952</span></cite></div><div class="cit-extra"><a href="{openurl}?query=rft.jtitle%253DOncotarget%26rft.volume%253D8%26rft.spage%253D103428%26rft_id%253Dinfo%253Adoi%252F10.18632%252Foncotarget.21952%26rft_id%253Dinfo%253Apmid%252F29262573%26rft.genre%253Darticle%26rft_val_fmt%253Dinfo%253Aofi%252Ffmt%253Akev%253Amtx%253Ajournal%26ctx_ver%253DZ39.88-2004%26url_ver%253DZ39.88-2004%26url_ctx_fmt%253Dinfo%253Aofi%252Ffmt%253Akev%253Amtx%253Actx" class="cit-ref-sprinkles cit-ref-sprinkles-openurl cit-ref-sprinkles-open-url"><span>OpenUrl</span></a><a href="/lookup/external-ref?access_num=10.18632/oncotarget.21952&link_type=DOI" class="cit-ref-sprinkles cit-ref-sprinkles-doi cit-ref-sprinkles-crossref"><span>CrossRef</span></a><a href="/lookup/external-ref?access_num=29262573&link_type=MED&atom=%2Fanticanres%2F45%2F2%2F639.atom" class="cit-ref-sprinkles cit-ref-sprinkles-medline"><span>PubMed</span></a></div></div></li><li><div class="cit ref-cit ref-journal no-rev-xref" id="cit-45.2.639.15" data-doi="10.1016/j.humpath.2016.12.002"><div class="cit-metadata"><ol class="cit-auth-list"><li><span class="cit-auth"><span class="cit-name-surname">Kim</span> <span class="cit-name-given-names">M</span></span>, </li><li><span class="cit-auth"><span class="cit-name-surname">Sohn</span> <span class="cit-name-given-names">M</span></span>, </li><li><span class="cit-auth"><span class="cit-name-surname">Shim</span> <span class="cit-name-given-names">M</span></span>, </li><li><span class="cit-auth"><span class="cit-name-surname">Choi</span> <span class="cit-name-given-names">S</span></span>, </li><li><span class="cit-auth"><span class="cit-name-surname">Park</span> <span class="cit-name-given-names">M</span></span>, </li><li><span class="cit-auth"><span class="cit-name-surname">Kim</span> <span class="cit-name-given-names">E</span></span>, </li><li><span class="cit-auth"><span class="cit-name-surname">Go</span> <span class="cit-name-given-names">H</span></span>, </li><li><span class="cit-auth"><span class="cit-name-surname">Park</span> <span class="cit-name-given-names">Y</span></span>, </li><li><span class="cit-auth"><span class="cit-name-surname">Cho</span> <span class="cit-name-given-names">YM</span></span>, </li><li><span class="cit-auth"><span class="cit-name-surname">Ro</span> <span class="cit-name-given-names">JY</span></span>, </li><li><span class="cit-auth"><span class="cit-name-surname">Jeong</span> <span class="cit-name-given-names">IG</span></span>, </li><li><span class="cit-auth"><span class="cit-name-surname">Song</span> <span class="cit-name-given-names">C</span></span>, </li><li><span class="cit-auth"><span class="cit-name-surname">Hong</span> <span class="cit-name-given-names">JH</span></span>, </li><li><span class="cit-auth"><span class="cit-name-surname">Kim</span> <span class="cit-name-given-names">CS</span></span>, </li><li><span class="cit-auth"><span class="cit-name-surname">Ahn</span> <span class="cit-name-given-names">H</span></span></li></ol><cite>: <span class="cit-article-title">Prognostic value of vascular endothelial growth factor (VEGF), VEGF receptor 2, platelet-derived growth factor- β (PDGF-β), and PDGF-β receptor expression in papillary renal cell carcinoma</span>. <abbr class="cit-jnl-abbrev">Hum Pathol</abbr> <span class="cit-vol">61</span>: <span class="cit-fpage">78</span>-<span class="cit-lpage">89</span>, <span class="cit-pub-date">2017</span>.<span class="cit-pub-id-sep cit-pub-id-doi-sep"> </span><span class="cit-pub-id-scheme">DOI: </span><span class="cit-pub-id cit-pub-id-doi">10.1016/j.humpath.2016.12.002</span></cite></div><div class="cit-extra"><a href="{openurl}?query=rft.jtitle%253DHum%2BPathol%26rft.volume%253D61%26rft.spage%253D78%26rft_id%253Dinfo%253Adoi%252F10.1016%252Fj.humpath.2016.12.002%26rft_id%253Dinfo%253Apmid%252F27989785%26rft.genre%253Darticle%26rft_val_fmt%253Dinfo%253Aofi%252Ffmt%253Akev%253Amtx%253Ajournal%26ctx_ver%253DZ39.88-2004%26url_ver%253DZ39.88-2004%26url_ctx_fmt%253Dinfo%253Aofi%252Ffmt%253Akev%253Amtx%253Actx" class="cit-ref-sprinkles cit-ref-sprinkles-openurl cit-ref-sprinkles-open-url"><span>OpenUrl</span></a><a href="/lookup/external-ref?access_num=10.1016/j.humpath.2016.12.002&link_type=DOI" class="cit-ref-sprinkles cit-ref-sprinkles-doi cit-ref-sprinkles-crossref"><span>CrossRef</span></a><a href="/lookup/external-ref?access_num=27989785&link_type=MED&atom=%2Fanticanres%2F45%2F2%2F639.atom" class="cit-ref-sprinkles cit-ref-sprinkles-medline"><span>PubMed</span></a></div></div></li><li><a class="rev-xref-ref" href="#xref-ref-16-1" title="View reference 16 in text" id="ref-16">↵</a><div class="cit ref-cit ref-journal" id="cit-45.2.639.16" data-doi="10.1016/j.urolonc.2017.09.003"><div class="cit-metadata"><ol class="cit-auth-list"><li><span class="cit-auth"><span class="cit-name-surname">Zucca</span> <span class="cit-name-given-names">LE</span></span>, </li><li><span class="cit-auth"><span class="cit-name-surname">Morini Matushita</span> <span class="cit-name-given-names">MA</span></span>, </li><li><span class="cit-auth"><span class="cit-name-surname">da Silva Oliveira</span> <span class="cit-name-given-names">RJ</span></span>, </li><li><span class="cit-auth"><span class="cit-name-surname">Scapulatempo-Neto</span> <span class="cit-name-given-names">C</span></span>, </li><li><span class="cit-auth"><span class="cit-name-surname">de Lima</span> <span class="cit-name-given-names">MA</span></span>, </li><li><span class="cit-auth"><span class="cit-name-surname">Ribeiro</span> <span class="cit-name-given-names">GG</span></span>, </li><li><span class="cit-auth"><span class="cit-name-surname">Viana</span> <span class="cit-name-given-names">CR</span></span>, </li><li><span class="cit-auth"><span class="cit-name-surname">Cárcano</span> <span class="cit-name-given-names">FM</span></span>, </li><li><span class="cit-auth"><span class="cit-name-surname">Reis</span> <span class="cit-name-given-names">RM</span></span></li></ol><cite>: <span class="cit-article-title">Expression of tyrosine kinase receptor AXL is associated with worse outcome of metastatic renal cell carcinomas treated with sunitinib</span>. <abbr class="cit-jnl-abbrev">Urol Oncol</abbr> <span class="cit-vol">36</span>(<span class="cit-issue">1</span>): <span class="cit-fpage">11.e13</span>-<span class="cit-lpage">11.e21</span>, <span class="cit-pub-date">2018</span>.<span class="cit-pub-id-sep cit-pub-id-doi-sep"> </span><span class="cit-pub-id-scheme">DOI: </span><span class="cit-pub-id cit-pub-id-doi">10.1016/j.urolonc.2017.09.003</span></cite></div><div class="cit-extra"><a href="{openurl}?query=rft.jtitle%253DUrol%2BOncol%26rft.volume%253D36%26rft.spage%253D11.e13%26rft_id%253Dinfo%253Adoi%252F10.1016%252Fj.urolonc.2017.09.003%26rft_id%253Dinfo%253Apmid%252F28986088%26rft.genre%253Darticle%26rft_val_fmt%253Dinfo%253Aofi%252Ffmt%253Akev%253Amtx%253Ajournal%26ctx_ver%253DZ39.88-2004%26url_ver%253DZ39.88-2004%26url_ctx_fmt%253Dinfo%253Aofi%252Ffmt%253Akev%253Amtx%253Actx" class="cit-ref-sprinkles cit-ref-sprinkles-openurl cit-ref-sprinkles-open-url"><span>OpenUrl</span></a><a href="/lookup/external-ref?access_num=10.1016/j.urolonc.2017.09.003&link_type=DOI" class="cit-ref-sprinkles cit-ref-sprinkles-doi cit-ref-sprinkles-crossref"><span>CrossRef</span></a><a href="/lookup/external-ref?access_num=28986088&link_type=MED&atom=%2Fanticanres%2F45%2F2%2F639.atom" class="cit-ref-sprinkles cit-ref-sprinkles-medline"><span>PubMed</span></a></div></div></li><li><a class="rev-xref-ref" href="#xref-ref-17-1" title="View reference 17 in text" id="ref-17">↵</a><div class="cit ref-cit ref-journal" id="cit-45.2.639.17" data-doi="10.1016/j.eururo.2021.04.042"><div class="cit-metadata"><ol class="cit-auth-list"><li><span class="cit-auth"><span class="cit-name-surname">Bedke</span> <span class="cit-name-given-names">J</span></span>, </li><li><span class="cit-auth"><span class="cit-name-surname">Albiges</span> <span class="cit-name-given-names">L</span></span>, </li><li><span class="cit-auth"><span class="cit-name-surname">Capitanio</span> <span class="cit-name-given-names">U</span></span>, </li><li><span class="cit-auth"><span class="cit-name-surname">Giles</span> <span class="cit-name-given-names">RH</span></span>, </li><li><span class="cit-auth"><span class="cit-name-surname">Hora</span> <span class="cit-name-given-names">M</span></span>, </li><li><span class="cit-auth"><span class="cit-name-surname">Lam</span> <span class="cit-name-given-names">TB</span></span>, </li><li><span class="cit-auth"><span class="cit-name-surname">Ljungberg</span> <span class="cit-name-given-names">B</span></span>, </li><li><span class="cit-auth"><span class="cit-name-surname">Marconi</span> <span class="cit-name-given-names">L</span></span>, </li><li><span class="cit-auth"><span class="cit-name-surname">Klatte</span> <span class="cit-name-given-names">T</span></span>, </li><li><span class="cit-auth"><span class="cit-name-surname">Volpe</span> <span class="cit-name-given-names">A</span></span>, </li><li><span class="cit-auth"><span class="cit-name-surname">Abu-Ghanem</span> <span class="cit-name-given-names">Y</span></span>, </li><li><span class="cit-auth"><span class="cit-name-surname">Dabestani</span> <span class="cit-name-given-names">S</span></span>, </li><li><span class="cit-auth"><span class="cit-name-surname">Pello</span> <span class="cit-name-given-names">SF</span></span>, </li><li><span class="cit-auth"><span class="cit-name-surname">Hofmann</span> <span class="cit-name-given-names">F</span></span>, </li><li><span class="cit-auth"><span class="cit-name-surname">Kuusk</span> <span class="cit-name-given-names">T</span></span>, </li><li><span class="cit-auth"><span class="cit-name-surname">Tahbaz</span> <span class="cit-name-given-names">R</span></span>, </li><li><span class="cit-auth"><span class="cit-name-surname">Powles</span> <span class="cit-name-given-names">T</span></span>, </li><li><span class="cit-auth"><span class="cit-name-surname">Bex</span> <span class="cit-name-given-names">A</span></span></li></ol><cite>: <span class="cit-article-title">The 2021 Updated European Association of Urology Guidelines on Renal Cell Carcinoma: Immune checkpoint inhibitor–based combination therapies for treatment-naive metastatic clear-cell renal cell carcinoma are standard of care</span>. <abbr class="cit-jnl-abbrev">Eur Urol</abbr> <span class="cit-vol">80</span>(<span class="cit-issue">4</span>): <span class="cit-fpage">393</span>-<span class="cit-lpage">397</span>, <span class="cit-pub-date">2021</span>.<span class="cit-pub-id-sep cit-pub-id-doi-sep"> </span><span class="cit-pub-id-scheme">DOI: </span><span class="cit-pub-id cit-pub-id-doi">10.1016/j.eururo.2021.04.042</span></cite></div><div class="cit-extra"><a href="{openurl}?query=rft.jtitle%253DEur%2BUrol%26rft_id%253Dinfo%253Adoi%252F10.1016%252Fj.eururo.2021.04.042%26rft_id%253Dinfo%253Apmid%252F34074559%26rft.genre%253Darticle%26rft_val_fmt%253Dinfo%253Aofi%252Ffmt%253Akev%253Amtx%253Ajournal%26ctx_ver%253DZ39.88-2004%26url_ver%253DZ39.88-2004%26url_ctx_fmt%253Dinfo%253Aofi%252Ffmt%253Akev%253Amtx%253Actx" class="cit-ref-sprinkles cit-ref-sprinkles-openurl cit-ref-sprinkles-open-url"><span>OpenUrl</span></a><a href="/lookup/external-ref?access_num=10.1016/j.eururo.2021.04.042&link_type=DOI" class="cit-ref-sprinkles cit-ref-sprinkles-doi cit-ref-sprinkles-crossref"><span>CrossRef</span></a><a href="/lookup/external-ref?access_num=34074559&link_type=MED&atom=%2Fanticanres%2F45%2F2%2F639.atom" class="cit-ref-sprinkles cit-ref-sprinkles-medline"><span>PubMed</span></a></div></div></li><li><a class="rev-xref-ref" href="#xref-ref-18-1" title="View reference 18 in text" id="ref-18">↵</a><div class="cit ref-cit ref-journal" id="cit-45.2.639.18" data-doi="10.1002/jcp.29969"><div class="cit-metadata"><ol class="cit-auth-list"><li><span class="cit-auth"><span class="cit-name-surname">Lai</span> <span class="cit-name-given-names">Y</span></span>, </li><li><span class="cit-auth"><span class="cit-name-surname">Tang</span> <span class="cit-name-given-names">F</span></span>, </li><li><span class="cit-auth"><span class="cit-name-surname">Huang</span> <span class="cit-name-given-names">Y</span></span>, </li><li><span class="cit-auth"><span class="cit-name-surname">He</span> <span class="cit-name-given-names">C</span></span>, </li><li><span class="cit-auth"><span class="cit-name-surname">Chen</span> <span class="cit-name-given-names">C</span></span>, </li><li><span class="cit-auth"><span class="cit-name-surname">Zhao</span> <span class="cit-name-given-names">J</span></span>, </li><li><span class="cit-auth"><span class="cit-name-surname">Wu</span> <span class="cit-name-given-names">W</span></span>, </li><li><span class="cit-auth"><span class="cit-name-surname">He</span> <span class="cit-name-given-names">Z</span></span></li></ol><cite>: <span class="cit-article-title">The tumour microenvironment and metabolism in renal cell carcinoma targeted or immune therapy</span>. <abbr class="cit-jnl-abbrev">J Cell Physiol</abbr> <span class="cit-vol">236</span>(<span class="cit-issue">3</span>): <span class="cit-fpage">1616</span>-<span class="cit-lpage">1627</span>, <span class="cit-pub-date">2021</span>.<span class="cit-pub-id-sep cit-pub-id-doi-sep"> </span><span class="cit-pub-id-scheme">DOI: </span><span class="cit-pub-id cit-pub-id-doi">10.1002/jcp.29969</span></cite></div><div class="cit-extra"><a href="{openurl}?query=rft.jtitle%253DJ%2BCell%2BPhysiol%26rft.volume%253D236%26rft.spage%253D1616%26rft_id%253Dinfo%253Adoi%252F10.1002%252Fjcp.29969%26rft_id%253Dinfo%253Apmid%252F32783202%26rft.genre%253Darticle%26rft_val_fmt%253Dinfo%253Aofi%252Ffmt%253Akev%253Amtx%253Ajournal%26ctx_ver%253DZ39.88-2004%26url_ver%253DZ39.88-2004%26url_ctx_fmt%253Dinfo%253Aofi%252Ffmt%253Akev%253Amtx%253Actx" class="cit-ref-sprinkles cit-ref-sprinkles-openurl cit-ref-sprinkles-open-url"><span>OpenUrl</span></a><a href="/lookup/external-ref?access_num=10.1002/jcp.29969&link_type=DOI" class="cit-ref-sprinkles cit-ref-sprinkles-doi cit-ref-sprinkles-crossref"><span>CrossRef</span></a><a href="/lookup/external-ref?access_num=32783202&link_type=MED&atom=%2Fanticanres%2F45%2F2%2F639.atom" class="cit-ref-sprinkles cit-ref-sprinkles-medline"><span>PubMed</span></a></div></div></li><li><a class="rev-xref-ref" href="#xref-ref-19-1" title="View reference 19 in text" id="ref-19">↵</a><div class="cit ref-cit ref-journal" id="cit-45.2.639.19" data-doi="10.1007/s10555-013-9453-5"><div class="cit-metadata"><ol class="cit-auth-list"><li><span class="cit-auth"><span class="cit-name-surname">Santoni</span> <span class="cit-name-given-names">M</span></span>, </li><li><span class="cit-auth"><span class="cit-name-surname">Santini</span> <span class="cit-name-given-names">D</span></span>, </li><li><span class="cit-auth"><span class="cit-name-surname">Massari</span> <span class="cit-name-given-names">F</span></span>, </li><li><span class="cit-auth"><span class="cit-name-surname">Conti</span> <span class="cit-name-given-names">A</span></span>, </li><li><span class="cit-auth"><span class="cit-name-surname">Iacovelli</span> <span class="cit-name-given-names">R</span></span>, </li><li><span class="cit-auth"><span class="cit-name-surname">Burattini</span> <span class="cit-name-given-names">L</span></span>, </li><li><span class="cit-auth"><span class="cit-name-surname">Tortora</span> <span class="cit-name-given-names">G</span></span>, </li><li><span class="cit-auth"><span class="cit-name-surname">Falconi</span> <span class="cit-name-given-names">M</span></span>, </li><li><span class="cit-auth"><span class="cit-name-surname">Montironi</span> <span class="cit-name-given-names">R</span></span>, </li><li><span class="cit-auth"><span class="cit-name-surname">Cascinu</span> <span class="cit-name-given-names">S</span></span></li></ol><cite>: <span class="cit-article-title">Heterogeneous drug target expression as possible basis for different clinical and radiological response to the treatment of primary and metastatic renal cell carcinoma: suggestions from bench to bedside</span>. <abbr class="cit-jnl-abbrev">Cancer Metastasis Rev</abbr> <span class="cit-vol">33</span>(<span class="cit-issue">1</span>): <span class="cit-fpage">321</span>-<span class="cit-lpage">331</span>, <span class="cit-pub-date">2014</span>.<span class="cit-pub-id-sep cit-pub-id-doi-sep"> </span><span class="cit-pub-id-scheme">DOI: </span><span class="cit-pub-id cit-pub-id-doi">10.1007/s10555-013-9453-5</span></cite></div><div class="cit-extra"><a href="{openurl}?query=rft.jtitle%253DCancer%2BMetastasis%2BRev%26rft.volume%253D33%26rft.spage%253D321%26rft_id%253Dinfo%253Adoi%252F10.1007%252Fs10555-013-9453-5%26rft_id%253Dinfo%253Apmid%252F24337954%26rft.genre%253Darticle%26rft_val_fmt%253Dinfo%253Aofi%252Ffmt%253Akev%253Amtx%253Ajournal%26ctx_ver%253DZ39.88-2004%26url_ver%253DZ39.88-2004%26url_ctx_fmt%253Dinfo%253Aofi%252Ffmt%253Akev%253Amtx%253Actx" class="cit-ref-sprinkles cit-ref-sprinkles-openurl cit-ref-sprinkles-open-url"><span>OpenUrl</span></a><a href="/lookup/external-ref?access_num=10.1007/s10555-013-9453-5&link_type=DOI" class="cit-ref-sprinkles cit-ref-sprinkles-doi cit-ref-sprinkles-crossref"><span>CrossRef</span></a><a href="/lookup/external-ref?access_num=24337954&link_type=MED&atom=%2Fanticanres%2F45%2F2%2F639.atom" class="cit-ref-sprinkles cit-ref-sprinkles-medline"><span>PubMed</span></a></div></div></li><li><a class="rev-xref-ref" href="#xref-ref-20-1" title="View reference 20 in text" id="ref-20">↵</a><div class="cit ref-cit ref-journal" id="cit-45.2.639.20" data-doi="10.1186/1472-6890-13-3"><div class="cit-metadata"><ol class="cit-auth-list"><li><span class="cit-auth"><span class="cit-name-surname">Aziz</span> <span class="cit-name-given-names">SA</span></span>, </li><li><span class="cit-auth"><span class="cit-name-surname">Sznol</span> <span class="cit-name-given-names">JA</span></span>, </li><li><span class="cit-auth"><span class="cit-name-surname">Adeniran</span> <span class="cit-name-given-names">A</span></span>, </li><li><span class="cit-auth"><span class="cit-name-surname">Parisi</span> <span class="cit-name-given-names">F</span></span>, </li><li><span class="cit-auth"><span class="cit-name-surname">Kluger</span> <span class="cit-name-given-names">Y</span></span>, </li><li><span class="cit-auth"><span class="cit-name-surname">Camp</span> <span class="cit-name-given-names">RL</span></span>, </li><li><span class="cit-auth"><span class="cit-name-surname">Kluger</span> <span class="cit-name-given-names">HM</span></span></li></ol><cite>: <span class="cit-article-title">Expression of drug targets in primary and matched metastatic renal cell carcinoma tumors</span>. <abbr class="cit-jnl-abbrev">BMC Clin Pathol</abbr> <span class="cit-vol">13</span>: <span class="cit-fpage">3</span>, <span class="cit-pub-date">2013</span>.<span class="cit-pub-id-sep cit-pub-id-doi-sep"> </span><span class="cit-pub-id-scheme">DOI: </span><span class="cit-pub-id cit-pub-id-doi">10.1186/1472-6890-13-3</span></cite></div><div class="cit-extra"><a href="{openurl}?query=rft.jtitle%253DBMC%2BClin%2BPathol%26rft.volume%253D13%26rft.spage%253D3%26rft_id%253Dinfo%253Adoi%252F10.1186%252F1472-6890-13-3%26rft_id%253Dinfo%253Apmid%252F23374878%26rft.genre%253Darticle%26rft_val_fmt%253Dinfo%253Aofi%252Ffmt%253Akev%253Amtx%253Ajournal%26ctx_ver%253DZ39.88-2004%26url_ver%253DZ39.88-2004%26url_ctx_fmt%253Dinfo%253Aofi%252Ffmt%253Akev%253Amtx%253Actx" class="cit-ref-sprinkles cit-ref-sprinkles-openurl cit-ref-sprinkles-open-url"><span>OpenUrl</span></a><a href="/lookup/external-ref?access_num=10.1186/1472-6890-13-3&link_type=DOI" class="cit-ref-sprinkles cit-ref-sprinkles-doi cit-ref-sprinkles-crossref"><span>CrossRef</span></a><a href="/lookup/external-ref?access_num=23374878&link_type=MED&atom=%2Fanticanres%2F45%2F2%2F639.atom" class="cit-ref-sprinkles cit-ref-sprinkles-medline"><span>PubMed</span></a></div></div></li><li><a class="rev-xref-ref" href="#xref-ref-21-1" title="View reference 21 in text" id="ref-21">↵</a><div class="cit ref-cit ref-journal" id="cit-45.2.639.21" data-doi="10.1038/s41598-023-48087-4"><div class="cit-metadata"><ol class="cit-auth-list"><li><span class="cit-auth"><span class="cit-name-surname">Sazuka</span> <span class="cit-name-given-names">T</span></span>, </li><li><span class="cit-auth"><span class="cit-name-surname">Matsushita</span> <span class="cit-name-given-names">Y</span></span>, </li><li><span class="cit-auth"><span class="cit-name-surname">Sato</span> <span class="cit-name-given-names">H</span></span>, </li><li><span class="cit-auth"><span class="cit-name-surname">Osawa</span> <span class="cit-name-given-names">T</span></span>, </li><li><span class="cit-auth"><span class="cit-name-surname">Hinata</span> <span class="cit-name-given-names">N</span></span>, </li><li><span class="cit-auth"><span class="cit-name-surname">Hatakeyama</span> <span class="cit-name-given-names">S</span></span>, </li><li><span class="cit-auth"><span class="cit-name-surname">Numakura</span> <span class="cit-name-given-names">K</span></span>, </li><li><span class="cit-auth"><span class="cit-name-surname">Ueda</span> <span class="cit-name-given-names">K</span></span>, </li><li><span class="cit-auth"><span class="cit-name-surname">Kimura</span> <span class="cit-name-given-names">T</span></span>, </li><li><span class="cit-auth"><span class="cit-name-surname">Takahashi</span> <span class="cit-name-given-names">M</span></span>, </li><li><span class="cit-auth"><span class="cit-name-surname">Tanaka</span> <span class="cit-name-given-names">H</span></span>, </li><li><span class="cit-auth"><span class="cit-name-surname">Kawasaki</span> <span class="cit-name-given-names">Y</span></span>, </li><li><span class="cit-auth"><span class="cit-name-surname">Kurahashi</span> <span class="cit-name-given-names">T</span></span>, </li><li><span class="cit-auth"><span class="cit-name-surname">Kato</span> <span class="cit-name-given-names">T</span></span>, </li><li><span class="cit-auth"><span class="cit-name-surname">Fujita</span> <span class="cit-name-given-names">K</span></span>, </li><li><span class="cit-auth"><span class="cit-name-surname">Miyake</span> <span class="cit-name-given-names">M</span></span>, </li><li><span class="cit-auth"><span class="cit-name-surname">Kojima</span> <span class="cit-name-given-names">T</span></span>, </li><li><span class="cit-auth"><span class="cit-name-surname">Kitamura</span> <span class="cit-name-given-names">H</span></span>, </li><li><span class="cit-auth"><span class="cit-name-surname">Miyake</span> <span class="cit-name-given-names">H</span></span>, </li><li><span class="cit-auth"><span class="cit-name-surname">Ichikawa</span> <span class="cit-name-given-names">T</span></span></li></ol><cite>: <span class="cit-article-title">Efficacy and safety of second-line cabozantinib after immuno-oncology combination therapy for advanced renal cell carcinoma: Japanese multicenter retrospective study</span>. <abbr class="cit-jnl-abbrev">Sci Rep</abbr> <span class="cit-vol">13</span>(<span class="cit-issue">1</span>): <span class="cit-fpage">20629</span>, <span class="cit-pub-date">2023</span>.<span class="cit-pub-id-sep cit-pub-id-doi-sep"> </span><span class="cit-pub-id-scheme">DOI: </span><span class="cit-pub-id cit-pub-id-doi">10.1038/s41598-023-48087-4</span></cite></div><div class="cit-extra"><a href="{openurl}?query=rft.jtitle%253DSci%2BRep%26rft.volume%253D13%26rft.spage%253D20629%26rft_id%253Dinfo%253Adoi%252F10.1038%252Fs41598-023-48087-4%26rft_id%253Dinfo%253Apmid%252F37996622%26rft.genre%253Darticle%26rft_val_fmt%253Dinfo%253Aofi%252Ffmt%253Akev%253Amtx%253Ajournal%26ctx_ver%253DZ39.88-2004%26url_ver%253DZ39.88-2004%26url_ctx_fmt%253Dinfo%253Aofi%252Ffmt%253Akev%253Amtx%253Actx" class="cit-ref-sprinkles cit-ref-sprinkles-openurl cit-ref-sprinkles-open-url"><span>OpenUrl</span></a><a href="/lookup/external-ref?access_num=10.1038/s41598-023-48087-4&link_type=DOI" class="cit-ref-sprinkles cit-ref-sprinkles-doi cit-ref-sprinkles-crossref"><span>CrossRef</span></a><a href="/lookup/external-ref?access_num=37996622&link_type=MED&atom=%2Fanticanres%2F45%2F2%2F639.atom" class="cit-ref-sprinkles cit-ref-sprinkles-medline"><span>PubMed</span></a></div></div></li><li><a class="rev-xref-ref" href="#xref-ref-22-1" title="View reference 22 in text" id="ref-22">↵</a><div class="cit ref-cit ref-journal" id="cit-45.2.639.22" data-doi="10.1158/0008-5472.CAN-04-1987"><div class="cit-metadata"><ol class="cit-auth-list"><li><span class="cit-auth"><span class="cit-name-surname">Zou</span> <span class="cit-name-given-names">L</span></span>, </li><li><span class="cit-auth"><span class="cit-name-surname">Barnett</span> <span class="cit-name-given-names">B</span></span>, </li><li><span class="cit-auth"><span class="cit-name-surname">Safah</span> <span class="cit-name-given-names">H</span></span>, </li><li><span class="cit-auth"><span class="cit-name-surname">Larussa</span> <span class="cit-name-given-names">VF</span></span>, </li><li><span class="cit-auth"><span class="cit-name-surname">Evdemon-Hogan</span> <span class="cit-name-given-names">M</span></span>, </li><li><span class="cit-auth"><span class="cit-name-surname">Mottram</span> <span class="cit-name-given-names">P</span></span>, </li><li><span class="cit-auth"><span class="cit-name-surname">Wei</span> <span class="cit-name-given-names">S</span></span>, </li><li><span class="cit-auth"><span class="cit-name-surname">David</span> <span class="cit-name-given-names">O</span></span>, </li><li><span class="cit-auth"><span class="cit-name-surname">Curiel</span> <span class="cit-name-given-names">TJ</span></span>, </li><li><span class="cit-auth"><span class="cit-name-surname">Zou</span> <span class="cit-name-given-names">W</span></span></li></ol><cite>: <span class="cit-article-title">Bone marrow is a reservoir for CD4+CD25+ regulatory T cells that traffic through CXCL12/CXCR4 signals</span>. <abbr class="cit-jnl-abbrev">Cancer Res</abbr> <span class="cit-vol">64</span>(<span class="cit-issue">22</span>): <span class="cit-fpage">8451</span>-<span class="cit-lpage">8455</span>, <span class="cit-pub-date">2004</span>.<span class="cit-pub-id-sep cit-pub-id-doi-sep"> </span><span class="cit-pub-id-scheme">DOI: </span><span class="cit-pub-id cit-pub-id-doi">10.1158/0008-5472.CAN-04-1987</span></cite></div><div class="cit-extra"><a href="{openurl}?query=rft.jtitle%253DCancer%2BResearch%26rft.stitle%253DCancer%2BRes.%26rft.aulast%253DZou%26rft.auinit1%253DL.%26rft.volume%253D64%26rft.issue%253D22%26rft.spage%253D8451%26rft.epage%253D8455%26rft.atitle%253DBone%2BMarrow%2BIs%2Ba%2BReservoir%2Bfor%2BCD4%252BCD25%252B%2BRegulatory%2BT%2BCells%2Bthat%2BTraffic%2Bthrough%2BCXCL12%252FCXCR4%2BSignals%26rft_id%253Dinfo%253Adoi%252F10.1158%252F0008-5472.CAN-04-1987%26rft_id%253Dinfo%253Apmid%252F15548717%26rft.genre%253Darticle%26rft_val_fmt%253Dinfo%253Aofi%252Ffmt%253Akev%253Amtx%253Ajournal%26ctx_ver%253DZ39.88-2004%26url_ver%253DZ39.88-2004%26url_ctx_fmt%253Dinfo%253Aofi%252Ffmt%253Akev%253Amtx%253Actx" class="cit-ref-sprinkles cit-ref-sprinkles-openurl cit-ref-sprinkles-open-url"><span>OpenUrl</span></a><a href="/lookup/ijlink/YTozOntzOjQ6InBhdGgiO3M6MTQ6Ii9sb29rdXAvaWpsaW5rIjtzOjU6InF1ZXJ5IjthOjQ6e3M6ODoibGlua1R5cGUiO3M6NDoiQUJTVCI7czoxMToiam91cm5hbENvZGUiO3M6NjoiY2FucmVzIjtzOjU6InJlc2lkIjtzOjEwOiI2NC8yMi84NDUxIjtzOjQ6ImF0b20iO3M6MjU6Ii9hbnRpY2FucmVzLzQ1LzIvNjM5LmF0b20iO31zOjg6ImZyYWdtZW50IjtzOjA6IiI7fQ==/YTozOntzOjQ6InBhdGgiO3M6Mjk5OiIvbG9va3VwL2lqbGluay9ZVG96T250ek9qUTZJbkJoZEdnaU8zTTZNVFE2SWk5c2IyOXJkWEF2YVdwc2FXNXJJanR6T2pVNkluRjFaWEo1SWp0aE9qUTZlM002T0RvaWJHbHVhMVI1Y0dVaU8zTTZORG9pUVVKVFZDSTdjem94TVRvaWFtOTFjbTVoYkVOdlpHVWlPM002TmpvaVkyRnVjbVZ6SWp0ek9qVTZJbkpsYzJsa0lqdHpPakV3T2lJMk5DOHlNaTg0TkRVeElqdHpPalE2SW1GMGIyMGlPM002TWpVNklpOWhiblJwWTJGdWNtVnpMelExTHpJdk5qTTVMbUYwYjIwaU8zMXpPamc2SW1aeVlXZHRaVzUwSWp0ek9qQTZJaUk3ZlE9PSI7czo1OiJxdWVyeSI7YTowOnt9czo4OiJmcmFnbWVudCI7czowOiIiO30=" class="cit-ref-sprinkles cit-ref-sprinkles-ijlink"><span><span class="cit-reflinks-abstract">Abstract</span><span class="cit-sep cit-reflinks-variant-name-sep">/</span><span class="cit-reflinks-full-text"><span class="free-full-text">FREE </span>Full Text</span></span></a></div></div></li><li><a class="rev-xref-ref" href="#xref-ref-23-1" title="View reference 23 in text" id="ref-23">↵</a><div class="cit ref-cit ref-journal" id="cit-45.2.639.23" data-doi="10.4049/jimmunol.166.1.678"><div class="cit-metadata"><ol class="cit-auth-list"><li><span class="cit-auth"><span class="cit-name-surname">Almand</span> <span class="cit-name-given-names">B</span></span>, </li><li><span class="cit-auth"><span class="cit-name-surname">Clark</span> <span class="cit-name-given-names">JI</span></span>, </li><li><span class="cit-auth"><span class="cit-name-surname">Nikitina</span> <span class="cit-name-given-names">E</span></span>, </li><li><span class="cit-auth"><span class="cit-name-surname">van Beynen</span> <span class="cit-name-given-names">J</span></span>, </li><li><span class="cit-auth"><span class="cit-name-surname">English</span> <span class="cit-name-given-names">NR</span></span>, </li><li><span class="cit-auth"><span class="cit-name-surname">Knight</span> <span class="cit-name-given-names">SC</span></span>, </li><li><span class="cit-auth"><span class="cit-name-surname">Carbone</span> <span class="cit-name-given-names">DP</span></span>, </li><li><span class="cit-auth"><span class="cit-name-surname">Gabrilovich</span> <span class="cit-name-given-names">DI</span></span></li></ol><cite>: <span class="cit-article-title">Increased production of immature myeloid cells in cancer patients: a mechanism of immunosuppression in cancer</span>. <abbr class="cit-jnl-abbrev">J Immunol</abbr> <span class="cit-vol">166</span>(<span class="cit-issue">1</span>): <span class="cit-fpage">678</span>-<span class="cit-lpage">689</span>, <span class="cit-pub-date">2001</span>.<span class="cit-pub-id-sep cit-pub-id-doi-sep"> </span><span class="cit-pub-id-scheme">DOI: </span><span class="cit-pub-id cit-pub-id-doi">10.4049/jimmunol.166.1.678</span></cite></div><div class="cit-extra"><a href="{openurl}?query=rft.jtitle%253DThe%2BJournal%2Bof%2BImmunology%26rft.stitle%253DJ.%2BImmunol.%26rft.aulast%253DAlmand%26rft.auinit1%253DB.%26rft.volume%253D166%26rft.issue%253D1%26rft.spage%253D678%26rft.epage%253D689%26rft.atitle%253DIncreased%2BProduction%2Bof%2BImmature%2BMyeloid%2BCells%2Bin%2BCancer%2BPatients%253A%2BA%2BMechanism%2Bof%2BImmunosuppression%2Bin%2BCancer%26rft_id%253Dinfo%253Adoi%252F10.4049%252Fjimmunol.166.1.678%26rft_id%253Dinfo%253Apmid%252F11123353%26rft.genre%253Darticle%26rft_val_fmt%253Dinfo%253Aofi%252Ffmt%253Akev%253Amtx%253Ajournal%26ctx_ver%253DZ39.88-2004%26url_ver%253DZ39.88-2004%26url_ctx_fmt%253Dinfo%253Aofi%252Ffmt%253Akev%253Amtx%253Actx" class="cit-ref-sprinkles cit-ref-sprinkles-openurl cit-ref-sprinkles-open-url"><span>OpenUrl</span></a><a href="/lookup/ijlink/YTozOntzOjQ6InBhdGgiO3M6MTQ6Ii9sb29rdXAvaWpsaW5rIjtzOjU6InF1ZXJ5IjthOjQ6e3M6ODoibGlua1R5cGUiO3M6NDoiQUJTVCI7czoxMToiam91cm5hbENvZGUiO3M6ODoiamltbXVub2wiO3M6NToicmVzaWQiO3M6OToiMTY2LzEvNjc4IjtzOjQ6ImF0b20iO3M6MjU6Ii9hbnRpY2FucmVzLzQ1LzIvNjM5LmF0b20iO31zOjg6ImZyYWdtZW50IjtzOjA6IiI7fQ==/YTozOntzOjQ6InBhdGgiO3M6Mjk5OiIvbG9va3VwL2lqbGluay9ZVG96T250ek9qUTZJbkJoZEdnaU8zTTZNVFE2SWk5c2IyOXJkWEF2YVdwc2FXNXJJanR6T2pVNkluRjFaWEo1SWp0aE9qUTZlM002T0RvaWJHbHVhMVI1Y0dVaU8zTTZORG9pUVVKVFZDSTdjem94TVRvaWFtOTFjbTVoYkVOdlpHVWlPM002T0RvaWFtbHRiWFZ1YjJ3aU8zTTZOVG9pY21WemFXUWlPM002T1RvaU1UWTJMekV2TmpjNElqdHpPalE2SW1GMGIyMGlPM002TWpVNklpOWhiblJwWTJGdWNtVnpMelExTHpJdk5qTTVMbUYwYjIwaU8zMXpPamc2SW1aeVlXZHRaVzUwSWp0ek9qQTZJaUk3ZlE9PSI7czo1OiJxdWVyeSI7YTowOnt9czo4OiJmcmFnbWVudCI7czowOiIiO30=" class="cit-ref-sprinkles cit-ref-sprinkles-ijlink"><span><span class="cit-reflinks-abstract">Abstract</span><span class="cit-sep cit-reflinks-variant-name-sep">/</span><span class="cit-reflinks-full-text"><span class="free-full-text">FREE </span>Full Text</span></span></a></div></div></li><li><a class="rev-xref-ref" href="#xref-ref-24-1" title="View reference 24 in text" id="ref-24">↵</a><div class="cit ref-cit ref-journal" id="cit-45.2.639.24" data-doi="10.1056/NEJMe068263"><div class="cit-metadata"><ol class="cit-auth-list"><li><span class="cit-auth"><span class="cit-name-surname">Brugarolas</span> <span class="cit-name-given-names">J</span></span></li></ol><cite>: <span class="cit-article-title">Renal-cell carcinoma – molecular pathways and therapies</span>. <abbr class="cit-jnl-abbrev">N Engl J Med</abbr> <span class="cit-vol">356</span>(<span class="cit-issue">2</span>): <span class="cit-fpage">185</span>-<span class="cit-lpage">187</span>, <span class="cit-pub-date">2007</span>.<span class="cit-pub-id-sep cit-pub-id-doi-sep"> </span><span class="cit-pub-id-scheme">DOI: </span><span class="cit-pub-id cit-pub-id-doi">10.1056/NEJMe068263</span></cite></div><div class="cit-extra"><a href="{openurl}?query=rft.jtitle%253DNew%2BEngland%2BJournal%2Bof%2BMedicine%26rft.stitle%253DNEJM%26rft.aulast%253DBrugarolas%26rft.auinit1%253DJ.%26rft.volume%253D356%26rft.issue%253D2%26rft.spage%253D185%26rft.epage%253D187%26rft.atitle%253DRenal-Cell%2BCarcinoma%2B--%2BMolecular%2BPathways%2Band%2BTherapies%26rft_id%253Dinfo%253Adoi%252F10.1056%252FNEJMe068263%26rft_id%253Dinfo%253Apmid%252F17215538%26rft.genre%253Darticle%26rft_val_fmt%253Dinfo%253Aofi%252Ffmt%253Akev%253Amtx%253Ajournal%26ctx_ver%253DZ39.88-2004%26url_ver%253DZ39.88-2004%26url_ctx_fmt%253Dinfo%253Aofi%252Ffmt%253Akev%253Amtx%253Actx" class="cit-ref-sprinkles cit-ref-sprinkles-openurl cit-ref-sprinkles-open-url"><span>OpenUrl</span></a><a href="/lookup/external-ref?access_num=10.1056/NEJMe068263&link_type=DOI" class="cit-ref-sprinkles cit-ref-sprinkles-doi cit-ref-sprinkles-crossref"><span>CrossRef</span></a><a href="/lookup/external-ref?access_num=17215538&link_type=MED&atom=%2Fanticanres%2F45%2F2%2F639.atom" class="cit-ref-sprinkles cit-ref-sprinkles-medline"><span>PubMed</span></a></div></div></li><li><a class="rev-xref-ref" href="#xref-ref-25-1" title="View reference 25 in text" id="ref-25">↵</a><div class="cit ref-cit ref-journal" id="cit-45.2.639.25" data-doi="10.3389/fimmu.2018.00070"><div class="cit-metadata"><ol class="cit-auth-list"><li><span class="cit-auth"><span class="cit-name-surname">Oliver</span> <span class="cit-name-given-names">AJ</span></span>, </li><li><span class="cit-auth"><span class="cit-name-surname">Lau</span> <span class="cit-name-given-names">PKH</span></span>, </li><li><span class="cit-auth"><span class="cit-name-surname">Unsworth</span> <span class="cit-name-given-names">AS</span></span>, </li><li><span class="cit-auth"><span class="cit-name-surname">Loi</span> <span class="cit-name-given-names">S</span></span>, </li><li><span class="cit-auth"><span class="cit-name-surname">Darcy</span> <span class="cit-name-given-names">PK</span></span>, </li><li><span class="cit-auth"><span class="cit-name-surname">Kershaw</span> <span class="cit-name-given-names">MH</span></span>, </li><li><span class="cit-auth"><span class="cit-name-surname">Slaney</span> <span class="cit-name-given-names">CY</span></span></li></ol><cite>: <span class="cit-article-title">Tissue-dependent tumor microenvironments and their impact on immunotherapy responses</span>. <abbr class="cit-jnl-abbrev">Front Immunol</abbr> <span class="cit-vol">9</span>: <span class="cit-fpage">70</span>, <span class="cit-pub-date">2018</span>.<span class="cit-pub-id-sep cit-pub-id-doi-sep"> </span><span class="cit-pub-id-scheme">DOI: </span><span class="cit-pub-id cit-pub-id-doi">10.3389/fimmu.2018.00070</span></cite></div><div class="cit-extra"><a href="{openurl}?query=rft.jtitle%253DFront%2BImmunol%26rft.volume%253D9%26rft.spage%253D70%26rft_id%253Dinfo%253Adoi%252F10.3389%252Ffimmu.2018.00070%26rft_id%253Dinfo%253Apmid%252F29445373%26rft.genre%253Darticle%26rft_val_fmt%253Dinfo%253Aofi%252Ffmt%253Akev%253Amtx%253Ajournal%26ctx_ver%253DZ39.88-2004%26url_ver%253DZ39.88-2004%26url_ctx_fmt%253Dinfo%253Aofi%252Ffmt%253Akev%253Amtx%253Actx" class="cit-ref-sprinkles cit-ref-sprinkles-openurl cit-ref-sprinkles-open-url"><span>OpenUrl</span></a><a href="/lookup/external-ref?access_num=10.3389/fimmu.2018.00070&link_type=DOI" class="cit-ref-sprinkles cit-ref-sprinkles-doi cit-ref-sprinkles-crossref"><span>CrossRef</span></a><a href="/lookup/external-ref?access_num=29445373&link_type=MED&atom=%2Fanticanres%2F45%2F2%2F639.atom" class="cit-ref-sprinkles cit-ref-sprinkles-medline"><span>PubMed</span></a></div></div></li><li><a class="rev-xref-ref" href="#xref-ref-26-1" title="View reference 26 in text" id="ref-26">↵</a><div class="cit ref-cit ref-journal" id="cit-45.2.639.26" data-doi="10.3390/vaccines8020203"><div class="cit-metadata"><ol class="cit-auth-list"><li><span class="cit-auth"><span class="cit-name-surname">Botticelli</span> <span class="cit-name-given-names">A</span></span>, </li><li><span class="cit-auth"><span class="cit-name-surname">Cirillo</span> <span class="cit-name-given-names">A</span></span>, </li><li><span class="cit-auth"><span class="cit-name-surname">Scagnoli</span> <span class="cit-name-given-names">S</span></span>, </li><li><span class="cit-auth"><span class="cit-name-surname">Cerbelli</span> <span class="cit-name-given-names">B</span></span>, </li><li><span class="cit-auth"><span class="cit-name-surname">Strigari</span> <span class="cit-name-given-names">L</span></span>, </li><li><span class="cit-auth"><span class="cit-name-surname">Cortellini</span> <span class="cit-name-given-names">A</span></span>, </li><li><span class="cit-auth"><span class="cit-name-surname">Pizzuti</span> <span class="cit-name-given-names">L</span></span>, </li><li><span class="cit-auth"><span class="cit-name-surname">Vici</span> <span class="cit-name-given-names">P</span></span>, </li><li><span class="cit-auth"><span class="cit-name-surname">De Galitiis</span> <span class="cit-name-given-names">F</span></span>, </li><li><span class="cit-auth"><span class="cit-name-surname">Di Pietro</span> <span class="cit-name-given-names">FR</span></span>, </li><li><span class="cit-auth"><span class="cit-name-surname">Cerbelli</span> <span class="cit-name-given-names">E</span></span>, </li><li><span class="cit-auth"><span class="cit-name-surname">Ghidini</span> <span class="cit-name-given-names">M</span></span>, </li><li><span class="cit-auth"><span class="cit-name-surname">D’Amati</span> <span class="cit-name-given-names">G</span></span>, </li><li><span class="cit-auth"><span class="cit-name-surname">Della Rocca</span> <span class="cit-name-given-names">C</span></span>, </li><li><span class="cit-auth"><span class="cit-name-surname">Mezi</span> <span class="cit-name-given-names">S</span></span>, </li><li><span class="cit-auth"><span class="cit-name-surname">Gelibter</span> <span class="cit-name-given-names">A</span></span>, </li><li><span class="cit-auth"><span class="cit-name-surname">Giusti</span> <span class="cit-name-given-names">R</span></span>, </li><li><span class="cit-auth"><span class="cit-name-surname">Cortesi</span> <span class="cit-name-given-names">E</span></span>, </li><li><span class="cit-auth"><span class="cit-name-surname">Ascierto</span> <span class="cit-name-given-names">PA</span></span>, </li><li><span class="cit-auth"><span class="cit-name-surname">Nuti</span> <span class="cit-name-given-names">M</span></span>, </li><li><span class="cit-auth"><span class="cit-name-surname">Marchetti</span> <span class="cit-name-given-names">P</span></span></li></ol><cite>: <span class="cit-article-title">The agnostic role of site of metastasis in predicting outcomes in cancer patients treated with immunotherapy</span>. <abbr class="cit-jnl-abbrev">Vaccines (Basel)</abbr> <span class="cit-vol">8</span>(<span class="cit-issue">2</span>): <span class="cit-fpage">203</span>, <span class="cit-pub-date">2020</span>.<span class="cit-pub-id-sep cit-pub-id-doi-sep"> </span><span class="cit-pub-id-scheme">DOI: </span><span class="cit-pub-id cit-pub-id-doi">10.3390/vaccines8020203</span></cite></div><div class="cit-extra"><a href="{openurl}?query=rft.jtitle%253DVaccines%2B%2528Basel%2529%26rft.volume%253D8%26rft.spage%253D203%26rft_id%253Dinfo%253Adoi%252F10.3390%252Fvaccines8020203%26rft_id%253Dinfo%253Apmid%252F32353934%26rft.genre%253Darticle%26rft_val_fmt%253Dinfo%253Aofi%252Ffmt%253Akev%253Amtx%253Ajournal%26ctx_ver%253DZ39.88-2004%26url_ver%253DZ39.88-2004%26url_ctx_fmt%253Dinfo%253Aofi%252Ffmt%253Akev%253Amtx%253Actx" class="cit-ref-sprinkles cit-ref-sprinkles-openurl cit-ref-sprinkles-open-url"><span>OpenUrl</span></a><a href="/lookup/external-ref?access_num=10.3390/vaccines8020203&link_type=DOI" class="cit-ref-sprinkles cit-ref-sprinkles-doi cit-ref-sprinkles-crossref"><span>CrossRef</span></a><a href="/lookup/external-ref?access_num=32353934&link_type=MED&atom=%2Fanticanres%2F45%2F2%2F639.atom" class="cit-ref-sprinkles cit-ref-sprinkles-medline"><span>PubMed</span></a></div></div></li><li><a class="rev-xref-ref" href="#xref-ref-27-1" title="View reference 27 in text" id="ref-27">↵</a><div class="cit ref-cit ref-journal" id="cit-45.2.639.27" data-doi="10.4149/neo_2020_200512N519"><div class="cit-metadata"><ol class="cit-auth-list"><li><span class="cit-auth"><span class="cit-name-surname">Vrdoljak</span> <span class="cit-name-given-names">E</span></span>, </li><li><span class="cit-auth"><span class="cit-name-surname">Magri</span> <span class="cit-name-given-names">C</span></span>, </li><li><span class="cit-auth"><span class="cit-name-surname">Gamulin</span> <span class="cit-name-given-names">M</span></span>, </li><li><span class="cit-auth"><span class="cit-name-surname">Bošković</span> <span class="cit-name-given-names">L</span></span>, </li><li><span class="cit-auth"><span class="cit-name-surname">Omrčen</span> <span class="cit-name-given-names">T</span></span>, </li><li><span class="cit-auth"><span class="cit-name-surname">Bajić</span> <span class="cit-name-given-names">Ž</span></span>, </li><li><span class="cit-auth"><span class="cit-name-surname">Dienes</span> <span class="cit-name-given-names">T</span></span>, </li><li><span class="cit-auth"><span class="cit-name-surname">Geczi</span> <span class="cit-name-given-names">L</span></span></li></ol><cite>: <span class="cit-article-title">Real-world safety and efficacy of nivolumab for ≥ 2nd line treatment of metastatic renal cell carcinoma: A retrospective cohort study in Croatia, Hungary, and Malta</span>. <abbr class="cit-jnl-abbrev">Neoplasma</abbr> <span class="cit-vol">68</span>(<span class="cit-issue">01</span>): <span class="cit-fpage">208</span>-<span class="cit-lpage">215</span>, <span class="cit-pub-date">2021</span>.<span class="cit-pub-id-sep cit-pub-id-doi-sep"> </span><span class="cit-pub-id-scheme">DOI: </span><span class="cit-pub-id cit-pub-id-doi">10.4149/neo_2020_200512N519</span></cite></div><div class="cit-extra"><a href="{openurl}?query=rft.jtitle%253DNeoplasma%26rft.volume%253D68%26rft.spage%253D208%26rft_id%253Dinfo%253Adoi%252F10.4149%252Fneo_2020_200512N519%26rft_id%253Dinfo%253Apmid%252F32940046%26rft.genre%253Darticle%26rft_val_fmt%253Dinfo%253Aofi%252Ffmt%253Akev%253Amtx%253Ajournal%26ctx_ver%253DZ39.88-2004%26url_ver%253DZ39.88-2004%26url_ctx_fmt%253Dinfo%253Aofi%252Ffmt%253Akev%253Amtx%253Actx" class="cit-ref-sprinkles cit-ref-sprinkles-openurl cit-ref-sprinkles-open-url"><span>OpenUrl</span></a><a href="/lookup/external-ref?access_num=10.4149/neo_2020_200512N519&link_type=DOI" class="cit-ref-sprinkles cit-ref-sprinkles-doi cit-ref-sprinkles-crossref"><span>CrossRef</span></a><a href="/lookup/external-ref?access_num=32940046&link_type=MED&atom=%2Fanticanres%2F45%2F2%2F639.atom" class="cit-ref-sprinkles cit-ref-sprinkles-medline"><span>PubMed</span></a></div></div></li><li><a class="rev-xref-ref" href="#xref-ref-28-1" title="View reference 28 in text" id="ref-28">↵</a><div class="cit ref-cit ref-journal" id="cit-45.2.639.28" data-doi="10.1080/2162402X.2018.1477461"><div class="cit-metadata"><ol class="cit-auth-list"><li><span class="cit-auth"><span class="cit-name-surname">Lin</span> <span class="cit-name-given-names">Z</span></span>, </li><li><span class="cit-auth"><span class="cit-name-surname">Liu</span> <span class="cit-name-given-names">L</span></span>, </li><li><span class="cit-auth"><span class="cit-name-surname">Xia</span> <span class="cit-name-given-names">Y</span></span>, </li><li><span class="cit-auth"><span class="cit-name-surname">Chen</span> <span class="cit-name-given-names">X</span></span>, </li><li><span class="cit-auth"><span class="cit-name-surname">Xiong</span> <span class="cit-name-given-names">Y</span></span>, </li><li><span class="cit-auth"><span class="cit-name-surname">Qu</span> <span class="cit-name-given-names">Y</span></span>, </li><li><span class="cit-auth"><span class="cit-name-surname">Wang</span> <span class="cit-name-given-names">J</span></span>, </li><li><span class="cit-auth"><span class="cit-name-surname">Bai</span> <span class="cit-name-given-names">Q</span></span>, </li><li><span class="cit-auth"><span class="cit-name-surname">Guo</span> <span class="cit-name-given-names">J</span></span>, </li><li><span class="cit-auth"><span class="cit-name-surname">Xu</span> <span class="cit-name-given-names">J</span></span></li></ol><cite>: <span class="cit-article-title">Tumor infiltrating CD19(+) B lymphocytes predict prognostic and therapeutic benefits in metastatic renal cell carcinoma patients treated with tyrosine kinase inhibitors</span>. <abbr class="cit-jnl-abbrev">Oncoimmunology</abbr> <span class="cit-vol">7</span>(<span class="cit-issue">10</span>): <span class="cit-fpage">e1477461</span>, <span class="cit-pub-date">2018</span>.<span class="cit-pub-id-sep cit-pub-id-doi-sep"> </span><span class="cit-pub-id-scheme">DOI: </span><span class="cit-pub-id cit-pub-id-doi">10.1080/2162402X.2018.1477461</span></cite></div><div class="cit-extra"><a href="{openurl}?query=rft.jtitle%253DOncoimmunology%26rft.volume%253D7%26rft.spage%253De1477461%26rft_id%253Dinfo%253Adoi%252F10.1080%252F2162402X.2018.1477461%26rft_id%253Dinfo%253Apmid%252F30288343%26rft.genre%253Darticle%26rft_val_fmt%253Dinfo%253Aofi%252Ffmt%253Akev%253Amtx%253Ajournal%26ctx_ver%253DZ39.88-2004%26url_ver%253DZ39.88-2004%26url_ctx_fmt%253Dinfo%253Aofi%252Ffmt%253Akev%253Amtx%253Actx" class="cit-ref-sprinkles cit-ref-sprinkles-openurl cit-ref-sprinkles-open-url"><span>OpenUrl</span></a><a href="/lookup/external-ref?access_num=10.1080/2162402X.2018.1477461&link_type=DOI" class="cit-ref-sprinkles cit-ref-sprinkles-doi cit-ref-sprinkles-crossref"><span>CrossRef</span></a><a href="/lookup/external-ref?access_num=30288343&link_type=MED&atom=%2Fanticanres%2F45%2F2%2F639.atom" class="cit-ref-sprinkles cit-ref-sprinkles-medline"><span>PubMed</span></a></div></div></li><li><a class="rev-xref-ref" href="#xref-ref-29-1" title="View reference 29 in text" id="ref-29">↵</a><div class="cit ref-cit ref-journal" id="cit-45.2.639.29" data-doi="10.1002/eji.201444625"><div class="cit-metadata"><ol class="cit-auth-list"><li><span class="cit-auth"><span class="cit-name-surname">Tao</span> <span class="cit-name-given-names">H</span></span>, </li><li><span class="cit-auth"><span class="cit-name-surname">Lu</span> <span class="cit-name-given-names">L</span></span>, </li><li><span class="cit-auth"><span class="cit-name-surname">Xia</span> <span class="cit-name-given-names">Y</span></span>, </li><li><span class="cit-auth"><span class="cit-name-surname">Dai</span> <span class="cit-name-given-names">F</span></span>, </li><li><span class="cit-auth"><span class="cit-name-surname">Wang</span> <span class="cit-name-given-names">Y</span></span>, </li><li><span class="cit-auth"><span class="cit-name-surname">Bao</span> <span class="cit-name-given-names">Y</span></span>, </li><li><span class="cit-auth"><span class="cit-name-surname">Lundy</span> <span class="cit-name-given-names">SK</span></span>, </li><li><span class="cit-auth"><span class="cit-name-surname">Ito</span> <span class="cit-name-given-names">F</span></span>, </li><li><span class="cit-auth"><span class="cit-name-surname">Pan</span> <span class="cit-name-given-names">Q</span></span>, </li><li><span class="cit-auth"><span class="cit-name-surname">Zhang</span> <span class="cit-name-given-names">X</span></span>, </li><li><span class="cit-auth"><span class="cit-name-surname">Zheng</span> <span class="cit-name-given-names">F</span></span>, </li><li><span class="cit-auth"><span class="cit-name-surname">Shu</span> <span class="cit-name-given-names">G</span></span>, </li><li><span class="cit-auth"><span class="cit-name-surname">Fang</span> <span class="cit-name-given-names">B</span></span>, </li><li><span class="cit-auth"><span class="cit-name-surname">Jiang</span> <span class="cit-name-given-names">J</span></span>, </li><li><span class="cit-auth"><span class="cit-name-surname">Xia</span> <span class="cit-name-given-names">J</span></span>, </li><li><span class="cit-auth"><span class="cit-name-surname">Huang</span> <span class="cit-name-given-names">S</span></span>, </li><li><span class="cit-auth"><span class="cit-name-surname">Li</span> <span class="cit-name-given-names">Q</span></span>, </li><li><span class="cit-auth"><span class="cit-name-surname">Chang</span> <span class="cit-name-given-names">AE</span></span></li></ol><cite>: <span class="cit-article-title">Antitumor effector B cells directly kill tumor cells via the Fas/FasL pathway and are regulated by IL-10</span>. <abbr class="cit-jnl-abbrev">Eur J Immunol</abbr> <span class="cit-vol">45</span>(<span class="cit-issue">4</span>): <span class="cit-fpage">999</span>-<span class="cit-lpage">1009</span>, <span class="cit-pub-date">2015</span>.<span class="cit-pub-id-sep cit-pub-id-doi-sep"> </span><span class="cit-pub-id-scheme">DOI: </span><span class="cit-pub-id cit-pub-id-doi">10.1002/eji.201444625</span></cite></div><div class="cit-extra"><a href="{openurl}?query=rft.jtitle%253DEur%2BJ%2BImmunol%26rft.volume%253D45%26rft.spage%253D999%26rft_id%253Dinfo%253Adoi%252F10.1002%252Feji.201444625%26rft_id%253Dinfo%253Apmid%252F25545618%26rft.genre%253Darticle%26rft_val_fmt%253Dinfo%253Aofi%252Ffmt%253Akev%253Amtx%253Ajournal%26ctx_ver%253DZ39.88-2004%26url_ver%253DZ39.88-2004%26url_ctx_fmt%253Dinfo%253Aofi%252Ffmt%253Akev%253Amtx%253Actx" class="cit-ref-sprinkles cit-ref-sprinkles-openurl cit-ref-sprinkles-open-url"><span>OpenUrl</span></a><a href="/lookup/external-ref?access_num=10.1002/eji.201444625&link_type=DOI" class="cit-ref-sprinkles cit-ref-sprinkles-doi cit-ref-sprinkles-crossref"><span>CrossRef</span></a><a href="/lookup/external-ref?access_num=25545618&link_type=MED&atom=%2Fanticanres%2F45%2F2%2F639.atom" class="cit-ref-sprinkles cit-ref-sprinkles-medline"><span>PubMed</span></a></div></div></li><li><a class="rev-xref-ref" href="#xref-ref-30-1" title="View reference 30 in text" id="ref-30">↵</a><div class="cit ref-cit ref-journal" id="cit-45.2.639.30" data-doi="10.1155/2015/192406"><div class="cit-metadata"><ol class="cit-auth-list"><li><span class="cit-auth"><span class="cit-name-surname">Shuch</span> <span class="cit-name-given-names">B</span></span>, </li><li><span class="cit-auth"><span class="cit-name-surname">Falbo</span> <span class="cit-name-given-names">R</span></span>, </li><li><span class="cit-auth"><span class="cit-name-surname">Parisi</span> <span class="cit-name-given-names">F</span></span>, </li><li><span class="cit-auth"><span class="cit-name-surname">Adeniran</span> <span class="cit-name-given-names">A</span></span>, </li><li><span class="cit-auth"><span class="cit-name-surname">Kluger</span> <span class="cit-name-given-names">Y</span></span>, </li><li><span class="cit-auth"><span class="cit-name-surname">Kluger</span> <span class="cit-name-given-names">HM</span></span>, </li><li><span class="cit-auth"><span class="cit-name-surname">Jilaveanu</span> <span class="cit-name-given-names">LB</span></span></li></ol><cite>: <span class="cit-article-title">MET expression in primary and metastatic clear cell renal cell carcinoma: Implications of correlative biomarker assessment to MET pathway inhibitors</span>. <abbr class="cit-jnl-abbrev">Biomed Res Int</abbr> <span class="cit-vol">2015</span>: <span class="cit-fpage">192406</span>, <span class="cit-pub-date">2015</span>.<span class="cit-pub-id-sep cit-pub-id-doi-sep"> </span><span class="cit-pub-id-scheme">DOI: </span><span class="cit-pub-id cit-pub-id-doi">10.1155/2015/192406</span></cite></div><div class="cit-extra"><a href="{openurl}?query=rft.jtitle%253DBiomed%2BRes%2BInt%26rft.volume%253D2015%26rft.spage%253D192406%26rft_id%253Dinfo%253Adoi%252F10.1155%252F2015%252F192406%26rft_id%253Dinfo%253Apmid%252F26448928%26rft.genre%253Darticle%26rft_val_fmt%253Dinfo%253Aofi%252Ffmt%253Akev%253Amtx%253Ajournal%26ctx_ver%253DZ39.88-2004%26url_ver%253DZ39.88-2004%26url_ctx_fmt%253Dinfo%253Aofi%252Ffmt%253Akev%253Amtx%253Actx" class="cit-ref-sprinkles cit-ref-sprinkles-openurl cit-ref-sprinkles-open-url"><span>OpenUrl</span></a><a href="/lookup/external-ref?access_num=10.1155/2015/192406&link_type=DOI" class="cit-ref-sprinkles cit-ref-sprinkles-doi cit-ref-sprinkles-crossref"><span>CrossRef</span></a><a href="/lookup/external-ref?access_num=26448928&link_type=MED&atom=%2Fanticanres%2F45%2F2%2F639.atom" class="cit-ref-sprinkles cit-ref-sprinkles-medline"><span>PubMed</span></a></div></div></li><li><a class="rev-xref-ref" href="#xref-ref-31-1" title="View reference 31 in text" id="ref-31">↵</a><div class="cit ref-cit ref-journal" id="cit-45.2.639.31" data-doi="10.1158/1535-7163.MCT-11-0264"><div class="cit-metadata"><ol class="cit-auth-list"><li><span class="cit-auth"><span class="cit-name-surname">Yakes</span> <span class="cit-name-given-names">FM</span></span>, </li><li><span class="cit-auth"><span class="cit-name-surname">Chen</span> <span class="cit-name-given-names">J</span></span>, </li><li><span class="cit-auth"><span class="cit-name-surname">Tan</span> <span class="cit-name-given-names">J</span></span>, </li><li><span class="cit-auth"><span class="cit-name-surname">Yamaguchi</span> <span class="cit-name-given-names">K</span></span>, </li><li><span class="cit-auth"><span class="cit-name-surname">Shi</span> <span class="cit-name-given-names">Y</span></span>, </li><li><span class="cit-auth"><span class="cit-name-surname">Yu</span> <span class="cit-name-given-names">P</span></span>, </li><li><span class="cit-auth"><span class="cit-name-surname">Qian</span> <span class="cit-name-given-names">F</span></span>, </li><li><span class="cit-auth"><span class="cit-name-surname">Chu</span> <span class="cit-name-given-names">F</span></span>, </li><li><span class="cit-auth"><span class="cit-name-surname">Bentzien</span> <span class="cit-name-given-names">F</span></span>, </li><li><span class="cit-auth"><span class="cit-name-surname">Cancilla</span> <span class="cit-name-given-names">B</span></span>, </li><li><span class="cit-auth"><span class="cit-name-surname">Orf</span> <span class="cit-name-given-names">J</span></span>, </li><li><span class="cit-auth"><span class="cit-name-surname">You</span> <span class="cit-name-given-names">A</span></span>, </li><li><span class="cit-auth"><span class="cit-name-surname">Laird</span> <span class="cit-name-given-names">AD</span></span>, </li><li><span class="cit-auth"><span class="cit-name-surname">Engst</span> <span class="cit-name-given-names">S</span></span>, </li><li><span class="cit-auth"><span class="cit-name-surname">Lee</span> <span class="cit-name-given-names">L</span></span>, </li><li><span class="cit-auth"><span class="cit-name-surname">Lesch</span> <span class="cit-name-given-names">J</span></span>, </li><li><span class="cit-auth"><span class="cit-name-surname">Chou</span> <span class="cit-name-given-names">YC</span></span>, </li><li><span class="cit-auth"><span class="cit-name-surname">Joly</span> <span class="cit-name-given-names">AH</span></span></li></ol><cite>: <span class="cit-article-title">Cabozantinib (XL184), a novel MET and VEGFR2 inhibitor, simultaneously suppresses metastasis, angiogenesis, and tumor growth</span>. <abbr class="cit-jnl-abbrev">Mol Cancer Ther</abbr> <span class="cit-vol">10</span>(<span class="cit-issue">12</span>): <span class="cit-fpage">2298</span>-<span class="cit-lpage">2308</span>, <span class="cit-pub-date">2011</span>.<span class="cit-pub-id-sep cit-pub-id-doi-sep"> </span><span class="cit-pub-id-scheme">DOI: </span><span class="cit-pub-id cit-pub-id-doi">10.1158/1535-7163.MCT-11-0264</span></cite></div><div class="cit-extra"><a href="{openurl}?query=rft.jtitle%253DMol%2BCancer%2BTher%26rft_id%253Dinfo%253Adoi%252F10.1158%252F1535-7163.MCT-11-0264%26rft_id%253Dinfo%253Apmid%252F21926191%26rft.genre%253Darticle%26rft_val_fmt%253Dinfo%253Aofi%252Ffmt%253Akev%253Amtx%253Ajournal%26ctx_ver%253DZ39.88-2004%26url_ver%253DZ39.88-2004%26url_ctx_fmt%253Dinfo%253Aofi%252Ffmt%253Akev%253Amtx%253Actx" class="cit-ref-sprinkles cit-ref-sprinkles-openurl cit-ref-sprinkles-open-url"><span>OpenUrl</span></a><a href="/lookup/ijlink/YTozOntzOjQ6InBhdGgiO3M6MTQ6Ii9sb29rdXAvaWpsaW5rIjtzOjU6InF1ZXJ5IjthOjQ6e3M6ODoibGlua1R5cGUiO3M6NDoiQUJTVCI7czoxMToiam91cm5hbENvZGUiO3M6MTA6Im1vbGNhbnRoZXIiO3M6NToicmVzaWQiO3M6MTA6IjEwLzEyLzIyOTgiO3M6NDoiYXRvbSI7czoyNToiL2FudGljYW5yZXMvNDUvMi82MzkuYXRvbSI7fXM6ODoiZnJhZ21lbnQiO3M6MDoiIjt9/YTozOntzOjQ6InBhdGgiO3M6MzAzOiIvbG9va3VwL2lqbGluay9ZVG96T250ek9qUTZJbkJoZEdnaU8zTTZNVFE2SWk5c2IyOXJkWEF2YVdwc2FXNXJJanR6T2pVNkluRjFaWEo1SWp0aE9qUTZlM002T0RvaWJHbHVhMVI1Y0dVaU8zTTZORG9pUVVKVFZDSTdjem94TVRvaWFtOTFjbTVoYkVOdlpHVWlPM002TVRBNkltMXZiR05oYm5Sb1pYSWlPM002TlRvaWNtVnphV1FpTzNNNk1UQTZJakV3THpFeUx6SXlPVGdpTzNNNk5Eb2lZWFJ2YlNJN2N6b3lOVG9pTDJGdWRHbGpZVzV5WlhNdk5EVXZNaTgyTXprdVlYUnZiU0k3ZlhNNk9Eb2labkpoWjIxbGJuUWlPM002TURvaUlqdDkiO3M6NToicXVlcnkiO2E6MDp7fXM6ODoiZnJhZ21lbnQiO3M6MDoiIjt9" class="cit-ref-sprinkles cit-ref-sprinkles-ijlink"><span><span class="cit-reflinks-abstract">Abstract</span><span class="cit-sep cit-reflinks-variant-name-sep">/</span><span class="cit-reflinks-full-text"><span class="free-full-text">FREE </span>Full Text</span></span></a></div></div></li><li><a class="rev-xref-ref" href="#xref-ref-32-1" title="View reference 32 in text" id="ref-32">↵</a><div class="cit ref-cit ref-journal" id="cit-45.2.639.32" data-doi="10.21873/invivo.12593"><div class="cit-metadata"><ol class="cit-auth-list"><li><span class="cit-auth"><span class="cit-name-surname">Kopecky</span> <span class="cit-name-given-names">J</span></span>, </li><li><span class="cit-auth"><span class="cit-name-surname">Kubecek</span> <span class="cit-name-given-names">O</span></span>, </li><li><span class="cit-auth"><span class="cit-name-surname">Buchler</span> <span class="cit-name-given-names">T</span></span>, </li><li><span class="cit-auth"><span class="cit-name-surname">Melichar</span> <span class="cit-name-given-names">B</span></span>, </li><li><span class="cit-auth"><span class="cit-name-surname">Poprach</span> <span class="cit-name-given-names">A</span></span>, </li><li><span class="cit-auth"><span class="cit-name-surname">Zemanova</span> <span class="cit-name-given-names">M</span></span>, </li><li><span class="cit-auth"><span class="cit-name-surname">Katolicka</span> <span class="cit-name-given-names">J</span></span>, </li><li><span class="cit-auth"><span class="cit-name-surname">Kiss</span> <span class="cit-name-given-names">I</span></span>, </li><li><span class="cit-auth"><span class="cit-name-surname">Hajek</span> <span class="cit-name-given-names">J</span></span>, </li><li><span class="cit-auth"><span class="cit-name-surname">Studentova</span> <span class="cit-name-given-names">H</span></span>, </li><li><span class="cit-auth"><span class="cit-name-surname">Spisarova</span> <span class="cit-name-given-names">M</span></span></li></ol><cite>: <span class="cit-article-title">Administration of nivolumab in metastatic renal cell cancer following treatment with mTOR inhibitors</span>. <abbr class="cit-jnl-abbrev">In Vivo</abbr> <span class="cit-vol">35</span>(<span class="cit-issue">5</span>): <span class="cit-fpage">2981</span>-<span class="cit-lpage">2990</span>, <span class="cit-pub-date">2021</span>.<span class="cit-pub-id-sep cit-pub-id-doi-sep"> </span><span class="cit-pub-id-scheme">DOI: </span><span class="cit-pub-id cit-pub-id-doi">10.21873/invivo.12593</span></cite></div><div class="cit-extra"><a href="{openurl}?query=rft.jtitle%253DIn%2BVivo%26rft.stitle%253DIn%2BVivo%26rft.aulast%253DKOPECKY%26rft.auinit1%253DJ.%26rft.volume%253D35%26rft.issue%253D5%26rft.spage%253D2981%26rft.epage%253D2990%26rft.atitle%253DAdministration%2Bof%2BNivolumab%2Bin%2BMetastatic%2BRenal%2BCell%2BCancer%2BFollowing%2BTreatment%2BWith%2BmTOR%2BInhibitors%26rft_id%253Dinfo%253Adoi%252F10.21873%252Finvivo.12593%26rft_id%253Dinfo%253Apmid%252F34410998%26rft.genre%253Darticle%26rft_val_fmt%253Dinfo%253Aofi%252Ffmt%253Akev%253Amtx%253Ajournal%26ctx_ver%253DZ39.88-2004%26url_ver%253DZ39.88-2004%26url_ctx_fmt%253Dinfo%253Aofi%252Ffmt%253Akev%253Amtx%253Actx" class="cit-ref-sprinkles cit-ref-sprinkles-openurl cit-ref-sprinkles-open-url"><span>OpenUrl</span></a><a href="/lookup/ijlink/YTozOntzOjQ6InBhdGgiO3M6MTQ6Ii9sb29rdXAvaWpsaW5rIjtzOjU6InF1ZXJ5IjthOjQ6e3M6ODoibGlua1R5cGUiO3M6NDoiQUJTVCI7czoxMToiam91cm5hbENvZGUiO3M6NjoiaW52aXZvIjtzOjU6InJlc2lkIjtzOjk6IjM1LzUvMjk4MSI7czo0OiJhdG9tIjtzOjI1OiIvYW50aWNhbnJlcy80NS8yLzYzOS5hdG9tIjt9czo4OiJmcmFnbWVudCI7czowOiIiO30=/YTozOntzOjQ6InBhdGgiO3M6Mjk1OiIvbG9va3VwL2lqbGluay9ZVG96T250ek9qUTZJbkJoZEdnaU8zTTZNVFE2SWk5c2IyOXJkWEF2YVdwc2FXNXJJanR6T2pVNkluRjFaWEo1SWp0aE9qUTZlM002T0RvaWJHbHVhMVI1Y0dVaU8zTTZORG9pUVVKVFZDSTdjem94TVRvaWFtOTFjbTVoYkVOdlpHVWlPM002TmpvaWFXNTJhWFp2SWp0ek9qVTZJbkpsYzJsa0lqdHpPams2SWpNMUx6VXZNams0TVNJN2N6bzBPaUpoZEc5dElqdHpPakkxT2lJdllXNTBhV05oYm5KbGN5ODBOUzh5THpZek9TNWhkRzl0SWp0OWN6bzRPaUptY21GbmJXVnVkQ0k3Y3pvd09pSWlPMzA9IjtzOjU6InF1ZXJ5IjthOjA6e31zOjg6ImZyYWdtZW50IjtzOjA6IiI7fQ==" class="cit-ref-sprinkles cit-ref-sprinkles-ijlink"><span><span class="cit-reflinks-abstract">Abstract</span><span class="cit-sep cit-reflinks-variant-name-sep">/</span><span class="cit-reflinks-full-text"><span class="free-full-text">FREE </span>Full Text</span></span></a></div></div></li><li><a class="rev-xref-ref" href="#xref-ref-33-1" title="View reference 33 in text" id="ref-33">↵</a><div class="cit ref-cit ref-journal" id="cit-45.2.639.33" data-doi="10.23736/S1824-4785.19.03193-5"><div class="cit-metadata"><ol class="cit-auth-list"><li><span class="cit-auth"><span class="cit-name-surname">Castello</span> <span class="cit-name-given-names">A</span></span>, </li><li><span class="cit-auth"><span class="cit-name-surname">Lopci</span> <span class="cit-name-given-names">E</span></span></li></ol><cite>: <span class="cit-article-title">Response assessment of bone metastatic disease: seeing the forest for the trees RECIST, PERCIST, iRECIST, and PCWG-2</span>. <abbr class="cit-jnl-abbrev">Q J Nucl Med Mol Imaging</abbr> <span class="cit-vol">63</span>(<span class="cit-issue">2</span>): <span class="cit-fpage">150</span>-<span class="cit-lpage">158</span>, <span class="cit-pub-date">2019</span>.<span class="cit-pub-id-sep cit-pub-id-doi-sep"> </span><span class="cit-pub-id-scheme">DOI: </span><span class="cit-pub-id cit-pub-id-doi">10.23736/S1824-4785.19.03193-5</span></cite></div><div class="cit-extra"><a href="{openurl}?query=rft.jtitle%253DQ%2BJ%2BNucl%2BMed%2BMol%2BImaging%26rft.volume%253D63%26rft.spage%253D150%26rft_id%253Dinfo%253Adoi%252F10.23736%252FS1824-4785.19.03193-5%26rft_id%253Dinfo%253Apmid%252F31286751%26rft.genre%253Darticle%26rft_val_fmt%253Dinfo%253Aofi%252Ffmt%253Akev%253Amtx%253Ajournal%26ctx_ver%253DZ39.88-2004%26url_ver%253DZ39.88-2004%26url_ctx_fmt%253Dinfo%253Aofi%252Ffmt%253Akev%253Amtx%253Actx" class="cit-ref-sprinkles cit-ref-sprinkles-openurl cit-ref-sprinkles-open-url"><span>OpenUrl</span></a><a href="/lookup/external-ref?access_num=10.23736/S1824-4785.19.03193-5&link_type=DOI" class="cit-ref-sprinkles cit-ref-sprinkles-doi cit-ref-sprinkles-crossref"><span>CrossRef</span></a><a href="/lookup/external-ref?access_num=31286751&link_type=MED&atom=%2Fanticanres%2F45%2F2%2F639.atom" class="cit-ref-sprinkles cit-ref-sprinkles-medline"><span>PubMed</span></a></div></div></li><li><a class="rev-xref-ref" href="#xref-ref-34-1" title="View reference 34 in text" id="ref-34">↵</a><div class="cit ref-cit ref-journal" id="cit-45.2.639.34" data-doi="10.3389/fonc.2022.871675"><div class="cit-metadata"><ol class="cit-auth-list"><li><span class="cit-auth"><span class="cit-name-surname">Asano</span> <span class="cit-name-given-names">Y</span></span>, </li><li><span class="cit-auth"><span class="cit-name-surname">Yamamoto</span> <span class="cit-name-given-names">N</span></span>, </li><li><span class="cit-auth"><span class="cit-name-surname">Demura</span> <span class="cit-name-given-names">S</span></span>, </li><li><span class="cit-auth"><span class="cit-name-surname">Hayashi</span> <span class="cit-name-given-names">K</span></span>, </li><li><span class="cit-auth"><span class="cit-name-surname">Takeuchi</span> <span class="cit-name-given-names">A</span></span>, </li><li><span class="cit-auth"><span class="cit-name-surname">Kato</span> <span class="cit-name-given-names">S</span></span>, </li><li><span class="cit-auth"><span class="cit-name-surname">Miwa</span> <span class="cit-name-given-names">S</span></span>, </li><li><span class="cit-auth"><span class="cit-name-surname">Igarashi</span> <span class="cit-name-given-names">K</span></span>, </li><li><span class="cit-auth"><span class="cit-name-surname">Higuchi</span> <span class="cit-name-given-names">T</span></span>, </li><li><span class="cit-auth"><span class="cit-name-surname">Yonezawa</span> <span class="cit-name-given-names">H</span></span>, </li><li><span class="cit-auth"><span class="cit-name-surname">Araki</span> <span class="cit-name-given-names">Y</span></span>, </li><li><span class="cit-auth"><span class="cit-name-surname">Morinaga</span> <span class="cit-name-given-names">S</span></span>, </li><li><span class="cit-auth"><span class="cit-name-surname">Saito</span> <span class="cit-name-given-names">S</span></span>, </li><li><span class="cit-auth"><span class="cit-name-surname">Sone</span> <span class="cit-name-given-names">T</span></span>, </li><li><span class="cit-auth"><span class="cit-name-surname">Kasahara</span> <span class="cit-name-given-names">K</span></span>, </li><li><span class="cit-auth"><span class="cit-name-surname">Tsuchiya</span> <span class="cit-name-given-names">H</span></span></li></ol><cite>: <span class="cit-article-title">The therapeutic effect and clinical outcome of immune checkpoint inhibitors on bone metastasis in advanced non-small-cell lung cancer</span>. <abbr class="cit-jnl-abbrev">Front Oncol</abbr> <span class="cit-vol">12</span>: <span class="cit-fpage">871675</span>, <span class="cit-pub-date">2022</span>.<span class="cit-pub-id-sep cit-pub-id-doi-sep"> </span><span class="cit-pub-id-scheme">DOI: </span><span class="cit-pub-id cit-pub-id-doi">10.3389/fonc.2022.871675</span></cite></div><div class="cit-extra"><a href="{openurl}?query=rft.jtitle%253DFront%2BOncol%26rft.volume%253D12%26rft.spage%253D871675%26rft_id%253Dinfo%253Adoi%252F10.3389%252Ffonc.2022.871675%26rft_id%253Dinfo%253Apmid%252F35433422%26rft.genre%253Darticle%26rft_val_fmt%253Dinfo%253Aofi%252Ffmt%253Akev%253Amtx%253Ajournal%26ctx_ver%253DZ39.88-2004%26url_ver%253DZ39.88-2004%26url_ctx_fmt%253Dinfo%253Aofi%252Ffmt%253Akev%253Amtx%253Actx" class="cit-ref-sprinkles cit-ref-sprinkles-openurl cit-ref-sprinkles-open-url"><span>OpenUrl</span></a><a href="/lookup/external-ref?access_num=10.3389/fonc.2022.871675&link_type=DOI" class="cit-ref-sprinkles cit-ref-sprinkles-doi cit-ref-sprinkles-crossref"><span>CrossRef</span></a><a href="/lookup/external-ref?access_num=35433422&link_type=MED&atom=%2Fanticanres%2F45%2F2%2F639.atom" class="cit-ref-sprinkles cit-ref-sprinkles-medline"><span>PubMed</span></a></div></div></li><li><a class="rev-xref-ref" href="#xref-ref-35-1" title="View reference 35 in text" id="ref-35">↵</a><div class="cit ref-cit ref-journal" id="cit-45.2.639.35" data-doi="10.21873/anticanres.17333"><div class="cit-metadata"><ol class="cit-auth-list"><li><span class="cit-auth"><span class="cit-name-surname">Ueda</span> <span class="cit-name-given-names">K</span></span>, </li><li><span class="cit-auth"><span class="cit-name-surname">Ito</span> <span class="cit-name-given-names">N</span></span>, </li><li><span class="cit-auth"><span class="cit-name-surname">Sakai</span> <span class="cit-name-given-names">Y</span></span>, </li><li><span class="cit-auth"><span class="cit-name-surname">Ohnishi</span> <span class="cit-name-given-names">S</span></span>, </li><li><span class="cit-auth"><span class="cit-name-surname">Hirano</span> <span class="cit-name-given-names">T</span></span>, </li><li><span class="cit-auth"><span class="cit-name-surname">Kurose</span> <span class="cit-name-given-names">H</span></span>, </li><li><span class="cit-auth"><span class="cit-name-surname">Chikui</span> <span class="cit-name-given-names">K</span></span>, </li><li><span class="cit-auth"><span class="cit-name-surname">Uemura</span> <span class="cit-name-given-names">K</span></span>, </li><li><span class="cit-auth"><span class="cit-name-surname">Nishihara</span> <span class="cit-name-given-names">K</span></span>, </li><li><span class="cit-auth"><span class="cit-name-surname">Nakiri</span> <span class="cit-name-given-names">M</span></span>, </li><li><span class="cit-auth"><span class="cit-name-surname">Suekane</span> <span class="cit-name-given-names">S</span></span>, </li><li><span class="cit-auth"><span class="cit-name-surname">Igawa</span> <span class="cit-name-given-names">T</span></span></li></ol><cite>: <span class="cit-article-title">Efficacy and safety of nivolumab with ipilimumab in elderly patients with advanced renal cell carcinoma</span>. <abbr class="cit-jnl-abbrev">Anticancer Res</abbr> <span class="cit-vol">44</span>(<span class="cit-issue">11</span>): <span class="cit-fpage">5087</span>-<span class="cit-lpage">5093</span>, <span class="cit-pub-date">2024</span>.<span class="cit-pub-id-sep cit-pub-id-doi-sep"> </span><span class="cit-pub-id-scheme">DOI: </span><span class="cit-pub-id cit-pub-id-doi">10.21873/anticanres.17333</span></cite></div><div class="cit-extra"><a href="{openurl}?query=rft.jtitle%253DAnticancer%2BResearch%26rft.stitle%253DAnticancer%2BRes%26rft.aulast%253DUEDA%26rft.auinit1%253DK.%26rft.volume%253D44%26rft.issue%253D11%26rft.spage%253D5087%26rft.epage%253D5093%26rft.atitle%253DEfficacy%2Band%2BSafety%2Bof%2BNivolumab%2BWith%2BIpilimumab%2Bin%2BElderly%2BPatients%2BWith%2BAdvanced%2BRenal%2BCell%2BCarcinoma%26rft_id%253Dinfo%253Adoi%252F10.21873%252Fanticanres.17333%26rft_id%253Dinfo%253Apmid%252F39477306%26rft.genre%253Darticle%26rft_val_fmt%253Dinfo%253Aofi%252Ffmt%253Akev%253Amtx%253Ajournal%26ctx_ver%253DZ39.88-2004%26url_ver%253DZ39.88-2004%26url_ctx_fmt%253Dinfo%253Aofi%252Ffmt%253Akev%253Amtx%253Actx" class="cit-ref-sprinkles cit-ref-sprinkles-openurl cit-ref-sprinkles-open-url"><span>OpenUrl</span></a><a href="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" class="cit-ref-sprinkles cit-ref-sprinkles-ijlink"><span><span class="cit-reflinks-abstract">Abstract</span><span class="cit-sep cit-reflinks-variant-name-sep">/</span><span class="cit-reflinks-full-text"><span class="free-full-text">FREE </span>Full Text</span></span></a></div></div></li><li><a class="rev-xref-ref" href="#xref-ref-36-1" title="View reference 36 in text" id="ref-36">↵</a><div class="cit ref-cit ref-journal" id="cit-45.2.639.36" data-doi="10.21873/anticanres.17426"><div class="cit-metadata"><ol class="cit-auth-list"><li><span class="cit-auth"><span class="cit-name-surname">Ishikawa</span> <span class="cit-name-given-names">G</span></span>, </li><li><span class="cit-auth"><span class="cit-name-surname">Tamura</span> <span class="cit-name-given-names">K</span></span>, </li><li><span class="cit-auth"><span class="cit-name-surname">Tsuchiya</span> <span class="cit-name-given-names">Y</span></span>, </li><li><span class="cit-auth"><span class="cit-name-surname">Watanabe</span> <span class="cit-name-given-names">S</span></span>, </li><li><span class="cit-auth"><span class="cit-name-surname">Ayana</span> <span class="cit-name-given-names">T</span></span>, </li><li><span class="cit-auth"><span class="cit-name-surname">Asuka</span> <span class="cit-name-given-names">S</span></span>, </li><li><span class="cit-auth"><span class="cit-name-surname">Watanabe</span> <span class="cit-name-given-names">K</span></span>, </li><li><span class="cit-auth"><span class="cit-name-surname">Watanabe</span> <span class="cit-name-given-names">H</span></span>, </li><li><span class="cit-auth"><span class="cit-name-surname">Matsushita</span> <span class="cit-name-given-names">Y</span></span>, </li><li><span class="cit-auth"><span class="cit-name-surname">Motoyama</span> <span class="cit-name-given-names">D</span></span>, </li><li><span class="cit-auth"><span class="cit-name-surname">Otsuka</span> <span class="cit-name-given-names">A</span></span>, </li><li><span class="cit-auth"><span class="cit-name-surname">Inamoto</span> <span class="cit-name-given-names">T</span></span></li></ol><cite>: <span class="cit-article-title">Comparing immuno-oncology combination therapy with tyrosine kinase inhibitor monotherapy for advanced renal cell carcinoma</span>. <abbr class="cit-jnl-abbrev">Anticancer Res</abbr> <span class="cit-vol">45</span>(<span class="cit-issue">1</span>): <span class="cit-fpage">379</span>-<span class="cit-lpage">386</span>, <span class="cit-pub-date">2025</span>.<span class="cit-pub-id-sep cit-pub-id-doi-sep"> </span><span class="cit-pub-id-scheme">DOI: </span><span class="cit-pub-id cit-pub-id-doi">10.21873/anticanres.17426</span></cite></div><div class="cit-extra"><a href="{openurl}?query=rft.jtitle%253DAnticancer%2BResearch%26rft.stitle%253DAnticancer%2BRes%26rft.aulast%253DISHIKAWA%26rft.auinit1%253DG.%26rft.volume%253D45%26rft.issue%253D1%26rft.spage%253D379%26rft.epage%253D386%26rft.atitle%253DComparing%2BImmuno-oncology%2BCombination%2BTherapy%2BWith%2BTyrosine%2BKinase%2BInhibitor%2BMonotherapy%2Bfor%2BAdvanced%2BRenal%2BCell%2BCarcinoma%26rft_id%253Dinfo%253Adoi%252F10.21873%252Fanticanres.17426%26rft_id%253Dinfo%253Apmid%252F39740850%26rft.genre%253Darticle%26rft_val_fmt%253Dinfo%253Aofi%252Ffmt%253Akev%253Amtx%253Ajournal%26ctx_ver%253DZ39.88-2004%26url_ver%253DZ39.88-2004%26url_ctx_fmt%253Dinfo%253Aofi%252Ffmt%253Akev%253Amtx%253Actx" class="cit-ref-sprinkles cit-ref-sprinkles-openurl cit-ref-sprinkles-open-url"><span>OpenUrl</span></a><a href="/lookup/ijlink/YTozOntzOjQ6InBhdGgiO3M6MTQ6Ii9sb29rdXAvaWpsaW5rIjtzOjU6InF1ZXJ5IjthOjQ6e3M6ODoibGlua1R5cGUiO3M6NDoiQUJTVCI7czoxMToiam91cm5hbENvZGUiO3M6MTA6ImFudGljYW5yZXMiO3M6NToicmVzaWQiO3M6ODoiNDUvMS8zNzkiO3M6NDoiYXRvbSI7czoyNToiL2FudGljYW5yZXMvNDUvMi82MzkuYXRvbSI7fXM6ODoiZnJhZ21lbnQiO3M6MDoiIjt9/YTozOntzOjQ6InBhdGgiO3M6Mjk5OiIvbG9va3VwL2lqbGluay9ZVG96T250ek9qUTZJbkJoZEdnaU8zTTZNVFE2SWk5c2IyOXJkWEF2YVdwc2FXNXJJanR6T2pVNkluRjFaWEo1SWp0aE9qUTZlM002T0RvaWJHbHVhMVI1Y0dVaU8zTTZORG9pUVVKVFZDSTdjem94TVRvaWFtOTFjbTVoYkVOdlpHVWlPM002TVRBNkltRnVkR2xqWVc1eVpYTWlPM002TlRvaWNtVnphV1FpTzNNNk9Eb2lORFV2TVM4ek56a2lPM002TkRvaVlYUnZiU0k3Y3pveU5Ub2lMMkZ1ZEdsallXNXlaWE12TkRVdk1pODJNemt1WVhSdmJTSTdmWE02T0RvaVpuSmhaMjFsYm5RaU8zTTZNRG9pSWp0OSI7czo1OiJxdWVyeSI7YTowOnt9czo4OiJmcmFnbWVudCI7czowOiIiO30=" class="cit-ref-sprinkles cit-ref-sprinkles-ijlink"><span><span class="cit-reflinks-abstract">Abstract</span><span class="cit-sep cit-reflinks-variant-name-sep">/</span><span class="cit-reflinks-full-text"><span class="free-full-text">FREE </span>Full Text</span></span></a></div></div></li></ol></div><span class="highwire-journal-article-marker-end"></span></div><span class="related-urls"></span></div></div> </div> </div> </div> </div> </div> </div></div> </div> </div> <div class="panel-separator"></div><div class="panel-pane pane-highwire-node-pager" > <div class="pane-content"> <div class="pager highwire-pager pager-mini clearfix highwire-node-pager highwire-article-pager"><span class="pager-prev"><a href="/content/45/2/625" title="Cyclin E Expression and p16 Loss Are Strong Prognostic Biomarkers in Primary Invasive Cutaneous Melanoma" rel="prev" class="pager-link-prev link-icon"><span class="icon-circle-arrow-left"></span> <span class="title">Previous</span></a></span><span class="pager-next"><a href="/content/45/2/651" title="Clinical Impact of Cellular Senescence and RNA Dysregulation in HCC Is Associated With MASLD and HCV-SVR" rel="next" class="pager-link-next link-icon-right link-icon"><span class="title">Next</span> <span class="icon-circle-arrow-right"></span></a></span></div> </div> </div> <div class="panel-separator"></div><div class="panel-pane pane-highwire-back-to-top" > <div class="pane-content"> <a href="#page" class="back-to-top" data-icon-position="" data-hide-link-title="0"><span class="icon-chevron-up"></span> Back to top</a> </div> </div> </div> </div> </div> <div class="sidebar-right-wrapper grid-10 omega"> <div class="panel-panel panel-region-sidebar-right"> <div class="inside"><div class="panel-pane pane-panels-mini pane-jnl-iiar-art-issue pane-style-alt-content" > <h2 class="pane-title">In this issue</h2> <div class="pane-content"> <div class="panel-display panel-1col clearfix" id="mini-panel-jnl_iiar_art_issue"> <div class="panel-panel panel-col"> <div><div class="panel-pane pane-highwire-article-citation" > <div class="pane-content"> <div class="highwire-article-citation highwire-citation-type-highwire-issue node83103" data-node-nid="83103" id="node-83103--2766808451" data-pisa="anticanres;45/2" data-pisa-master="anticanres;45/2" data-apath="/anticanres/45/2.atom"><div class="highwire-cite highwire-cite-highwire-issue highwire-citation-jcore-issue-widget clearfix"> <div class="highwire-cite-highlight"><a href="/content/45/2" class="highlight-image-linked"><img class="highlight-image" src="https://ar.iiarjournals.org/sites/default/files/styles/medium/public/highwire/anticanres/45/2.cover-source.jpg?itok=kYVByFmq" alt="Anticancer Research: 45 (2)" /></a></div> <div class="highwire-cite-col"> <a href="/content/45/2" class="highwire-cite-linked-title" data-icon-position="" data-hide-link-title="0"><span class="highwire-cite-title">Anticancer Research</span></a> <div class="highwire-cite-metadata"><span class="highwire-cite-metadata-volume highwire-cite-metadata">Vol. 45</span>, <span class="highwire-cite-metadata-issue highwire-cite-metadata">Issue 2 </span><div class="highwire-cite-metadata-pubdate highwire-cite-metadata">February 2025 </div></div> <div class="highwire-cite-extras"><div class='highwire-article-citation-variant-list'><ul class="links variants-list"><li class="toc first"><a href="/content/45/2.toc" class="highwire-variant-link variant-toc " title="Table of Contents" rel="alternate" type="text/html" data-icon-position="" data-hide-link-title="0">Table of Contents</a></li><li class="tocpdf"><a href="/content/45/2.toc.pdf" class="highwire-variant-link variant-tocpdf " title="Table of Contents (PDF)" rel="alternate" type="application/pdf" data-icon-position="" data-hide-link-title="0">Table of Contents (PDF)</a></li><li class="cover-expansion"><a href="/content/45/2.cover-expansion" class="highwire-variant-link variant-cover-expansion " title="About the Cover" rel="alternate" data-icon-position="" data-hide-link-title="0">About the Cover</a></li><li class="index-by-author"><a href="/content/45/2.index-by-author" class="highwire-variant-link variant-index-by-author " title="Index by author" rel="alternate" data-icon-position="" data-hide-link-title="0">Index by author</a></li><li class="enclosure-back-matter"><a href="/content/anticanres/45/2/local/back-matter.pdf" class="highwire-variant-link variant-enclosure" title="Back Matter (PDF)" rel="alternative" data-icon-position="" data-hide-link-title="0">Back Matter (PDF)</a></li><li class="enclosure-ed-board"><a href="/content/anticanres/45/2/local/ed-board.pdf" class="highwire-variant-link variant-enclosure" title="Ed Board (PDF)" rel="alternative" data-icon-position="" data-hide-link-title="0">Ed Board (PDF)</a></li><li class="enclosure-front-matter last"><a href="/content/anticanres/45/2/local/front-matter.pdf" class="highwire-variant-link variant-enclosure" title="Front Matter (PDF)" rel="alternative" data-icon-position="" data-hide-link-title="0">Front Matter (PDF)</a></li></ul></div></div> </div> </div></div> </div> </div> </div> </div> </div> </div> </div> <div class="panel-separator"></div><div class="panel-pane pane-panels-mini pane-jnl-iiar-art-tools" > <div class="pane-content"> <div id="mini-panel-jnl_iiar_art_tools" class="highwire-2col-stacked panel-display"> <div class="panel-row-wrapper clearfix"> <div class="content-left-wrapper content-column"> <div class="panel-panel panel-region-content-left"> <div class="inside"><div class="panel-pane pane-highwire-variant-link" > <div class="pane-content"> <a href="/content/anticanres/45/2/639.full-text.print" target="_blank" rel="nofollow" class="link-icon"><span class="icon-print"></span> <span class="title">Print</span></a> </div> </div> <div class="panel-pane pane-highwire-variant-link text-no-wrap" > <div class="pane-content"> <a href="/content/anticanres/45/2/639.full-text.pdf" target="_blank" class="link-icon"><span class="icon-download-alt"></span> <span class="title">Download PDF</span></a> </div> </div> <div class="panel-pane pane-minipanel-dialog-link pane-jnl-iiar-art-alert" > <div class="pane-content"> <div class='minipanel-dialog-wrapper'><div class='minipanel-dialog-link-link'><a href="/" oncontextmenu="javascript: return false;" class="minipanel-dialog-link-trigger link-icon" title="Alerts for this Article"><span class="icon-exclamation-sign"></span> <span class="title">Article Alerts</span></a></div><div class='minipanel-dialog-link-mini' style='display:none'><div class="panel-display panel-1col clearfix" id="mini-panel-jnl_iiar_art_alert"> <div class="panel-panel panel-col"> <div><div class="panel-pane pane-article-add-form" > <div class="pane-content"> <div id = "alerts-form-wrapper"><form action="/content/45/2/639" method="post" id="highwire-user-opportunity-login" accept-charset="UTF-8"><div><div class="form-item form-item-label-before form-type-textfield form-item-name"> <label for="edit-name">User Name <span class="form-required" title="This field is required.">*</span></label> <input type="text" id="edit-name" name="name" value="" size="60" maxlength="128" class="form-text required" /> </div> <div class="form-item form-item-label-before form-type-password form-item-pass"> <label for="edit-pass">Password <span class="form-required" title="This field is required.">*</span></label> <input type="password" id="edit-pass" name="pass" size="60" maxlength="128" class="form-text required" /> </div> <div id="alerts_email">Sign In to Email Alerts with your Email Address</div><div class="form-item form-item-label-before form-type-textfield form-item-highwire-alerts-email"> <label for="edit-highwire-alerts-email">Email <span class="form-required" title="This field is required.">*</span></label> <input type="text" id="edit-highwire-alerts-email" name="highwire_alerts_email" value="" size="60" maxlength="128" class="form-text required" /> </div> <input type="submit" id="edit-submit--3" name="op" value="Submit" class="form-submit" /><input type="hidden" name="form_build_id" value="form-348Uu52j64LZV40ArT3y0JhVly_70Nrkx8-nHrx-ArE" /> <input type="hidden" name="form_id" value="highwire_alerts_article_sign_up_form" /> <input type="hidden" name="current_path" value="content/45/2/639" /> </div></form></div> </div> </div> </div> </div> </div> </div></div> </div> </div> <div class="panel-pane pane-minipanel-dialog-link pane-jnl-iiar-art-email" > <div class="pane-content"> <div class='minipanel-dialog-wrapper'><div class='minipanel-dialog-link-link'><a href="/" oncontextmenu="javascript: return false;" class="minipanel-dialog-link-trigger link-icon" title="Email this Article"><span class="icon-envelope"></span> <span class="title">Email Article</span></a></div><div class='minipanel-dialog-link-mini' style='display:none'><div class="panel-display panel-1col clearfix" id="mini-panel-jnl_iiar_art_email"> <div class="panel-panel panel-col"> <div><div class="panel-pane pane-block pane-forward-form pane-forward" > <div class="pane-content"> <form action="/content/45/2/639" method="post" id="forward-form" accept-charset="UTF-8"><div><div id="edit-instructions" class="form-item form-item-label-before form-type-item"> <p>Thank you for your interest in spreading the word on Anticancer Research.</p><p>NOTE: We only request your email address so that the person you are recommending the page to knows that you wanted them to see it, and that it is not junk mail. We do not capture any email address.</p> </div> <div class="form-item form-item-label-before form-type-textfield form-item-email"> <label for="edit-email">Your Email <span class="form-required" title="This field is required.">*</span></label> <input type="text" id="edit-email" name="email" value="" size="58" maxlength="256" class="form-text required" /> </div> <div class="form-item form-item-label-before form-type-textfield form-item-name"> <label for="edit-name--2">Your Name <span class="form-required" title="This field is required.">*</span></label> <input type="text" id="edit-name--2" name="name" value="" size="58" maxlength="256" class="form-text required" /> </div> <div class="form-item form-item-label-before form-type-textarea form-item-recipients"> <label for="edit-recipients">Send To <span class="form-required" title="This field is required.">*</span></label> <div class="form-textarea-wrapper resizable"><textarea id="edit-recipients" name="recipients" cols="50" rows="5" class="form-textarea required"></textarea></div> <div class="description">Enter multiple addresses on separate lines or separate them with commas.</div> </div> <div id="edit-page" class="form-item form-item-label-before form-type-item"> <label for="edit-page">You are going to email the following </label> <a href="/content/45/2/639" class="active" data-icon-position="" data-hide-link-title="0">Efficacy of Second-line Nivolumab Versus Tyrosine Kinase Inhibitors for Renal Cell Carcinoma With Bone Metastases</a> </div> <div id="edit-subject" class="form-item form-item-label-before form-type-item"> <label for="edit-subject">Message Subject </label> (Your Name) has sent you a message from Anticancer Research </div> <div id="edit-body" class="form-item form-item-label-before form-type-item"> <label for="edit-body">Message Body </label> (Your Name) thought you would like to see the Anticancer Research web site. </div> <div class="form-item form-item-label-before form-type-textarea form-item-message"> <label for="edit-message--2">Your Personal Message </label> <div class="form-textarea-wrapper resizable"><textarea id="edit-message--2" name="message" cols="50" rows="10" class="form-textarea"></textarea></div> </div> <input type="hidden" name="path" value="node/83129" /> <input type="hidden" name="path_cid" value="" /> <input type="hidden" name="forward_footer" value="" /> <input type="hidden" name="form_build_id" value="form-7EC9ibA6KvYuS6yTNFPVfzObQjWWugas8LPrJHV6IZE" /> <input type="hidden" name="form_id" value="forward_form" /> <fieldset class="captcha form-wrapper"><legend><span class="fieldset-legend">CAPTCHA</span></legend><div class="fieldset-wrapper"><div class="fieldset-description">This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.</div><input type="hidden" name="captcha_sid" value="312073210" /> <input type="hidden" name="captcha_token" value="c73f16eaf1b2679a32218216483eff2b" /> <div class="form-item form-item-label-before form-type-textfield form-item-captcha-response"> <label for="edit-captcha-response">Math question <span class="form-required" title="This field is required.">*</span></label> <span class="field-prefix">6 + 7 = </span> <input type="text" id="edit-captcha-response" name="captcha_response" value="" size="4" maxlength="2" class="form-text required" /> <div class="description">Solve this simple math problem and enter the result. E.g. for 1+3, enter 4.</div> </div> </div></fieldset> <div class="form-actions form-wrapper" id="edit-actions"><input type="submit" id="edit-submit--4" name="op" value="Send Message" class="form-submit" /></div></div></form> </div> </div> </div> </div> </div> </div></div> </div> </div> <div class="panel-pane pane-minipanel-dialog-link pane-jnl-iiar-cite-tool" > <div class="pane-content"> <div class='minipanel-dialog-wrapper'><div class='minipanel-dialog-link-link'><a href="/highwire/citation/83129/download" oncontextmenu="javascript: return false;" class="minipanel-dialog-link-trigger link-icon" title="Citation Tools"><span class="icon-globe"></span> <span class="title">Citation Tools</span></a></div><div class='minipanel-dialog-link-mini' style='display:none'><div class="panel-display panel-1col clearfix" id="mini-panel-jnl_iiar_cite_tool"> <div class="panel-panel panel-col"> <div><div class="panel-pane pane-highwire-citation-export" > <div class="pane-content"> <div class="highwire-citation-export"> <div class="highwire-citation-info"> <div class="highwire-article-citation highwire-citation-type-highwire-article cite-tool-node83129" data-node-nid="83129" id="citation-node-83129--2575569328" data-pisa="anticanres;45/2/639" data-pisa-master="anticanres;45/2/639" data-apath="/anticanres/45/2/639.atom"><div class="highwire-cite highwire-cite-highwire-article highwire-citation-jcore-standard clearfix"> <div class="highwire-cite-title">Efficacy of Second-line Nivolumab <em>Versus</em> Tyrosine Kinase Inhibitors for Renal Cell Carcinoma With Bone Metastases</div> <div class="highwire-cite-authors"><span class="highwire-citation-authors"><span class="highwire-citation-author first" data-delta="0"><span class="nlm-given-names">GAKU</span> <span class="nlm-surname">YAMAMICHI</span></span>, <span class="highwire-citation-author" data-delta="1"><span class="nlm-given-names">TAIGO</span> <span class="nlm-surname">KATO</span></span>, <span class="highwire-citation-author" data-delta="2"><span class="nlm-given-names">AKIHIRO</span> <span class="nlm-surname">YOSHIMURA</span></span>, <span class="highwire-citation-author" data-delta="3"><span class="nlm-given-names">MASARU</span> <span class="nlm-surname">TANI</span></span>, <span class="highwire-citation-author" data-delta="4"><span class="nlm-given-names">YUKI</span> <span class="nlm-surname">HORIBE</span></span>, <span class="highwire-citation-author" data-delta="5"><span class="nlm-given-names">YUTONG</span> <span class="nlm-surname">LIU</span></span>, <span class="highwire-citation-author" data-delta="6"><span class="nlm-given-names">NESRINE</span> <span class="nlm-surname">SASSI</span></span>, <span class="highwire-citation-author" data-delta="7"><span class="nlm-given-names">YOHEI</span> <span class="nlm-surname">OKUDA</span></span>, <span class="highwire-citation-author" data-delta="8"><span class="nlm-given-names">TOSHIKI</span> <span class="nlm-surname">OKA</span></span>, <span class="highwire-citation-author" data-delta="9"><span class="nlm-given-names">TOSHIHIRO</span> <span class="nlm-surname">UEMURA</span></span>, <span class="highwire-citation-author" data-delta="10"><span class="nlm-given-names">AKINARU</span> <span class="nlm-surname">YAMAMOTO</span></span>, <span class="highwire-citation-author" data-delta="11"><span class="nlm-given-names">YU</span> <span class="nlm-surname">ISHIZUYA</span></span>, <span class="highwire-citation-author" data-delta="12"><span class="nlm-given-names">TAKUJI</span> <span class="nlm-surname">HAYASHI</span></span>, <span class="highwire-citation-author" data-delta="13"><span class="nlm-given-names">YOSHIYUKI</span> <span class="nlm-surname">YAMAMOTO</span></span>, <span class="highwire-citation-author" data-delta="14"><span class="nlm-given-names">KOJI</span> <span class="nlm-surname">HATANO</span></span>, <span class="highwire-citation-author" data-delta="15"><span class="nlm-given-names">ATSUNARI</span> <span class="nlm-surname">KAWASHIMA</span></span>, <span class="highwire-citation-author" data-delta="16"><span class="nlm-given-names">TETSUYA</span> <span class="nlm-surname">TAKAO</span></span>, <span class="highwire-citation-author" data-delta="17"><span class="nlm-given-names">KENSAKU</span> <span class="nlm-surname">NISHIMURA</span></span>, <span class="highwire-citation-author" data-delta="18"><span class="nlm-given-names">SHINGO</span> <span class="nlm-surname">TAKADA</span></span>, <span class="highwire-citation-author" data-delta="19"><span class="nlm-given-names">MASAO</span> <span class="nlm-surname">TSUJIHATA</span></span>, <span class="highwire-citation-author" data-delta="20"><span class="nlm-given-names">NORIO</span> <span class="nlm-surname">NONOMURA</span></span></span></div> <div class="highwire-cite-metadata"><span class="highwire-cite-metadata-oa-ind highwire-cite-metadata"><i class="highwire-oa-indicator"></i> </span><span class="highwire-cite-metadata-journal highwire-cite-metadata">Anticancer Research </span><span class="highwire-cite-metadata-date highwire-cite-metadata">Feb 2025, </span><span class="highwire-cite-metadata-volume highwire-cite-metadata">45 </span><span class="highwire-cite-metadata-issue highwire-cite-metadata">(2) </span><span class="highwire-cite-metadata-pages highwire-cite-metadata">639-650; </span><span class="highwire-cite-metadata-doi highwire-cite-metadata"><span class="label">DOI:</span> 10.21873/anticanres.17451 </span></div> </div> </div> </div> <div class="highwire-citation-formats"> <h2>Citation Manager Formats</h2> <div class="highwire-citation-formats-links"> <span class="Z3988" title="ctx_ver=Z39.88-2004&rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&rft.spage=639&rft.epage=650&rft.atitle=Efficacy%20of%20Second-line%20Nivolumab%20Versus%20Tyrosine%20Kinase%20Inhibitors%20for%20Renal%20Cell%20Carcinoma%20With%20Bone%20Metastases&rft.volume=45&rft.issue=2&rft.date=2025-02-01%2000%3A00%3A00&rft.stitle&rft.jtitle=Anticancer%20Research&rft.au=YAMAMICHI%2C+GAKU&rft.au=KATO%2C+TAIGO&rft.au=YOSHIMURA%2C+AKIHIRO&rft.au=TANI%2C+MASARU&rft.au=HORIBE%2C+YUKI&rft.au=LIU%2C+YUTONG&rft.au=SASSI%2C+NESRINE&rft.au=OKUDA%2C+YOHEI&rft.au=OKA%2C+TOSHIKI&rft.au=UEMURA%2C+TOSHIHIRO&rft.au=YAMAMOTO%2C+AKINARU&rft.au=ISHIZUYA%2C+YU&rft.au=HAYASHI%2C+TAKUJI&rft.au=YAMAMOTO%2C+YOSHIYUKI&rft.au=HATANO%2C+KOJI&rft.au=KAWASHIMA%2C+ATSUNARI&rft.au=TAKAO%2C+TETSUYA&rft.au=NISHIMURA%2C+KENSAKU&rft.au=TAKADA%2C+SHINGO&rft.au=TSUJIHATA%2C+MASAO&rft.au=NONOMURA%2C+NORIO"></span><ul class="hw-citation-links inline button button-alt button-grid clearfix"><li class="bibtext first"><a href="/highwire/citation/83129/bibtext" class="hw-download-citation-link" data-icon-position="" data-hide-link-title="0">BibTeX</a></li><li class="bookends"><a href="/highwire/citation/83129/bookends" class="hw-download-citation-link" data-icon-position="" data-hide-link-title="0">Bookends</a></li><li class="easybib"><a href="/highwire/citation/83129/easybib" class="hw-download-citation-link" data-icon-position="" data-hide-link-title="0">EasyBib</a></li><li class="endnote-tagged"><a href="/highwire/citation/83129/endnote-tagged" class="hw-download-citation-link" data-icon-position="" data-hide-link-title="0">EndNote (tagged)</a></li><li class="endnote-8-xml"><a href="/highwire/citation/83129/endnote-8-xml" class="hw-download-citation-link" data-icon-position="" data-hide-link-title="0">EndNote 8 (xml)</a></li><li class="medlars"><a href="/highwire/citation/83129/medlars" class="hw-download-citation-link" data-icon-position="" data-hide-link-title="0">Medlars</a></li><li class="mendeley"><a href="/highwire/citation/83129/mendeley" class="hw-download-citation-link" data-icon-position="" data-hide-link-title="0">Mendeley</a></li><li class="papers"><a href="/highwire/citation/83129/papers" class="hw-download-citation-link" data-icon-position="" data-hide-link-title="0">Papers</a></li><li class="refworks-tagged"><a href="/highwire/citation/83129/refworks-tagged" class="hw-download-citation-link" data-icon-position="" data-hide-link-title="0">RefWorks Tagged</a></li><li class="reference-manager"><a href="/highwire/citation/83129/reference-manager" class="hw-download-citation-link" data-icon-position="" data-hide-link-title="0">Ref Manager</a></li><li class="ris"><a href="/highwire/citation/83129/ris" class="hw-download-citation-link" data-icon-position="" data-hide-link-title="0">RIS</a></li><li class="zotero last"><a href="/highwire/citation/83129/zotero" class="hw-download-citation-link" data-icon-position="" data-hide-link-title="0">Zotero</a></li></ul> </div> </div> </div> </div> </div> </div> </div> </div> </div></div> </div> </div> <div class="panel-pane pane-highwire-permission-link" > <div class="pane-content"> <a href="https://www.copyright.com/openurl.do?contentIdType=doi&issn=17917530&contentId=10.21873/anticanres.17451" target="_blank" class="highwire-permission-link link-icon"><span class="icon-copyright"></span> <span class="title">Reprints and Permissions</span></a> </div> </div> </div> </div> </div> <div class="content-right-wrapper content-column"> <div class="panel-panel panel-region-content-right"> <div class="inside"><div class="panel-pane pane-highwire-share-link highwire_clipboard_link_ajax" id="shareit"> <div class="pane-content"> <a href="/" class="link-icon"><span class="icon-share-alt"></span> <span class="title">Share</span></a> </div> </div> <div class="panel-pane pane-panels-mini pane-jnl-iiar-share highwire_clipboard_form_ajax_shareit" > <div class="pane-content"> <div class="panel-display panel-1col clearfix" id="mini-panel-jnl_iiar_share"> <div class="panel-panel panel-col"> <div><div class="panel-pane pane-highwire-article-citation large-margin-bottom" > <div class="pane-content"> <div class="highwire-article-citation highwire-citation-type-highwire-article node83129--3" data-node-nid="83129" id="share-node-83129--41575649561" data-pisa="anticanres;45/2/639" data-pisa-master="anticanres;45/2/639" data-apath="/anticanres/45/2/639.atom"><div class="highwire-cite highwire-cite-highwire-article highwire-citation-jcore-standard clearfix"> <div class="highwire-cite-title">Efficacy of Second-line Nivolumab <em>Versus</em> Tyrosine Kinase Inhibitors for Renal Cell Carcinoma With Bone Metastases</div> <div class="highwire-cite-authors"><span class="highwire-citation-authors"><span class="highwire-citation-author first" data-delta="0"><span class="nlm-given-names">GAKU</span> <span class="nlm-surname">YAMAMICHI</span></span>, <span class="highwire-citation-author" data-delta="1"><span class="nlm-given-names">TAIGO</span> <span class="nlm-surname">KATO</span></span>, <span class="highwire-citation-author" data-delta="2"><span class="nlm-given-names">AKIHIRO</span> <span class="nlm-surname">YOSHIMURA</span></span>, <span class="highwire-citation-author" data-delta="3"><span class="nlm-given-names">MASARU</span> <span class="nlm-surname">TANI</span></span>, <span class="highwire-citation-author" data-delta="4"><span class="nlm-given-names">YUKI</span> <span class="nlm-surname">HORIBE</span></span>, <span class="highwire-citation-author" data-delta="5"><span class="nlm-given-names">YUTONG</span> <span class="nlm-surname">LIU</span></span>, <span class="highwire-citation-author" data-delta="6"><span class="nlm-given-names">NESRINE</span> <span class="nlm-surname">SASSI</span></span>, <span class="highwire-citation-author" data-delta="7"><span class="nlm-given-names">YOHEI</span> <span class="nlm-surname">OKUDA</span></span>, <span class="highwire-citation-author" data-delta="8"><span class="nlm-given-names">TOSHIKI</span> <span class="nlm-surname">OKA</span></span>, <span class="highwire-citation-author" data-delta="9"><span class="nlm-given-names">TOSHIHIRO</span> <span class="nlm-surname">UEMURA</span></span>, <span class="highwire-citation-author" data-delta="10"><span class="nlm-given-names">AKINARU</span> <span class="nlm-surname">YAMAMOTO</span></span>, <span class="highwire-citation-author" data-delta="11"><span class="nlm-given-names">YU</span> <span class="nlm-surname">ISHIZUYA</span></span>, <span class="highwire-citation-author" data-delta="12"><span class="nlm-given-names">TAKUJI</span> <span class="nlm-surname">HAYASHI</span></span>, <span class="highwire-citation-author" data-delta="13"><span class="nlm-given-names">YOSHIYUKI</span> <span class="nlm-surname">YAMAMOTO</span></span>, <span class="highwire-citation-author" data-delta="14"><span class="nlm-given-names">KOJI</span> <span class="nlm-surname">HATANO</span></span>, <span class="highwire-citation-author" data-delta="15"><span class="nlm-given-names">ATSUNARI</span> <span class="nlm-surname">KAWASHIMA</span></span>, <span class="highwire-citation-author" data-delta="16"><span class="nlm-given-names">TETSUYA</span> <span class="nlm-surname">TAKAO</span></span>, <span class="highwire-citation-author" data-delta="17"><span class="nlm-given-names">KENSAKU</span> <span class="nlm-surname">NISHIMURA</span></span>, <span class="highwire-citation-author" data-delta="18"><span class="nlm-given-names">SHINGO</span> <span class="nlm-surname">TAKADA</span></span>, <span class="highwire-citation-author" data-delta="19"><span class="nlm-given-names">MASAO</span> <span class="nlm-surname">TSUJIHATA</span></span>, <span class="highwire-citation-author" data-delta="20"><span class="nlm-given-names">NORIO</span> <span class="nlm-surname">NONOMURA</span></span></span></div> <div class="highwire-cite-metadata"><span class="highwire-cite-metadata-oa-ind highwire-cite-metadata"><i class="highwire-oa-indicator"></i> </span><span class="highwire-cite-metadata-journal highwire-cite-metadata">Anticancer Research </span><span class="highwire-cite-metadata-date highwire-cite-metadata">Feb 2025, </span><span class="highwire-cite-metadata-volume highwire-cite-metadata">45 </span><span class="highwire-cite-metadata-issue highwire-cite-metadata">(2) </span><span class="highwire-cite-metadata-pages highwire-cite-metadata">639-650; </span><span class="highwire-cite-metadata-doi highwire-cite-metadata"><span class="label">DOI:</span> 10.21873/anticanres.17451 </span></div> </div> </div> </div> </div> <div class="panel-separator"></div><div class="panel-pane pane-highwire-article-clipboard-copy large-margin-bottom" > <div class="pane-content"> <div class = "clipboard-copy"> <span class="label-url"> <label for="dynamic">Share This Article:</label> </span> <span class="input-text-url"> <input type="text" id="dynamic" value="https://ar.iiarjournals.org/content/45/2/639" size="50"/> </span> <span class="copy-button button"> <button id="copy-dynamic" class="clipboardjs-button" data-clipboard-target="#dynamic" data-clipboard-alert-style="tooltip" data-clipboard-alert-text="Copied!">Copy</button> </span> </div> </div> </div> <div class="panel-separator"></div><div class="panel-pane pane-service-links" > <div class="pane-content"> <div class="service-links"><a href="https://twitter.com/share?url=https%3A//ar.iiarjournals.org/content/45/2/639&text=Efficacy%20of%20Second-line%20Nivolumab%20Versus%20Tyrosine%20Kinase%20Inhibitors%20for%20Renal%20Cell%20Carcinoma%20With%20Bone%20Metastases" id="twitter" title="Share this on Twitter" class="service-links-twitter" rel="nofollow" target="_blank" data-icon-position="" data-hide-link-title="0"><img src="https://ar.iiarjournals.org/sites/all/modules/highwire/highwire/images/twitter.png" alt="Twitter logo" /></a> <a href="https://www.facebook.com/sharer.php?u=https%3A//ar.iiarjournals.org/content/45/2/639&t=Efficacy%20of%20Second-line%20Nivolumab%20Versus%20Tyrosine%20Kinase%20Inhibitors%20for%20Renal%20Cell%20Carcinoma%20With%20Bone%20Metastases" id="facebook" title="Share on Facebook" class="service-links-facebook" rel="nofollow" target="_blank" data-icon-position="" data-hide-link-title="0"><img src="https://ar.iiarjournals.org/sites/all/modules/highwire/highwire/images/fb-blue.png" alt="Facebook logo" /></a> <a href="http://www.mendeley.com/import/?url=https%3A//ar.iiarjournals.org/content/45/2/639&title=Efficacy%20of%20Second-line%20Nivolumab%20Versus%20Tyrosine%20Kinase%20Inhibitors%20for%20Renal%20Cell%20Carcinoma%20With%20Bone%20Metastases" id="mendeley" title="Share on Mendeley" class="service-links-mendeley" rel="nofollow" target="_blank" data-icon-position="" data-hide-link-title="0"><img src="https://ar.iiarjournals.org/sites/all/modules/highwire/highwire/images/mendeley.png" alt="Mendeley logo" /></a></div> </div> </div> </div> </div> </div> </div> </div> <div class="panel-pane pane-service-links" > <div class="pane-content"> <div class="service-links"><div class="item-list"><ul><li class="first"><a href="https://twitter.com/share?url=https%3A//ar.iiarjournals.org/content/45/2/639&count=horizontal&via=&text=Efficacy%20of%20Second-line%20Nivolumab%20Versus%20Tyrosine%20Kinase%20Inhibitors%20for%20Renal%20Cell%20Carcinoma%20With%20Bone%20Metastases&counturl=https%3A//ar.iiarjournals.org/content/45/2/639" class="twitter-share-button service-links-twitter-widget" id="twitter_widget" title="Tweet This" rel="nofollow" target="_blank" data-icon-position="" data-hide-link-title="0"><span class="element-invisible">Tweet Widget</span></a></li><li><a href="https://www.facebook.com/plugins/like.php?href=https%3A//ar.iiarjournals.org/content/45/2/639&layout=button_count&show_faces=false&action=like&colorscheme=light&width=100&height=21&font=&locale=" id="facebook_like" title="I Like it" class="service-links-facebook-like" rel="nofollow" target="_blank" data-icon-position="" data-hide-link-title="0"><span class="element-invisible">Facebook Like</span></a></li><li class="last"><a href="https://ar.iiarjournals.org/content/45/2/639" id="google_plus_one" title="Plus it" class="service-links-google-plus-one" rel="nofollow" target="_blank" data-icon-position="" data-hide-link-title="0"><span class="element-invisible">Google Plus One</span></a></li></ul></div></div> </div> </div> </div> </div> </div> </div> <!-- /.panel-row-wrapper --> </div> </div> </div> <div class="panel-separator"></div><div class="panel-pane pane-highwire-article-nav mobile-hidden pane-style-alt-content" > <h2 class="pane-title">Jump to section</h2> <div class="pane-content"> <div class="highwire-list-wrapper highwire-article-nav highwire-nav-float"><div class="highwire-list"><ul data-highwire-float="1" data-highwire-float-class="grid-10 alpha omega"><li class="parent first odd"><a href="/content/45/2/639" class="highwire-article-nav-jumplink" data-panel-ajax-tab="jnl_iiar_tab_art" data-is-tab-link="true" data-icon-position="" data-hide-link-title="0">Article</a><div class="highwire-list"><ul><li class="first odd"><a href="#abstract-1" class="highwire-article-nav-jumplink first" data-panel-ajax-tab="jnl_iiar_tab_art" data-icon-position="" data-hide-link-title="0">Abstract</a></li><li class="even"><a href="#sec-1" class="highwire-article-nav-jumplink" data-panel-ajax-tab="jnl_iiar_tab_art" data-icon-position="" data-hide-link-title="0">Patients and Methods</a></li><li class="odd"><a href="#sec-2" class="highwire-article-nav-jumplink" data-panel-ajax-tab="jnl_iiar_tab_art" data-icon-position="" data-hide-link-title="0">Results</a></li><li class="even"><a href="#sec-3" class="highwire-article-nav-jumplink" data-panel-ajax-tab="jnl_iiar_tab_art" data-icon-position="" data-hide-link-title="0">Discussion</a></li><li class="odd"><a href="#fn-group-1" class="highwire-article-nav-jumplink" data-panel-ajax-tab="jnl_iiar_tab_art" data-icon-position="" data-hide-link-title="0">Footnotes</a></li><li class="last even"><a href="#ref-list-1" class="highwire-article-nav-jumplink last" data-panel-ajax-tab="jnl_iiar_tab_art" data-icon-position="" data-hide-link-title="0">References</a></li></ul></div></li><li class="even"><a href="/content/45/2/639/tab-figures-data" class="highwire-article-nav-jumplink" data-panel-ajax-tab="jnl_iiar_tab_data" data-is-tab-link="true" data-icon-position="" data-hide-link-title="0">Figures & Data</a></li><li class="odd"><a href="/content/45/2/639/tab-article-info" class="highwire-article-nav-jumplink" data-panel-ajax-tab="jnl_iiar_tab_info" data-is-tab-link="true" data-icon-position="" data-hide-link-title="0">Info & Metrics</a></li><li class="last even"><a href="/content/45/2/639.full.pdf" class="highwire-article-nav-jumplink" data-icon-position="" data-hide-link-title="0"><i class="icon-file-alt"></i> PDF</a></li></ul></div></div> </div> </div> <div class="panel-separator"></div><div class="panel-pane pane-panels-mini pane-jnl-iiar-accordion" > <div class="pane-content"> <div class="panel-display panel-1col clearfix" id="mini-panel-jnl_iiar_accordion"> <div class="panel-panel panel-col"> <div><div id="highwire_article_accordion_container"><h3 ><i class="icon-caret-right"></i> Related Articles</h3><div><div class="highwire-list highwire-related-articles highwire-article-citation-list"><ul class="highwire-related-articles-list"><li class="first last odd"><div class="no-results">No related articles found.</div></li></ul></div><div class='highwire-list-footer'><div class="highwire-related-articles-footer"><ul class="links inline"><li class="related-pubmed first"><a href="/lookup/external-ref?link_type=MED_NBRS&access_num=39890197" target="_blank" class="" data-icon-position="" data-hide-link-title="0">PubMed</a></li><li class="related-google-scholar last"><a href="/lookup/google-scholar?link_type=googlescholar&gs_type=related&author%5B0%5D=GAKU%2BYAMAMICHI&author%5B1%5D=TAIGO%2BKATO&author%5B2%5D=AKIHIRO%2BYOSHIMURA&author%5B3%5D=MASARU%2BTANI&author%5B4%5D=YUKI%2BHORIBE&author%5B5%5D=YUTONG%2BLIU&author%5B6%5D=NESRINE%2BSASSI&author%5B7%5D=YOHEI%2BOKUDA&author%5B8%5D=TOSHIKI%2BOKA&author%5B9%5D=TOSHIHIRO%2BUEMURA&author%5B10%5D=AKINARU%2BYAMAMOTO&author%5B11%5D=YU%2BISHIZUYA&author%5B12%5D=TAKUJI%2BHAYASHI&author%5B13%5D=YOSHIYUKI%2BYAMAMOTO&author%5B14%5D=KOJI%2BHATANO&author%5B15%5D=ATSUNARI%2BKAWASHIMA&author%5B16%5D=TETSUYA%2BTAKAO&author%5B17%5D=KENSAKU%2BNISHIMURA&author%5B18%5D=SHINGO%2BTAKADA&author%5B19%5D=MASAO%2BTSUJIHATA&author%5B20%5D=NORIO%2BNONOMURA&title=Efficacy%2Bof%2BSecond-line%2BNivolumab%2BVersus%2BTyrosine%2BKinase%2BInhibitors%2Bfor%2BRenal%2BCell%2BCarcinoma%2BWith%2BBone%2BMetastases&publication_year=2025&path=content/45/2/639" target="_blank" class="" data-icon-position="" data-hide-link-title="0">Google Scholar</a></li></ul></div></div></div><h3 ><i class="icon-caret-right"></i> Cited By...</h3><div><div class="highwire-list highwire-cited-by"><ul><li class="first last odd"><div class="no-results">No citing articles found.</div></li></ul></div><div class='highwire-list-footer'><ul class="links inline"><li class="citing-google-scholar first last"><a href="/lookup/google-scholar?link_type=googlescholar&gs_type=citedby&path=content/45/2/639" target="_blank" class="" data-icon-position="" data-hide-link-title="0">Google Scholar</a></li></ul></div></div><h3 ><i class="icon-caret-right"></i> More in this TOC Section</h3><div><div class="highwire-list highwire-article-citation-list"><ul><li class="first odd"><div class="highwire-article-citation highwire-citation-type-highwire-article node83107" data-node-nid="83107" id="node-83107--2531585334" data-pisa="anticanres;45/2/685" data-pisa-master="anticanres;45/2/685" data-apath="/anticanres/45/2/685.atom"><div class="highwire-cite highwire-cite-highwire-article highwire-citation-jcore-standard-title-only clearfix"> <a href="/content/45/2/685" class="highwire-cite-linked-title" data-icon-position="" data-hide-link-title="0"><span class="highwire-cite-title">Enhanced Potential of Durvalumab in the Initial Treatment of Advanced Biliary Tract Cancer</span></a> </div> </div></li><li class="even"><div class="highwire-article-citation highwire-citation-type-highwire-article node83126" data-node-nid="83126" id="node-83126--2201670142" data-pisa="anticanres;45/2/773" data-pisa-master="anticanres;45/2/773" data-apath="/anticanres/45/2/773.atom"><div class="highwire-cite highwire-cite-highwire-article highwire-citation-jcore-standard-title-only clearfix"> <a href="/content/45/2/773" class="highwire-cite-linked-title" data-icon-position="" data-hide-link-title="0"><span class="highwire-cite-title">Prognostic Significance of Splenic Vein Invasion for Pancreatic Cancer Patients With Pancreatectomy: A Retrospective Study</span></a> </div> </div></li><li class="last odd"><div class="highwire-article-citation highwire-citation-type-highwire-article node83108" data-node-nid="83108" id="node-83108--21002205515" data-pisa="anticanres;45/2/751" data-pisa-master="anticanres;45/2/751" data-apath="/anticanres/45/2/751.atom"><div class="highwire-cite highwire-cite-highwire-article highwire-citation-jcore-standard-title-only clearfix"> <a href="/content/45/2/751" class="highwire-cite-linked-title" data-icon-position="" data-hide-link-title="0"><span class="highwire-cite-title">Prognostic Stratification Using Early Prostate-specific Antigen Kinetics in Men With Metastatic Hormone-sensitive Prostate Cancer</span></a> </div> </div></li></ul></div><div class='highwire-list-footer'><a href="/content/by/section/Clinical%20Studies" class="" data-icon-position="" data-hide-link-title="0">Show more <span class="wrapper">Clinical Studies</span></a></div></div><h3 ><i class="icon-caret-right"></i> Similar Articles</h3><div><div class="highwire-search-similar-ajax-wrapper" id="highwire-search-similar-articles-list-1"><div class="highwire-ajax-loading"><span class="icon-spinner icon-spin icon-2x"></span></div></div></div></div></div> </div> </div> </div> </div> <div class="panel-separator"></div><div class="panel-pane pane-highwire-term-full-title" > <h2 class="pane-title">Keywords</h2> <div class="pane-content"> <div class="highwire-list highwire-a-full-title"><ul class="field-items inline comma-separated"><li class="first odd"><a href="/keyword/renal-cell-carcinoma" class="" data-icon-position="" data-hide-link-title="0"><span class="wrapper">Renal cell carcinoma</span></a></li><li class="even"><a href="/keyword/bone-metastasis" class="" data-icon-position="" data-hide-link-title="0"><span class="wrapper">bone metastasis</span></a></li><li class="odd"><a href="/keyword/second-line-treatment" class="" data-icon-position="" data-hide-link-title="0"><span class="wrapper">second-line treatment</span></a></li><li class="even"><a href="/keyword/nivolumab" class="" data-icon-position="" data-hide-link-title="0"><span class="wrapper">nivolumab</span></a></li><li class="odd"><a href="/keyword/tyrosine-kinase-inhibitor" class="" data-icon-position="" data-hide-link-title="0"><span class="wrapper">tyrosine kinase inhibitor</span></a></li><li class="last even"><a href="/keyword/overall-survival" class="" data-icon-position="" data-hide-link-title="0"><span class="wrapper">overall survival</span></a></li></ul></div> </div> </div> </div> </div> </div> </div> <!-- /.panel-row-wrapper --> </div> </div> </div> </div> </div> </div> </div> </section> <footer id="section-footer" class="section section-footer"> <div id="zone-footer" class="zone zone-footer clearfix container-30"> <div class="grid-28 suffix-1 prefix-1 region region-footer-first" id="region-footer-first"> <div class="region-inner region-footer-first-inner"> <div class="block block-panels-mini block-jnl-iiar-foot-info block-panels-mini-jnl-iiar-foot-info odd block-without-title" id="block-panels-mini-jnl-iiar-foot-info"> <div class="block-inner clearfix"> <div class="content clearfix"> <div class="panel-display panel-1col clearfix" id="mini-panel-jnl_iiar_foot_info"> <div class="panel-panel panel-col"> <div><div class="panel-pane pane-page-logo-footer" > <div class="pane-content"> <a href="/" class="linked-footer-logo" data-icon-position="" data-hide-link-title="0"><img class="footer-logo" src="https://ar.iiarjournals.org/sites/default/files/ar-footer.png" width="460" height="59" alt="Anticancer Research" /></a> </div> </div> <div class="panel-separator"></div><div class="panel-pane pane-snippet pane-footer-copyright-text" > <div class="pane-content"> <div class="snippet footer-copyright-text" id="footer-copyright-text"> <div class="snippet-content"> <p>© 2025 Anticancer Research</p> </div> </div> </div> </div> <div class="panel-separator"></div><div class="panel-pane pane-highwire-branding" > <div class="pane-content"> <a href="http://home.highwire.org" target="_blank" class="highwire-branding-link" data-icon-position="" data-hide-link-title="0"><img class="logo-highwire" src="https://ar.iiarjournals.org/sites/all/modules/highwire/highwire/plugins/content_types/images/logo_small_hw_white.png" width="190" height="31" alt="Powered by HighWire" /></a> </div> </div> </div> </div> </div> </div> </div> </div> </div> </div> </div> </footer> </div> <div class="region region-page-bottom" id="region-page-bottom"> <div class="region-inner region-page-bottom-inner"> </div> </div><script type="text/javascript" src="/sites/default/files/advagg_js/js__OPKq91E0HJ5CPkh17iFMBl49HmT_mxwB0JrBjVnws54__yhrrZSUsjWzTSPuI24K06PaZ7jWNGAWzUE3iWXCof7c__FTZ25lEcrtnzSW3JzKpn0j1z_ccWiSdhuJwjpWHa4ec.js"></script> <script type="text/javascript" src="/sites/default/files/advagg_js/js__2WRbxlwOW0MEUc_hSWU5MBepQg6Lch6O5SZwefpJ6IE__HCL0YQJqLkOhrLPZZYGqosGvtFsEHMGghHIkSx4y9vA__FTZ25lEcrtnzSW3JzKpn0j1z_ccWiSdhuJwjpWHa4ec.js" defer="defer"></script> <script type="text/javascript" src="/sites/default/files/advagg_js/js__7JcO4FSl5jd0Ka8T_VnshezxUM7PtQSO7sKX4gvf-g8__00CRL0zf_Zia_vqj6R6JALHj3oqIsE4FfJDoLxQwyto__FTZ25lEcrtnzSW3JzKpn0j1z_ccWiSdhuJwjpWHa4ec.js"></script> <script type="text/javascript" src="/sites/default/files/advagg_js/js__Jd5dsvNznZMdglFu8sSni1wCsUfzvQbApHPAZwt5TY4__65Mqa1DMRwcSvPxjJEn6BXgMm-ckF3oOvkUTG9HRADI__FTZ25lEcrtnzSW3JzKpn0j1z_ccWiSdhuJwjpWHa4ec.js" defer="defer"></script> <script type="text/javascript" src="/sites/default/files/advagg_js/js__WcTpt-w0y1FyXrxZNriX8Ts1KjsFTDpdvZaw9yhRn24__aFJpdvsZPb1v9rWrq-WXbz_WQ9IThQN-mFTCdm1cfXc__FTZ25lEcrtnzSW3JzKpn0j1z_ccWiSdhuJwjpWHa4ec.js"></script> <script type="text/javascript"> <!--//--><![CDATA[//><!-- function euCookieComplianceLoadScripts() {} //--><!]]> </script> <script type="text/javascript"> <!--//--><![CDATA[//><!-- var eu_cookie_compliance_cookie_name = ""; //--><!]]> </script> </body> </html>